Rational design of vaccines for the control of Campylobacter in chickens by Chintoan-Uta, Cosmin
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
   
 
Rational design of vaccines for the control 
of Campylobacter in chickens 
 
Cosmin Chintoan-Uta 
 
 
 
 
 
 
 
Doctor of Philosophy 
The University of Edinburgh 
2015 
 
I 
 
 
Declaration 
 
 
 
I hereby declare that the research described within this thesis is my own work, unless 
acknowledged in the text. I certify that the work has not been submitted for any other degree 
or professional qualification. 
 
Date: 30.09.2015 
 
 
 
 
 
 
 
 
 
Cosmin Chintoan-Uta BVSc, MSc(R), MRCVS 
Roslin Institute 
University of Edinburgh 
Easter Bush 
Roslin 
Midlothian 
EH25 9RG 
United Kingdom 
II 
 
 
 
Acknowledgements 
 
I would like to give my sincere thanks to Professor Mark Stevens for his scientific guidance 
and advice throughout my doctoral studies and also for his kind support during my time at 
The Roslin Institute. Many thanks also to my other supervisors, Professors Pete Kaiser, 
David G.E. Smith and Nick Sparks for their advice and comments on my research. I would 
like to extend a special thank you to Dr. Jo Stevens and Dr. Lonneke Vervelde for their help, 
training in laboratory techniques and general support over the years. Dr. Robin Cassady-Cain 
deserves a special thank you also for support both in the lab during endless days of plating 
and counting samples and for being such a good friend outside the lab. 
Very special thanks go to my parents Marin and Liana for their constant support throughout 
all my studies so far and to my partner Adrian Philpott for his love and support during my 
doctoral studies. Many thanks to all my friends also and in particular Seema Jasim for 
always listening to me during difficult periods in my PhD and to Dr. Louise Welch and 
Michael Jeans for their support throughout the last few years. 
III 
 
 
 
Abstract 
Campylobacter is the leading cause of bacterial food-borne diarrhoeal disease in the 
developed world and a significant cause of infant morbidity and mortality in developing 
countries. Epidemiological studies implicate poultry as a key source of infection, with up to 
80% of human cases being attributable to the avian reservoir. An effective vaccine for 
broilers is predicted to limit the incidence of human campylobacteriosis. Vaccination of 
chickens with CjaA, either in recombinant form or vectored in live-attenuated Salmonella, 
has been reported to significantly reduce caecal colonisation by C. jejuni, with more invasive 
carriers eliciting greater protection. However, protection remains modest and is slow to 
develop. I therefore sought to improve such vaccines, first by vectoring codon-optimised 
CjaA in a licensed avian pathogenic E. coli ΔaroA vaccine. In two independent trials, White 
Leghorn birds were vaccinated subcutaneously on the day of hatch and 14 days later then 
challenged with C. jejuni M1 at 28 days post-hatch. No protection was observed despite 
significant induction of CjaA-specific serum IgY, however, a previously described S. 
Typhimurium ΔaroA vaccine vectoring CjaA also failed to protect. 
Owing to the variability observed with live CjaA-based vaccines in these and 
previous studies, other candidate antigens were sought and evaluated as subunits. Twenty-
one candidate C. jejuni antigens were cloned and expressed as glutathione-S-transferase 
(GST) fusions. Nine of these could be purified in adequate soluble quantities to be tested in 
vivo. The intervals of vaccination and challenge were as above, with GST alone or GST-
CjaA acting as negative and positive controls, respectively. Each antigen was administered 
subcutaneously in TiterMax Gold® adjuvant at the molar equivalent of the doses of GST-
CjaA. Repeated testing of initially promising candidates revealed that, when averaged across 
three independent trials, GST-SodB and GST-FliD induced statistically significant 
reductions in caecal colonisation of 1-2 log10 colony-forming units of C. jejuni at 48 and 56 
days post-hatch compared to negative controls. Induction of antigen-specific serum IgY was 
measured by enzyme linked-immunosorbent assays using maltose-binding protein fusions to 
each antigen. This revealed significant induction of antigen specific serum IgY for the 
majority of the antigens tested, even when no protection was observed. In the SodB- and 
FliD-vaccinated groups, the peak of antigen-specific serum IgY was not coincident with the 
onset of protection and the fold-change in specific IgY levels in individual birds did not 
correlate with caecal Campylobacter numbers. Furthermore, sera from SodB-vaccinated 
birds failed to detect SodB in the outer membrane or surface of Campylobacter cells, 
indicating that SodB-specific antibodies are unlikely to be neutralising.  
Taken together, these studies identified two novel protective antigens that, with 
further optimisation, could form part of an anti-Campylobacter vaccine for broilers. 
However further studies are required to define the nature and consequences of immune 
responses required for protection. 
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Lay summary 
Campylobacter is the most common cause of bacterial food-borne diarrhoeal disease 
in the developed world. Consumption or handling of contaminated chicken meat is the main 
source of human infections. Campylobacter reaches very high numbers in the intestines of 
chickens and carcasses often become contaminated with gut contents during the slaughter 
process. Strategies to control Campylobacter at source in chickens are expected to lower the 
incidence of human disease. Some laboratories have achieved this by vaccinating chickens, 
but protection is often modest or slow to develop. Towards the goal of an improved 
Campylobacter vaccine for chickens I initially modified existing live vaccines for birds 
based on E. coli or Salmonella by engineering them to express a Campylobacter protein 
previously reported to confer immunity. These so-called ‘vectored’ vaccines were evaluated 
in two independent trials in chickens but they did not elicit protection, despite inducing 
antibodies specific to the Campylobacter protein.  
In order to identify other constituents of Campylobacter that may be protective in 
birds I surveyed the literature and identified 21 proteins that may be suitable for use as 
vaccines. It was feasible to purify nine of these on a large scale and these were tested 
individually in chickens for their ability to induce immune responses and protect birds 
against experimental Campylobacter infection. From three independent trials, two of these 
vaccines reduced colonisation of the chicken intestines by Campylobacter by up to 100-fold. 
These two vaccines were based on Campylobacter proteins called superoxide dismutase 
(SodB), which helps the bacteria respond to oxidative stress, and a flagellum protein (FliD) 
which is part of a structure the bacteria use to swim. It was shown previously that SodB and 
the flagellum are required for chicken colonisation. We were able to detect antibodies 
against the SodB and FliD proteins after vaccination, however the levels of these antibodies 
did not correlate with the protection against colonisation. Furthermore, SodB was not 
detectable on the bacterial surface, suggesting that antibodies against SodB would be unable 
to locate their target. These findings suggest that antibodies may not play a major role in 
vaccine-induced protection against Campylobacter in birds and further studies are needed to 
understand which immune responses are important. My research nevertheless identified two 
new protective vaccines that can be added to the limited repertoire available. This knowledge 
will aid the further development of anti-Campylobacter vaccines for meat-producing birds.
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1. Introduction 
 
1.1 Campylobacter biology 
1.1.1 General characteristics 
Campylobacter is a Gram-negative spiral-shaped bacterium and part of the class 
Epsilonproteobacteria (On, 2001). It is part of the Campylobacterales order, which includes 
other important pathogens such as Helicobacter pylori, associated with gastric ulceration and 
cancer in humans (Bauer and Meyer, 2011). Gupta (2006) described unique molecular 
features of this order than can be used in its identification and also unique molecular markers 
for individual genera and species. Currently, the genus Campylobacter comprises 17 species 
and 6 subspecies, of which C. jejuni subsp. jejuni and C. coli are the most important species 
causing food-borne diarrhoeal disease in humans (WHO, 2011). Other species such as C. lari 
and C. upsaliensis have also been isolated from human clinical cases but are less frequent 
(Miller et al, 2008; Parsons et al, 2012). In addition to humans, Campylobacter can infect a 
large number of different hosts including shellfish (Soonthornchaikul and Garelick, 2009) 
and all of the vertebrate classes. They have been isolated from fish (as reviewed in Novotny 
et al, 2004), possibly from amphibians (Gossling et al, 1982), from reptiles (Gilbert et al, 
2014) and it is widely known that they infect birds and mammals. Clinical signs within each 
of the hosts vary from asymptomatic carriage in lower vertebrates and birds to severe in 
mammals, e.g. abortion induced by Campylobacter fetus in sheep (The Merck Veterinary 
Manual (a), 2014) and dogs (Sahin et al, 2014), reproductive losses in cattle (The Merck 
Veterinary Manual (b), 2014) and gastrointestinal disease in dogs and cats (Marks et al, 
2011), non-human primates (Kalashnikova et al, 2002) and humans (reviewed below). 
 
 
1.1.2. Genetic characteristics 
Campylobacter have a relatively small but variable AT-rich genome, comprised of 
approximately 2000 genes in the core-genome with approximately as much again in the pan-
genome of C. jejuni (Friis et al, 2010), all encoded on a single chromosome. Parkhill et al 
(2000) sequenced the first complete genome of C. jejuni and revealed a structure lacking 
features commonly found in other Proteobacteria; for example there are no prophage-
associated sequences, obvious pathogenicity islands and few typical regulators. Its genome 
was shown to contain homopolymeric tracts (Parkhill et al, 2000), particularly in genes 
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predicted to encode biosynthesis-associated molecules and modifications of surface-exposed 
structures. Slipped-strand mis-pairing of these homopolymeric tracts during DNA synthesis 
can lead to variation in number of these homopolymeric repeats and phase variation with 
on/off switching of the encoded genes (Bayliss et al, 2012). This high rate of genomic 
variation is believed to be involved in survival strategies of Campylobacter and evasion of 
the immune system. Gilbert et al (2002) showed that phase variation induces variability in 
the structure of surface lipooligosaccharides (LOS) and Thompson (2002) showed that 
genetic variation induces changes in surface-expressed S-layer proteins and allows evasion 
of the immune system by C. fetus. 
 
1.1.3 Phenotypic characteristics 
In vitro, campylobacters have variable motility and morphology, ranging from highly 
motile long spiral-shaped rods (Fig. 1) to non-motile coccoid forms, depending on the phase 
of the growth cycle and the culturing conditions (Ng et al, 1985; Thomas et al, 1999). They 
are microaerophilic organisms, requiring culture in reduced oxygen conditions, most 
commonly in 5% oxygen, although they can grow in levels of oxygen of up to 10% (Davies 
and DiRita, 2008). Most Campylobacter species are thermophilic, with ideal growth 
temperatures of around 40-42 oC, which corresponds to the body temperature of chickens 
and may partly explain their ability to efficiently colonise the avian intestines. Furthermore, 
Campylobacter is fastidious in terms of the requirements of its culture media – they grow 
best in Mueller Hinton broth or agar (Davies and DiRita, 2008), often used with the addition 
of 5% (v/v) lysed horse blood and beta-nicotinamide adenine dinucleotide (β-NAD) when 
used for standardised culture and antibiotic sensitivity testing (EUCAST, 2015). A selective 
medium commonly used for isolation of Campylobacter from animal or environmental 
samples is modified charcoal cefoperazone deoxycholate agar (mCCDA), which selects for 
Campylobacter through the presence of cefoperazone and sodium desoxycholate, to which 
Campylobacter is intrinsically resistant and aids growth through the presence of sodium 
pyruvate and ferrous sulphate as nutrients and charcoal as detoxifying agent that reduced 
oxygen tension. 
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Figure 1.1 Morphology of Campylobacter jejuni. A. The spiral-shaped rod form of C. 
jejuni illustrated through light microscopy (100x). B. The same morphology illustrated 
through immunofluorescent staining with an anti-C. jejuni whole cell antibody. Both images 
are my own production. C. Transmission electron microscopy of C. jejuni showing polar 
flagella (Stevens laboratory, The Roslin Institute), 
 
 
 
1.2 Campylobacter as a cause of human diarrhoeal disease  
Campylobacter infections are the main cause of acute food-borne diarrhoeal illness in 
humans worldwide (WHO, 2011). It invades intestinal epithelial cells and causes a severe 
inflammatory reaction and diarrhoeal disease (as reviewed by Young et al, 2007).   
 
1.2.1 Clinical manifestations of Campylobacter infection in humans 
The dose required to establish infection in humans can be as low as 500 colony-forming 
units (CFU) in milk as demonstrated by Robinson (1981) who infected himself with C. jejuni 
contaminated milk. This was confirmed in other experimental studies on larger cohorts, e.g. 
Black at al (1988) demonstrated that a dose as low as 800 CFU of two different strains 
results in clinical infections in each case. The same study also demonstrated that the severity 
of the diarrhoeal disease induced by infection varies with the strain of Campylobacter and 
with the individual infected. Further modelling work on the data obtained by Black et al 
(1988) showed a slowly rising dose-response relation when considering infection only as the 
outcome (Medema et al, 1996), however the relationship between challenge dose and the 
occurrence of clinical signs did not follow a dose-related trend as the highest illness-to-
infection ratio was found at a dose of 9x104 CFU. Additional modelling work on field-
acquired infection showed a nearly sigmoidal relationship between dose and clinical 
manifestation (Teunis et al, 2005), highlighting potential differences between laboratory-
grown inocula and naturally occurring ones. 
C. 
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Following ingestion of infectious Campylobacter cells, the incubation period varies 
from 2 days to over a week, depending on the dose ingested. This data was determined by 
Skirrow and Blaser (1995) through calculations following outbreak investigations. Blaser 
(1997) describes the clinical signs of Campylobacter infections observed in developed 
countries as involving non-specific prodromal symptoms such as headache, myalgia and 
pyrexia lasting over 24h. These are followed by acute diarrhoeal illness, which is the main 
clinical manifestation and can often involve acute abdominal pain. The diarrhoea is watery 
and frequently bloody, with over eight bowel movements per day at its peak. Abdominal 
cramps may appear as severe as the pain of appendicitis. Following a peak which usually 
lasts 24-48h, the illness then gradually resolves over approximately a week, however it can 
be longer lasting in a proportion of cases. If no treatment is provided, relapses occur in as 
many as 20% of infections. To exemplify the severity of Campylobacter infections, an 
outbreak at a military base in the United States (U.S.) due to contamination of water supply 
resulted in 249 people exhibiting clinical signs of whom as many as 32% required 
hospitalisation. Infection rates varied amongst companies but were as high as 70% of 141 
recruits in the company situated in immediate vicinity to the infected water tank (DeFraites 
et al, 2014).  
In contrast, in developing countries, Campylobacter infection mainly affects children 
under the age of 5, being a major cause of morbidity and mortality (Blaser, 1997). A study 
undertaken in children under 5 years old admitted to hospital with confirmed Campylobacter 
infection in Kenya highlighted a mortality rate as high as 8.8% (O’Reilly et al, 2007). In the 
same age group, Taylor et al (1993) demonstrated potent seroconversion in 80% of 
confirmed infections and also showed that the duration of excretion following infection 
declines with age. This is suggestive of an age-related development of protective immunity 
within the population in developing countries. This is further supported by the short duration 
and less intense clinical signs in adults in developing countries (as reviewed in Coker et al, 
2002). 
 
1.2.2 Sequelae of Campylobacter infection in humans 
Although most Campylobacter infections resolve without complications, links have 
been shown to various long-lasting sequelae. Evidence is mounting to suggest that in a 
minority of cases, infection with Campylobacter can lead to chronic gastrointestinal clinical 
signs, namely inflammatory bowel syndrome (IBS) and inflammatory bowel disease (IBD), 
including Crohn’s disease. Borgaonkar et al (2006) describes that 4.2% of patients with 
Campylobacter infection developed IBS in a three month follow-up study compared to 2.6% 
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of Salmonella-infected patients. Furthermore, Spiller et al (2000) proposed an 
immunological mechanism that may contribute to the induction of IBS by Campylobacter 
and demonstrates that increased enteroendocrine cells, T lymphocytes and gut permeability 
can persist for over a year following campylobacteriosis. These findings have been 
confirmed to be a feature of patients that develop IBS following infections with enteric 
pathogens (reviewed by DuPont, 2008). Regarding IBD, it has been shown that 
Campylobacter and Salmonella infections result in an increased risk of this clinical 
manifestation, both in the short term as well as long term (15 years) and the IBDs developed 
include Crohn’s disease (Gradel et al, 2009). A novel mechanism for this disease following 
Campylobacter infection has been proposed, involving translocation of the commensal 
microflora through the intestinal wall via lipid rafts (Khalischuk et al, 2009). The increase in 
intestinal permeability and the breakdown of the normal barrier function is in line with the 
aforementioned studies that demonstrated long-term increased gut permeability following 
campylobacteriosis. In contrast, other studies found no links between the two and 
Campylobacter infection. Jess et al (2010) suggested that the perceived increased risk of 
post-infectious IBD is only due to detection bias around the time of first-hospitalisation due 
to clinical signs of IBD. 
More severe sequelae can occur, namely inflammatory neuropathies and reactive 
arthritis. A link has been shown between C. jejuni infections and Guillain-Barré syndrome 
(GBS; Tam et al. 2007), an inflammatory neuropathy that can involve transient paralysis. 
Due to the similarity of the lipooligosaccharide (LOS) present on some strains of C. jejuni 
with human neural gangliosides, antibodies raised against C. jejuni LOS during infection 
may cross-react later with neural gangliosides (Ang et al. 2002). Certain C. jejuni strains, 
e.g. ICDCC07001, have even been associated with outbreaks of campylobacteriosis and 
GBS. This strain was isolated from a 36-case outbreak of GBS in China in 2007 (Zhang et 
al, 2010). The mechanisms behind GBS induction by Campylobacter still warrant further 
elucidation but it is evident that different alleles of certain bacterial virulence factors are 
associated with the presentation or not. Koga et al (2005) showed that Campylobacter strains 
that have the cst-II(Thr5) gene, involved in the biosynthesis of ganglioside-like lipo-
oligosaccharide, are more likely to cause neurological clinical signs than strains than those 
with cst-II(Asn55). A link between Campylobacter infections and Miller Fisher syndrome, a 
variant of GBS, has also been identified (Neisser et al. 1997).  
In addition, Campylobacter infections also cause reactive arthritis or Reiter’s 
syndrome. A review by Pope et al (2007) estimates that reactive arthritis following 
Campylobacter infection can occur in between 1 and 5% of those infected and that its annual 
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incidence may be 4.3/100,000 cases. Work on reactive arthritis due to gastrointestinal 
infections is limited and further research is warranted to shed light into this manifestation 
and its causes. 
 
1.2.3 Pathological mechanisms and immune responses in acute diarrhoeal disease 
1.2.3.1 Descriptive studies in human infections 
Histopathologically, campylobacteriosis is classified as inflammatory diarrhoea as it 
has been demonstrated through colonic biopsies of infected humans that diffuse 
inflammatory colitis is induced by these bacteria and that polymorphonuclear cells and red 
blood cells (RBCs) are present in the stool of over two thirds of patients (Blaser et al, 1982). 
Pyrexia is often observed during campylobacteriosis and is another sign typical of 
inflammatory conditions. These observations are suggestive of a mechanism of pathogenesis 
involving bacterial adherence, invasion and replication within the intestinal cells, with an 
associated inflammatory response leading to blood-containing inflammatory diarrhoea (as 
reviewed in Janssen et al, 2008).  
In human patients it has been difficult to establish in vivo the roles of different arms 
of immunity but studies suggest that innate, humoral and cell-mediated arms of immunity are 
all involved in control and/or pathogenesis of this disease to varying degrees. Young et al 
(2007) reviewed the immune responses to Campylobacter infection in humans and suggest 
that a predominantly Th1 polarised (cell-mediated) immunity is likely to be responsible for 
control and clearance of infection (Fig. 1.2), with dendritic cells (DCs) and macrophages 
playing a key role. DCs were suggested to encounter and internalise C. jejuni, which induces 
secretion of NF-κB, TNFα and several other cytokines associated with maturing DCs. The 
role of macrophages in this response is less clear as different studies highlighted in this 
review gave conflicting evidence using different cell lines and strains of Campylobacter. 
This model of infection control is supported by studies undertaken in varied systems. 
Local cellular and cytokine responses are difficult to describe in humans as they would 
require invasive colonic biopsies. However, this technique has been used in a limited number 
of studies. Enocksson et al (2004) described that patients with gastroenteritis symptoms 
infected with Campylobacter have higher levels of nitric oxide release from rectal tissue. 
Following natural infection with C. jejuni for 8-12 hours, it was shown that IFNγ, IL-22 and 
IL-17A were induced suggesting induction of both innate and adaptive immunity in the 
initial phase of the infection. Furthermore, flow cytometry indicated that cells with markers 
indicative of Th1 and Th17 responses and cells with double positive Th1/Th17 markers were 
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significantly increased suggesting an involvement of cell-mediated immunity in the control 
of this disease.  
In contrast, antibody responses are easier to characterise in human patients as only 
blood samples are required. As described above, epidemiological studies suggest 
involvement of antibodies in control of the infection as observations of increasing antibody 
levels and decreasing severity of clinical symptoms has been described. Furthermore, the 
increased severity of the disease in agammaglobulinaemic or hypogammaglobulinaemic 
patients confirms the importance of antibodies in control of Campylobacter infection 
(Melamed et al, 1983). Both local mucosal IgA and serum IgG are likely to be involved in 
playing a role in different outcomes of the disease as a study of a patient that was deficient in 
IgA and IgM described long-term intestinal carriage with transient bacteraemia that cleared 
upon the induction of serum IgG (Johnson et al, 1984). Furthermore, a role of maternal 
antibodies has been suggested in humans. Children that had Campylobacter infection within 
the first 6 months of life had significantly lower maternal-derived anti-flagellum antibody 
titres at birth compared to those that did not exhibit infection (Martin et al, 1989), implying a 
possible protective role. 
 
1.2.3.2 Animal models of diarrhoeal disease 
The nature of the immune response and the molecular pathological mechanisms in 
humans associated with Campylobacter infection have been difficult to characterise due to 
the lack of adequate models of this disease. Good animal models of human diarrhoeal 
disease caused by infection with C. jejuni or C. coli are lacking, as laboratory animals are 
either not easily colonised by Campylobacter infection is either asymptomatic or elicits 
milder clinical signs. Mice are not easily colonised by Campylobacter unless they are infant 
or their intestinal flora is depleted before infection. Lee et al, 1986 described the use of a 
model in which gnotobiotic BALB/c mice had to be treated with magnesium sulphate and 
three antibiotics to acquire C. jejuni infection. 
More recently, transgenic mice have been used to develop models of human 
campylobacteriosis and have provided novel insights into the nature of the immune 
responses to this infection, however their findings are seldom validated in human patients. 
For example, Watson et al (2006) report efficient colonisation of MyD88-deficient mice by 
C. jejuni which suggests a role for toll-like receptors (TLRs) in the immune response in this  
8 
 
 
Figure 1.2 Model of the immune response in human Campylobacter infection leading to 
pathogenesis and clearance. (Proposed by and adapted from Young et al, 2007). C. jejuni 
interacts with human intestinal epithelial cells and invades them. Secretion of IL-8 and other 
pro-inflammatory cytokines by these cells attracts neutrophils, macrophages and dendritic 
cells at the site of infection and sets up the milieu for a highly pro-inflammatory 
environment. 
 
host as MyD88 is involved in signal transduction through most TLRs. It was also 
demonstrated that such mice can resolve phenotypes of bacterial mutants lacking known 
virulence factors, however, their usefulness for immunological studies may be precluded by 
impaired immune response in an arm of native immunity known to be essential in defences 
against bacterial infections. In contrast, Stahl et al (2014) demonstrate that Sigirr-/- C57BL/6 
mice that have upregulated MyD88 signalling exhibit severe gastroenteritis, similar to the 
human condition. It was shown that in this infection model, the mice have an increased 
Th1/Th17 cytokine profile, suggesting a role of cellular immune responses in the 
pathogenesis and possibly resolution of this disease. Furthermore, the same study described a 
protective role of TLR2 in preserving mucosal integrity and reducing clinical symptoms and 
a pro-inflammatory role of TLR4 in the enteritis symptoms observed. The increased Th1 
cytokine profile in this study is in line with the observations of Edwards et al (2010) 
described above. 
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Other animal models include a model of haemorrhagic diarrhoea in gnotobiotic 
colostrum-derived neonatal piglets (Babakhani et al, 1993), however, using animals at such a 
young age without a fully-developed immune system and intestinal microbiota may not 
adequately replicate the nature of the immune response in human adult diarrhoea. Ferrets 
have provided a more adequate model of human infection as they can become colonised by 
C. jejuni and develop diarrhoea. However, they are not as widely available and the disease is 
mild and transient in adult ferrets (Bell and Manning, 1990) and only mimics human adult 
diarrhoea in weaning-age animals (Fox et al, 1987). Some of the closest models of human 
infection have been developed in primates (Russell et al, 1989; Baqar et al, 1995), however, 
these are only rarely available.  
A contribution of the human microbiota to the outcome of the infection and the 
nature of the immune responses has been described. Bereswill et al (2011) reported that 
gnotobiotic mice given human microbiota can be easily and stably colonised by C. jejuni. In 
contrast to mice with typical murine microbiota, those with human microbiota exhibited a 
more severe infiltration of T- and B-lymphocytes, regulatory T cells and neutrophils and 
increased concentration of TNFα, IL-6 and monocyte chemoattractant protein 1 (MCP-1) in 
their colonic mucosa. This study confirms the findings of Stahl et al (2014) that TLR4 plays 
a central role in pathogenesis but also demonstrated a role for TLR6 in this processes. 
In addition to the above studies pointing towards a Th1-biased response in 
Campylobacter-induced colitis, Malik et al (2014) further describe the nature of the immune 
responses in a mouse colitis model. Their study shows a role for both innate and adaptive 
immunity in the induction of colitis as Thy1+ lymphocytes were shown to be required for the 
appearance of this presentation but they were insufficient as Rag1-/- mice did not exhibit 
colitis. Furthermore, this study also showed that colitogenic (C. jejuni 11168) or GBS-
inducing strains (C. jejuni 260.94) induce different responses, with colitogenic strains 
biasing the response towards Th1 immunity and antibodies of the IgGb, IgG2c and IgG3 
isotypes and GBS-inducing strains biasing responses towards Th2 immunity and antibodies 
of the IgG1 isotype. While Th2-type immunity was required for the induction of IgG1 
antibodies cross-reacting to human neural gangliosides GM1 and GD1a, it appeared that 
their cross-reaction was a property of the strain used as IgG1 antibodies against 11168 raised 
in a Th2-biased response in IL-17 and IFNγ depleted mice did cross-react with human neural 
gangliosides (Malik et al, 2014). 
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1.2.3.3. In vitro studies using human tissue cultures 
Due to the above limitations, the immune response in humans has also been 
characterised through studies undertaken in vitro in human cell cultures. Hickey et al (1999) 
showed that C. jejuni induces secretion of interleukin 8 (IL-8) from INT407 cells, that it 
required live bacterial cells and invasion, and that induction and release of IL-8 occurs early 
in the interaction of bacterial and eukaryotic cells. Al-Saloom et al (2003) showed that C. 
jejuni induces release of IFN-γ, IL-10, TNF-α and IL-4 from INT407 cells and Bakhiet et al 
(2004) showed that the same cells presented with C. jejuni produce IL-8, CCL4 and CCL2 
but not CCL3 or CCL5. Caco-2 cells, a human colonic epithelial line, have been proposed as 
a model of intestinal epithelia as a polarised layer of these cells was successfully used as a 
model for invasion and transcytosis (Everest et al, 1992). Furthermore, they were shown to 
have increased mitogen-activated protein kinase (MAPK), which plays a role in many host 
signalling pathways, following C. jejuni infection, similarly to primary human colonic tissue 
(MacCallum et al, 2005). Based on in vitro studies, a model of invasion of intestinal cells has 
been described by O’Croinin and Backert (2012), highlighting host factors involved in this 
process (summarised in Fig 1.3). 
A limitation of such studies is that monocellular tissue cultures lack the complexity 
of immune responses induced in whole organisms. While they can identify individual 
molecules involved in immune responses, the relative contribution to these molecules to the 
immune response generated in an entire organism is difficult to assess without further 
confirmatory studies. Furthermore, different cells lines vary in their response to infection. 
MacCallum et al (2006) confirmed IL-8 secretion from INT407 cells but demonstrated 
minimal IL-8 secretion from Caco-2 cells and levels of IL-8 secretion from HeLa and T84 
cells matching that of primary human intestinal tissue. 
 
1.2.4 Bacterial virulence factors involved in human diarrhoeal disease 
The majority of Campylobacter virulence factors that have been well-characterised, 
such as the flagellum and systems for nutrient acquisition, chemotaxis and oxidative stress 
resistance play a conserved role in the colonisation of most hosts that Campylobacter is able 
to infect (reviewed by Wassenaar and Blaser, 1999). However, there are some virulence 
factors that have been described to be implicated in human disease, including the interplay 
with the particular types of immune responses elicited by the human hosts.  
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Figure 1.3 A hypothetical model of C. jejuni invasion into host intestinal cells. This 
diagram, reproduced from O’Croinin and Backert (2012) summarises some of the bacterial 
and host factors leading to attachment and successful establishment of Campylobacter 
infection in the human host. Authors propose that, following interaction between numerous 
described and unknown virulence factors (marked with “?”) of C. jejuni and the described 
host cellular factors, local actin and tubulin re-arrangement at the site of attachment of C. 
jejuni result in engulfment and bacterial uptake. 
 
Campylobacter invasion into intestinal cells is considered more common in human 
infections than in infections of other hosts. With regards to the model of invasion described 
above, while both microfilaments and microtubules are likely to be involved in membrane 
re-shaping around the invading C. jejuni cells, it is unclear as to which are the major 
contributors. Hu and Kopeko (1999) showed that the interaction between microtubules and 
Campylobacter is crucial for invasion as inhibition of actin polymerisation did not reduce C. 
jejuni invasion but inhibition of tubulin polymerisation nearly abolished invasion. In 
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contrast, Biswas et al (2003) described that inhibition of microfilament formation had a 
greater inhibitory effect on C. jejuni invasion than inhibition of microtubule formation. 
In addition to direct invasion, production of toxins has been implicated in the 
pathogenesis of diarrhoeal disease. Although typical enterotoxins (cytotonic enterotoxins 
similar to those of V. cholerae and E. coli) have not been identified in Campylobacter (as 
reviewed by Wassenaar and Blaser, 1999), cytotoxins have been described. Wassenaar 
(1997) reviewed the Campylobacter proteins that were shown to have cytotoxic activity and 
may be involved in pathogenesis of the human disease and classified them into six groups: a 
70kD cytotoxin, a Vero/HeLa cell cytotoxin, a cytolethal distending toxin (CDT), a Shiga-
like toxin, haemolytic cytotoxins and hepatotoxins. The sequencing of the C. jejuni genome 
(Parkhill et al, 2000) revealed that C. jejuni 11168H did not contain a cholera-like toxin gene 
but confirmed the presence of CDT and highlighted the presence of a contact-dependent 
haemolysin (CJ0588), a membrane protein with a haemolysin domain (Cj0183) and a 
phospholipase (PldA). 
The activity of most of the Campylobacter proteins that have been described as 
cytotoxins remains poorly characterised. The Campylobacter CDT (one of the bacterial 
virulence factors well characterised in other pathogens) has been shown to have a similar 
role to that from E. coli, in that it arrests the cell cycle and leads to cell death (Johnson et al, 
1988). It has also been shown to be recognised by the human immune system but not by the 
chicken (AbuOun et al, 2005). Even so, it is insufficient to cause the observed clinical signs 
on its own as Mortensen et al (2011) showed that no differences in the clinical outcome of 
patients infected with Campylobacter strains with different titres of CDT. Although well 
characterised in other bacterial species, the Campylobacter Shiga-like toxin has only been 
reported in one study and as such it presence and role remains anecdotal (Moore et al, 1988) 
and was not confirmed by the sequencing of C. jejuni’s genome (Parkhill et al, 2000). 
Furthermore, even though Campylobacter do not possess a classical type III 
secretion system (T3SS), they have been proposed to be able to secrete effectors into host 
cells through flagella, which are considered T3SS analogues (Neal-McKinney and Konkel, 
2012). Approximately 10% of C. jejuni strains have also been shown to possess a type VI 
secretion system (T6SS) which induces haemolysis in capsule-deficient strains and has been 
isolated from patients that developed bacteraemia (Bleumink-Pluym et al, 2013). Konkel et 
al (1999) described the Campylobacter invasion antigens (Cia) excreted through the 
flagellum and showed that they are involved in invasion of host cells as mutants lacking 
CiaB bound equally well to host cells as the wild-type (WT) but significantly lower numbers 
of C. jejuni were found intracellularly. Furthermore, it was shown that for these proteins to 
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exert their function an intact flagellar hook (composed of FlgE, FlgK and FlgL) was required 
for their delivery into host cells (Neal-McKinney and Konkel, 2012).  
With regards to other possible factors involved in human disease, Jin et al (2003) has 
shown that JlpA, a surface lipoprotein mediates attachment to host epithelial cells (Jin et al, 
2001), interacts with Hep-2 cell surface heat shock protein and induces activation of NF-
kappaB and p38 MAP kinase, that stimulate inflammatory responses in host cells. CadF 
(Konkel et al, 2003) and FlpA (Flanagan et al, 2009) have also been described as adhesins. 
More recently, transposon mutagenesis of a hyper-invasive clinical isolate identified 
additional virulence factors and highlighted Cj01/51_0497 as a potential adhesin (Javed et al, 
2010). Another transposon mutagenesis screen identified aspA, aspB and sodB as required 
for survival in within epithelial cells (Novik et al, 2010). 
 
1.2.5 Epidemiology of Campylobacter infection in humans  
Campylobacter is the leading cause of acute food-borne diarrhoeal illness in humans in 
the developed world. DEFRA (2011) reported that following the introduction of an effective 
anti-Salmonella vaccine in the poultry industry in late 1990’s, Campylobacter replaced non-
typhoidal Salmonella as the most common foodborne gastrointestinal pathogen in the UK.  
 
1.2.5.1 Incidence and economic burden 
In 2013, 66,575 laboratory-confirmed cases of human campylobacteriosis were 
recorded in the UK, most due to C. jejuni subspecies jejuni and C. coli (DEFRA, 2015). 
Furthermore, the Infectious Intestinal Diseases (IID) II study estimated that for every case 
captured by national surveillance, a further 9.3 cases occur in the community but are not 
recorded owing to the mostly self-limiting nature of the disease and the lack of laboratory 
investigations (Tam et al. 2011). As such the true burden of human campylobacteriosis in the 
UK may be c. 700,000 infections per annum. The majority of human campylobacteriosis 
represents sporadic cases, however outbreaks are occasionally recorded. The most common 
cause for these is the consumption of undercooked chicken liver parfait (HPA, 2011). The 
latest Zoonoses Report (DEFRA, 2015) highlights 19 outbreaks during 2013, a significant 
increase on the 8 reported in 2012, with 14 being food-borne and 9 of these due to chicken 
liver parfait. Figure 1.4 below highlights the increasing number of laboratory-confirmed 
Campylobacter infections in humans between 1992 and 2012 and it is apparent that apart 
from a period of reduction between 2000 and 2004, the incidence of human infections has 
generally risen. These infections have a high recurring economic and societal cost. The cost 
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of foodborne illness in the UK has been estimated at approximately £1.8 billion per year 
(FSA, 2013). As Campylobacter is responsible for ~60% of foodborne illness and 92% of 
hospital admissions due to these (FSA, 2013), it may be inferred that the cost of human 
campylobacteriosis is in the region of £1 billion/year in the UK. The problem is not limited 
to the UK as the European Food Standards Agency estimates that there are nine million cases 
of human campylobacteriosis per year across EU27 countries, with the disease and its 
sequelae causing 0.35 million disability-adjusted life years per annum at an annual cost of 
€2.4 billion (EFSA, 2011).  
 
 
 
Figure 1.4 The trend of laboratory-confirmed cases of Campylobacter infections in the 
UK between 1992 and 2012. A. The number of laboratory-confirmed cases between 2000 
and 2012, as given in the DEFRA Zoonoses report for each year, demonstrating the 
reduction in Campylobacter cases between 2000 and 2004. B. Incidence of Campylobacter 
in the UK between 1992 and 2012. Numbers are given as cases per 1000,000 of population. 
(Data adapted from DEFRA Zoonoses Report 2000 and DEFRA Zoonoses Report 2012 for 
the number of Campylobacter infections and the Office for National Statistics for population 
estimates between 1992 and 2012). 
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1.2.5.2 Source of human Campylobacter infections 
While poultry have been recognised as the main source of infection with C. jejuni, recent 
advances in molecular typing and high-throughput sequencing have allowed the assignment 
of relative contributions of sources of infection to the burden of human disease. Studies 
carried out in Scotland (Sheppard et al, 2009; Fig. 1.5) and England (Wilson et al, 2008) 
indicated that, second to poultry, sheep and cattle are the next major sources of 
contamination, with the environment and wild birds playing smaller roles. . Furthermore, 
even studies in other countries have observed a similar pattern of source attribution of 
campylobacteriosis, e.g. in New Zealand (Mullner et al, 2009) it was shown that chickens 
are the main source of human infection and, uniquely, it was possible to assign cases to three 
major retailers due to the particular structure of the poultry industry in the country. More 
recently Sheppard et al (2014) described specialist and generalist lineages of C. jejuni and 
provided evidence of recombination amongst generalist and specialist species of a common 
lineage but little recombination amongst different generalist lineages. Due to this, they 
propose a cryptic niche structure that acts as an ecological barrier to recombination. 
Furthermore, Dearlove et al (2015) suggest that high rates of host-switching amongst 
generalist lineages of Campylobacter may hinder source attribution but even so the majority 
of clinical cases can be attributed to chickens sources. 
While sources other than those mentioned above may contribute to human cases, 
these represent a minor contribution. For example, although campylobacteriosis has been 
reported in pets, particularly dogs, it has been shown that they are colonised mainly by other 
species than those commonly pathogenic to humans and that the prevalence of C. jejuni was 
only 1.2% (Parsons et al, 2010).  
 
Figure 1.5 Source attribution of human clinical Campylobacter cases. (Adapted from 
Pascoe et al, 2013) A. Sources of infection for human Campylobacter cases. These are: 
chickens (yellow), cattle (blue), sheep (grey), wild birds (brown) and the environment 
(green) B. Probabilistic model of source attribution of human clinical Campylobacter cases. 
Each vertical bar represents a single isolate and the different colours indicate the probability 
of it originating from each of the sources described in panel A. Up to 70% of human 
infections in Scotland are predicted to have originated from chickens in the period studied. 
A 
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1.2.5.3 The avian reservoir as a source of human infection 
Up to 80% of the total number of infections may be attributable to the avian 
reservoir as a whole (Wilson et al, 2008; Müllner et al, 2010; Dearlove et al, 2015) and 
within this category, handling or consumption of contaminated poultry meat is the main 
source of C. jejuni infection in humans. In Scotland, Sheppard et al (2009) attributed 
between 58% and 78% of C. jejuni and between 40% and 56% of C. coli isolates from 
humans (depending on the model used for data analysis) to contaminated chicken meat. This 
is in agreement with earlier findings of Kramer et al (2000) who showed that Campylobacter 
isolates in chicken and lamb on retail sale shared the most subtypes with human 
Campylobacter isolates. In this study, chicken meat also showed the highest prevalence of 
Campylobacter contamination (83.3%), followed by lamb (72.9%). 
In accounting for the difference between cases attributed directly to contaminated 
chicken meat and the avian reservoir as a whole, wild birds and pet chickens may also pose a 
threat to human through indirect transmission via environmental contamination. For 
example, Thomas et al (1998) reviewed the evidence available for Campylobacter infection 
from aquatic sources, including both untreated and contaminated mains water. Although 
traditionally thought to be a pathogen with specific requirements for survival, Rollins and 
Colwell (1986) showed the presence of viable but non-culturable stages in water. 
Furthermore, poultry other than chickens are likely to contribute to human 
campylobacteriosis as Campylobacter has been reported in turkeys (39% of turkey on retail 
in the USA was found to be contaminated; Loque et al, 2003), pheasants (70% of farmed 
pheasants in the Czech Republic; Nebola et al, 2007) and other birds destined for human 
consumption. 
The previous two reports of the UK Food Standards Agency (FSA) showed that 
between 2005 and 2009 levels of Campylobacter contamination of poultry carcasses on sale 
did not change significantly being approximately 70% in 2005 (FSA, 2005a) and 64.5% in 
2009 (FSA, 2009a), despite targets set for a 50% reduction within that period. In another 
attempt to control human campylobacteriosis, in 2010 the FSA made reduction of food-borne 
campylobacteriosis a key aim for their 2010-2015 strategic plan and their Campylobacter 
Risk Management Programme aims to reduce the proportion of highly contaminated 
chickens (>1000 colony-forming units/g faeces) from 27% in 2008 to under 10% in 2015 
(FSA, 2010a).  Despite this renewed target, the latest FSA survey has indicated no reduction 
in Campylobacter isolated from chicken on sale in the UK. Following a year-long survey, 
the FSA announced that in 2015 an average of 73% of raw chicken on sale was contaminated 
and that 19.4% of chickens were contaminated with >1000 CFU/g (FSA, 2015a). While 
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there has been a reduction in the proportion of the highest contaminated group from 27% in 
2008 to 19.4% in 2015, this is still far from achieving the 10% target set by the FSA in 2010. 
  Post-slaughter processing is an important source of carcass contamination and Allen 
et al (2007) showed that processing practices can lead to high level colonisation of chicken 
carcasses. Commonly 100% of processed carcasses are contaminated with an average of 5.3 
log10 CFU and even carcasses from flocks with low or no Campylobacter colonisation 
present become contaminated post-processing (Allen et al, 2007). The caecal load of C. 
jejuni frequently exceeds 108 CFU/g, meaning that even milligram quantities of intestinal 
contents can present a significant threat of contamination. This is particularly worrying 
considering that the human infectious dose is very low, thought to be <500 bacterial cells 
(FSA, 2005b). The same document mentions that studies to determine the exact number of 
cells associated with contaminated poultry that will cause human infection were inconclusive 
but examination of a bottle of bird-pecked milk which was of a batch implicated in a nursery 
outbreak showed contamination levels of under 10 cells of C. jejuni per 100 ml, lower than 
the reported in previous studies (Black et al, 1988). When considering the avian reservoir as 
potential for contamination of other food-sources, evidence suggests that the level of 
Campylobacter transmission between chickens and other farm animals is low (Boes et al, 
2005). 
 
1.2.5.4 Temporal and spatial epidemiology of Campylobacter infection in chickens 
and humans 
Louis et al (2005) revealed in a review of human campylobacteriosis cases between 
1990 and 1999, spatial and temporal differences in epidemiology. There were regional 
differences in the number of Campylobacter infections in the UK (Wales and the SW of 
England having higher numbers than the SE of England), differences in seasonality 
(increases in Campylobacter cases correlated with temperature) and differences in gender of 
infected subjects (males more than females). This study also found a correlation between the 
seasonality of human infections and temperature. The seasonal trends and gender differences 
in human infection were replicated in other studies within the UK (Cody et al, 2012). 
A similar seasonal trend has been described in chickens: Meldrum et al (2005) reported 
that in 2002 in Wales human cases peaked between weeks 22 and 25 (early June) while 
chicken cases peaked between weeks 24 and 26 (late June) and suggest that the peak in 
humans is not due to a rise in chicken contamination. In support of this assumption, other 
studies identified that the seasonality in chickens is related to sunshine hours, temperature 
and rainfall (Wallace et al, 1997; Jorgensen et al, 2011). These studies indicate that the 
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seasonal pattern of human and chicken Campylobacter infection is linked to the environment 
and that successful strategies for control of infections with this pathogen will most likely 
have to combine interventions addressing both food-borne and environmental infections. 
 
 
1.3 Campylobacter infections in chickens 
1.3.1 Characteristics of the infection in chickens 
In contrast to human campylobacteriosis, Campylobacter infections in chickens are 
often asymptomatic. In chickens, Campylobacter colonises mainly the caeca, large intestine 
and cloaca, with densely packed Campylobacter cells observed in mucous crypts (Beery et 
al, 1988) but it does not typically induce a profound inflammatory response or clinical signs 
in chickens or turkeys (Lam et al, 1992). Campylobacter can frequently reach numbers as 
high as 108 CFU/g of caecal contents (Hue et al, 2011) or even higher (as observed in our 
experimental studies) and this high level of colonisation of chickens, combined with the 
slaughter practices utilised by the poultry industry leads to a high level of carcass 
contamination.  
Even though older studies describe Campylobacter as an avian commensal, more 
recent studies highlighted that C. jejuni elicits prolonged inflammatory responses, damage to 
intestinal mucosa and diarrhoea in some commercial breeds of broiler chicken (Humphrey et 
al, 2014). Moreover, it was recently reported that C. jejuni adversely affects villus 
morphology, epithelial barrier integrity and body mass gain in broilers (Awad et al, 2015), 
with defects in energy retention possibly being due to repression of nutrient uptake systems 
(Awad et al, 2014). Field data supporting these experimental observations has been obtained 
for the first time in the UK (Nick Sparks, personal communication). Campylobacter-positive 
birds are also more likely to exhibit digital dermatitis and signs of colibacillosis (Bull et al, 
2008), though causal links have yet to be formally proven. Furthermore, Young et al (1999) 
recovered Campylobacter from the liver of day-old Leghorn chicks infected with C. jejuni 
and, even though low level, the invasiveness of C. jejuni in chickens further suggests that 
this bacterium is not a true commensal in this host. The relevance of spread of C. jejuni from 
the gut to liver is evidenced by the outbreaks due to undercooked chicken liver pate and 
parfait (DEFRA, 2015). 
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1.3.2. Immune responses to Campylobacter infection in chickens  
Young et al (2007) reviewed the immune responses during chicken colonisation and 
describe differences compared to responses in humans (Fig. 1.6). They describe that, in 
contrast to the human infection, C. jejuni resides primarily in the mucous layer in the 
chicken, with lower levels of invasion in the intestinal mucosa. Even though heterophils and 
macrophages are recruited to the site of infection, there is no subsequent strong 
inflammatory response as in humans. While some host and pathogen factors that may 
contribute to this apparent tolerance towards Campylobacter in the chicken have been 
described, the exact mechanisms that lead to persistent colonisation in the chicken are yet to 
be elucidated. Evidence on the nature of the immune response in chickens from experimental 
and natural infections is reviewed below. 
 
 
Figure 1.6. Summary of immune responses to Campylobcter in chickens and outcome of 
infection (adapted from Young et al, 2007). Campylobacter reside mainly in the mucous 
layer in the chicken and do not invade the intestinal mucosa to a level as high as in human 
infection. The exact mechanisms that lead to apparent tolerance of Campylobacter and its 
long term persistence in the avian host have not yet been elucidated (denoted by the question 
marks). 
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1.3.2.1 Humoral immune responses 
 The nature of the immune response induced by Campylobacter following natural 
infection of broilers has been described extensively, however, the majority of studies focused 
on humoral responses due to them being relatively easier to describe than the cellular arm of 
immunity. Even though studies have described the ability of 2-day-old chicks to be as 
efficiently colonised as 2-weeks-old chicks by C. jejuni through direct oral or cloacal 
challenge (Shanker et al, 1988) or in seeder challenge models (Shanker et al, 1990), multiple 
epidemiological studies have described that broiler flocks are commonly negative for 
Campylobacter until 2-3 weeks of age. Smitherman et al (1984) describes that chicks housed 
in sheds in which the previous batch of birds was Campylobacter positive only become 
positive at 12 days of age when the litter is not changed or at 40-46 days of age when the 
litter is changed. Such findings were reproduced by Genigeorgis et al (1986), Lindblom et al 
(1986) and others.  
Subsequent studies suggest that maternal anti-Campylobacter antibodies transmitted 
in egg yolk are responsible for this delay in colonisation. Sahin et al (2001) measured the 
levels of anti-C. jejuni IgG in sera of chicks originating from Campylobacter infected layers 
and describe that decreasing antibody titres at weeks 3 and 4 of age coincided with the 
incursion of Campylobacter into the flocks. Furthermore, this observation was validated 
experimentally as Sahin et al (2003) showed a significantly lower percentage of chicks 
colonised by C. jejuni following challenge at 3-days-old if they originated from birds raised 
at specified pathogen-free (SPF) status that had been experimentally infected with C. jejuni, 
compared to chicks originating from non-infected birds. More recently, experimental 
infection studies have identified individual proteins that are recognised by these maternally-
derived antibodies (Shoaf-Sweeney et al, 2008) and some of these are discussed later as 
potential vaccine candidates. Some of these proteins have been independently validated as 
being immunogenic in adult birds infected with C. jejuni: Cawthraw et al (1994) showed that 
flagellin is the immunodominant antigen in experimentally infected day-old chicks, Yeh et al 
(2015) identify FlgE1, FlgK, FlhF, FliG and FliY as the predominantly immunogenic 
proteins within the flagellum apart from flagellin and Yeh et al (2014a) identified Cj0473 of 
C. jejuni D1-39 as the predominantly immunogenic chemotaxis protein from the 15 tested. 
An alternative hypothesis that has been proposed for the delay in incursion of 
Campylobacter into broiler flocks is the effect of the intestinal microbiota. However, 
Shanker et al (1990) did not significantly change the susceptibility of chicks to 
Campylobacter colonisation following treatment with adult microflora. Furthermore, 
Skanseng et al (2013) showed that although increasing complexity of feed can reduce 
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Campylobacter spread within a flock, individual diet components did not have an effect on 
its spread from bird to bird. Even in the face of a reduction in Campylobacter transmission 
between birds, the microbiota only changed significantly in the upper, but not the lower, 
intestine following introduction of complex feed. 
 
1.3.2.2 Cellular immune responses 
In vitro studies of immune molecular mechanisms induced in the chicken by 
Campylobacter infection are few. Smith et al. (2005) showed that INT407 cells and 
epithelial chicken kidney cells (CKC) were both similarly invaded by C. jejuni 11168H. 
However, in in vitro cultures of HD11 chicken macrophage cell line, C. jejuni showed 
decreased survival when these cells were pre-treated with recombinant chicken IFN-γ, 
suggesting a possible role of this type of immune response, which was described as 
protective in humans, in resistance to colonisation. Furthermore, avian HD11 cells and CKCs 
increase their production of IL-1β, IL-6 and IL-8 in response to infection with C. jejuni, 
suggesting that the outcome of infection in chickens is not due to their inability to develop a 
pro-inflammatory response. Another study investigated comparatively the activation of 
chicken and human immune responses following Campylobacter infection (de Zoete et al, 
2009). It was shown that both human MM6 monocytic cells and chicken HD11 macrophages 
secrete similar levels of IL-8 and IL-1β, with higher activation by lysed Campylobacter cells 
compared to live intact cells. Furthermore, in the same study, various Toll-like Receptors 
(TLRs) were transfected into HeLa 57A or HEK293 cells. Notably, even though both live 
and lysed Campylobacter activated both human and chicken TLR4 similarly as evidenced by 
similar amounts of NF-κB, there was a marked difference in the expression profile of IFN-γ 
between chicken and human cells stimulated with either live or lysed bacteria. This 
suggested that signalling through the MyD88-independent pathway via TLR4, with 
subsequent activation of IFN-γ inducible genes, is reduced in the chicken and may partially 
explain differences in the outcome of infection in these two hosts as it has been shown that 
there is an association between the level of IFN-γ expression in humans and protection from 
illness (Tribble et al, 2010; Section 1.2.3).  
In vivo, Smith et al. 2008 showed that experimental Campylobacter infection in both 
day-of-hatch and 2-week-old Light Sussex chickens induced a significant, but time- and 
magnitude-limited, increase in production of pro-inflammatory cytokines. In both age 
groups, CXCLi1 and CXCLi2 were significantly increased at 12-24h post-infection in caecal 
tissue while CXCLi1 was also increased in ileal tissue in the 2 week-old group and levels of 
both cytokines decreased by day 7 in both groups. Kogut (2002) has shown that CXCLi1 and 
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CXCLi2 are both involved in chemotaxis of phagocytes which is in accordance with the 
findings of Smith et al (2008) that there was a significant increase in the number of 
heterophils in both caecal and ileal sections (only in the two week-old group). 
Furthermore, the pattern of TLR activation has also been characterised in vivo and 
supports the findings of the in vitro studies mentioned above. Shaughnessy et al (2009) 
compared activation of TLR gene expression by Salmonella and Campylobacter infections in 
chickens and report that TLR4 and TLR21 expression is increased by both genera of bacteria 
and TLR5 and TLR15 was increased by Salmonella only. The same study highlighted also 
that although both bacteria increased TLR4 expression, expression of IFN-γ was only 
induced in response to Salmonella infection, suggesting a role of cell-mediated immunity in 
clearance of Salmonella. This was demonstrated by Beal et al (2006), who showed that 
antibody-deficient surgically-bursectomised chickens clear primary and secondary 
Salmonella infections just as effectively as intact birds. While the contrast between the 
outcomes of these two infections suggests a possible lack of activation of cell-mediated 
immunity in Campylobacter infections may lead to its long-term persistence, studies to 
formally test this hypothesis not been performed in chickens to date. 
Even though the differences in host immune responses in chickens and humans have 
been characterised, the extent of evasion or subversion of host responses by Campylobacter 
leading to long-term colonisation in chickens are not fully understood. The mechanisms 
through which Campylobacter appears not to induce adequate Th1-polarised immunity and 
through which the initial pro-inflammatory immune response is dampened remain to be 
clearly defined. Apart from mechanisms of bacterial immune subversion described below, 
Bingham-Ramos et al (2008) has shown that Campylobacter also colonises the Bursa of 
Fabricius in chicks of up to 28 days at levels of between 104 to 107 CFU/g tissue and 
suggested that this may play a role in the modulation of the avian immune response to 
Campylobacter, resulting in partial tolerance and a low inflammatory response to its 
presence. 
More recent experiments tried to characterise the changes in gene expression 
following infection of chickens with Campylobacter through RNA sequencing. Connel et al 
(2010) reported that genes involved in innate immune responses, cytokine signalling, B and 
T cell activation and immunoglobulin production were significantly upregulated in resistant 
birds compared to susceptible birds. However, due to the high number of genes that change 
expression and lack of subsequent validation, interpretation of specific immune mechanisms 
responsible for this difference is difficult. 
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1.3.3. Campylobacter factors influencing colonisation in chickens 
As reviewed by Hermans et al (2011), identification of Campylobacter factors that 
influence colonisation in chickens has been aided by the ability to screen random and 
defined mutants in experimental animals. As is the case for human infection (Grant et al, 
1993; Newell et al, 1985), the flagellum has been shown to be important in colonisation of 
the avian host. The C. jejuni flagellum is composed of two flagellar subunits, namely FlaA 
(major flagellin) and FlaB (minor flagellin) and it has been shown that while both are 
important for a fully functional flagellum, FlaA only is sufficient for motility (Guerry et al, 
1991). Grant et al (1993) showed that mutants in FlaA and FlaB adhere equally well to cells 
in culture but they exhibited decreased internalisation, suggesting that the presence of both is 
required for full flagellar function. Although both proteins form a heterodimer along the 
length of the flagellar filament, it appears that FlaB epitopes are poorly surface-exposed 
(Guerry et al, 1991). In vivo, the presence of the major flagellin, FlaA, has been 
demonstrated to be vital for chicken colonisation as a mutant lacking this gene did not 
colonise chickens (Wassenaar et al, 1993). Independent reports confirmed FlaA as essential 
for colonisation (Jones et al, 2004). A mutant that was able to assemble FlaA-only flagella (it 
was lacking only FlaB) had 100-fold enhanced colonisation compared to the WT (Wassenaar 
et al, 1993). Furthermore, the same study showed that high and low motility C. jejuni 
mutants expressing FlaA only were both able to colonise chickens, suggesting that the 
presence of flagella rather than motility per se is vital. This hypothesis is also supported by 
studies indicating the ability of non-motile C. jejuni mutants to colonise when given at high 
doses (Wosten et al, 2004). Mutations in other flagellar genes have been show to result in 
abolished colonisation, e.g. FlgK (Fernando et al, 2007), however such mutations completely 
abolish the formation of the flagellar filament. 
As well as the presence of flagella, their glycosylation may contribute to long-term 
persistence in the chicken by allowing C. jejuni to evade the immune response to flagellin 
(Szymaski et al, 2003). The major modification of Campylobacter flagella is based on strain-
specific derivatives of pseudaminic acid (Thibault et al, 2001) and mutants lacking this 
flagellar modification have been shown to be attenuated in vitro and in a ferret model of 
diarrhoea (Guerry et al, 2006). Campylobacter flagella can also contain strain-specific 
legionaminic acid modifications (McNally et al, 2007). Howard et al (2009) showed that 
mutation of the cj1324 gene in the O-linked flagellin glycosylation island results in the 
absence of two legionaminic acid glycan modifications and a reduction in the potential to 
colonise chickens. Furthermore, the same study described the wide spread presence of these 
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two modifications in chicken isolates, suggesting that certain glycan-modifications of 
flagellin may be associated with adaptation to particular hosts. 
In addition to flagellar presence and glycosylation, numerous other colonisation 
factors have been described (reviewed by Hermans et al, 2011) and these are involved in 
chemotaxis, bile resistance, immune evasion through glycosylation, temperature regulation 
and heat-shock responses, oxidative stress defences, iron transport, nutrient uptake and 
metabolism. Additionally, particular factors involved in adhesion to chicken intestinal cells 
have been described more recently and have shown promise as vaccine candidates, e.g. the 
adhesins CadF (Konkel et al, 2003) and FlpA (Flanagan et al, 2009). Evidence for the role of 
some of these factors in chicken colonisation is described in Section 4.1 in relation to their 
use as vaccine candidates against Campylobacter colonisation in chickens. 
In studies using signature-tagged transposon mutagenesis, Hendrixson and DiRita 
(2004) reported factors required for colonisation to include flagellar-associated proteins (the 
flagellar motor proteins MotA and MotB and the flagellar hook protein FlgK), chemotaxis 
regulating proteins (CheY), proteins involved in glycosylation (PglE, F and H) and proteins 
proposed to be involved in oxidative defence mechanisms (DocA). Some of these proteins 
were validated in a high-throughput sequencing study using signature-tagged transposon 
mutagenesis (Johnson et al, 2013). This latter study also described additional factors that 
may be involved in colonisation, such as additional flagellar proteins, including the flagellar 
capping protein FliD, methyl-accepting chemotaxis proteins, iron ABC-transporter protein 
and other transmembrane transporter proteins. The capsule was inferred as important in 
chicken colonisation in an independent signature-tagged transposon mutagenesis study 
(Grant et al, 2005) as it was consistently absent from colonised birds. However, the same 
study also revealed the stochastic nature of mutant loss and colonisation when using 
Campylobacter as the identity of the mutants that colonised and were lost was different 
between experiments and birds within the same experiment. As such, genes found to be 
involved in colonisation from such studies should be interpreted with caution unless 
validated through colonisation studies using single mutants. A capsule-deficient mutant 
(ΔkpsM) was shown to be attenuated in colonisation/disease causation in chicken, ferret and 
murine models of campylobacteriosis (Jones et al, 2004; Bacon et al, 2001; Maue et al, 
2013) and another capsule-deficient mutant (ΔkpsE) showed a 2log10 CFU C. jejuni/g caecal 
contents reduced colonisation in chickens (Bachtiar et al, 2006). Some of the above-
mentioned genes have also been found to be up-regulated in a transcriptional profiling study 
of C. jejuni 11168H using microarray analysis of genes expressed during chicken infection 
(Woodall et al, 2005).  Apart from upregulation of genes involved in electron transport and 
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central metabolic pathways, suggesting a change in physiological state of Campylobacter 
during adaptation to the chicken intestinal environment compared to growth in broth culture, 
iron acquisition genes (chuA and chuB) and oxidative stress defence genes (cj0020c and 
cj0358) were highly upregulated. 
 
1.3.4 Risk factors for Campylobacter infection in chickens 
 As mentioned above, there is a summer peak of Campylobacter infection in both 
humans and chickens. A major study investigating risk factors for Campylobacter 
colonisation of farmed broilers identified the months of July, August and September as 
having an increased risk of chicken colonisation (Ellis-Iversen et al, 2009). The presence of 
cattle on or near the farm also increased the risk of infection. In addition, the practice of 
thinning or partial depopulation has been demonstrated to have a major impact on flock 
positivity. Humphrey et al (1993) first described that farms that do not practice boot dipping 
become colonised with Campylobacter by day 10, whereas those that used a phenolic 
disinfectant remained Campylobacter-free until slaughter. Subsequently, Hald et al (2001) 
showed in a study of 10 flocks that partial depopulation increases the number of 
Campylobacter-positive flocks and Allen et al (2008) demonstrated through the study of 51 
flocks within the UK that the practice of thinning is a risk factor for Campylobacter 
colonisation. These findings highlight the importance of adequate disinfection before 
entering the bird house during production. 
Other factors that increase the risk of Campylobacter-positive flocks are the type of 
management, with free-range and organic birds being more likely to be colonised (Heuer et 
al, 2001). Furthermore, the outcome of Campylobacter colonisation has been shown to be 
different in birds with different growth rates, with fast-growing breads having more watery 
faeces and an increased incidence of hock marks and pododermatitis (Williams et al, 2013). 
This may be linked to the genotype of the different breeds used in the study. However, under 
both experimental infection, as used in the aforementioned study, or in natural field 
infection, fast and slow growing chickens harbour equally high numbers of Campylobacter 
and bird growth rate has not been identified as a risk factor for colonisation (Gormley et al, 
2014). Interestingly, the use of fly screens in broiler houses was shown to reduce the 
percentage of Campylobacter positive flocks from 51.4% to 15.4% (Hald et al, 2007) 
implying a role for flies and vectors and this is another measure that could easily be 
implemented in addition to the above at a relatively low cost. 
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1.4 Measures to reduce Campylobacter colonisation in chickens 
To date, no effective control measures for the reduction of Campylobacter in poultry 
have been widely implemented in spite of the UK government making its control a food 
safety and public health priority in recent years. A 2 log10 reduction in chicken carcass 
contamination levels has been modelled to translate into a reduction in human cases due to 
fresh chicken of over 12-fold (Lindqvist and Lindblad, 2008).  However, such a reduction in 
carcass contamination is likely to require a more substantial reduction in caecal colonisation 
levels given the way in which chickens are processed in the slaughterhouse. Furthermore, no 
control measures for reduction of carcass contamination that are highly effective, easy to 
implement, cost effective and widely acceptable to the public have yet been found, though 
topical application of organic acids, bacteriophages and blast chilling can achieve modest 
reductions of c. 1 log10 CFU in skin contamination. 
In addition to the limitations mentioned above for, topical carcass treatments would not 
address the issue of Campylobacter contamination of organs and deep muscular tissue. An 
approach that can reduce liver as well as carcass contamination would reduce the most 
important cause of food-borne Campylobacter outbreaks. In a systematic review, Newell et 
al (2011) identified 2621 original research articles on Campylobacter in poultry, with at least 
173 references on control through bio-security measures alone. Due to the vast amount of 
literature available, rather than forming an exhaustive review, this section will outline with 
examples, the measures that have been tested to date for control of Campylobacter at various 
levels within the food chain. 
 
1.4.1 On-farm control measures 
Following the EU-wide ban of antibiotics in animal feed in January 2006, the 
number of laboratory-confirmed Campylobacter human infection has been on the increase 
(Fig. 1.4). Since then, on farm control measures for the reduction of Campylobacter have 
had to rely on alternative control strategies. Measures advocated by the FSA include 
biosecurity measures designed to protect the flock such as washing of hands, wearing 
protective clothing, dedicated footwear, cleaning and disinfection of equipment, cleaning and 
disinfection of the house prior to re-stocking, control of visitors, provision of 
Campylobacter-free water, feed and litter (FSA, 2010b). These measures are based on the 
Norwegian study of Lyngstad et al (2008) which showed that water sources, specific houses 
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on a single farm, hired stockmen, multiple broiler houses on farm and less than 9 days 
between destocking and repopulation act as risk factors for flock Campylobacter positivity.  
 At least in the UK, biosecurity measures are generally viewed positively by poultry 
farmers and there is general recognition that, apart from controlling Campylobacter, good 
biosecurity would safeguard against other diseases and protect their future (Ringrose and 
Hall, 2015). However, the same survey highlighted uncertainty as to which control measures 
are the most effective and should be implemented. Newell et al (2011) highlighted in a 
systematic review of the literature on biosecurity measures for the control of Campylobacter 
that there is a lack of understanding of the source of this infection in poultry flocks. 
Consequently, it is difficult to assess which control measures are most likely to result in 
flocks being Campylobacter-negative. The review also concluded that although the rigorous 
application of biosecurity measures is likely to help the control of Campylobacter, effective 
control leading to negative flocks will most likely require additional measures such as 
vaccination, probiotics, etc. Even so, biosecurity measures can be used to successfully keep 
flocks free of Campylobacter and lessons can be learnt from Iceland, where the proportion of 
Campylobacter-positive flocks declined from 40% to around 10% following the introduction 
of strict biosecurity measures and the policy of freezing produce from Campylobacter-
positive flocks (Fridriksdottir, 2011) in 1999-2000. 
An alternative approach for controlling Campylobacter in poultry at the farm level is 
the selective breeding of poultry with improved heritable resistance to Campylobacter 
colonisation. Boyd et al (2005) showed that chicks from two inbred layer lines show levels 
of Campylobacter colonisation that are 10 to 100 fold different and the difference is 
consistent from 24 hours post-challenge to the end of the study (3 weeks). The same study 
also showed, through backcrossing experiments of the two inbred lines, that these 
differences were inherited in a way consistent with genetic control through a single 
autosomal dominant locus and the effect was observed with different C. jejuni challenge 
strains. Fife et al (2010) further investigated the heritable resistance against Campylobacter 
and Salmonella in the in-bred lines used in the aforementioned study and fine-mapped the 
quantitative trait loci (QTLs) associated with resistance to Salmonella. Ongoing studies at 
The Roslin Institute will further map QTLs associated with resistance to Campylobacter in 
inbred lines and assess their penetrance in commercial populations of chickens. A survery of 
the genotype and Campylobacter burden of over 3000 broilers in a commercial context is 
also ongoing to estimate heritability of resistance and identify candidate resistance genes 
(Kaiser et al, unpublished). 
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Modified diets have also been considered for the control of Campylobacter on farm. 
The use of medium-chain fatty acids has been trialled but intestinal mucus appears to protect 
against their action even though they are effective in vitro (Hermans et al, 2010). Organic 
acids have also been tested in drinking water in experimental flocks but they only reduced 
colonisation by 2log10 CFU/g caecal contents if the birds were challenged with 103 CFU of 
C. jejuni (Chaveerah et al, 2004). No reductions were observed when birds were challenged 
with 105 CFU of C. jejuni.  As mentioned above, Skanseng et al (2013) attempted to alter the 
intestinal microflora through diet and increase resistance of chickens to Campylobacter but 
their results suggested that the observed modest decrease was due to a direct effect of the 
feed rather than changes in the microbiota. Other feed additives are reviewed below 
alongside their potential use for carcass decontamination. 
 
1.4.2 Control at slaughter  
Reductions in Campylobacter colonisation at farm level could be aided by measures 
applied at slaughter designed to further reduce carcass contamination. The WHO produced 
through Codex Alimentarius, a document that outlines potential control measures of 
Campylobacter at this stage (Codex Alimentarius, 
http://www.who.int/foodsafety/micro/jemra/guidelines/cxg_078/en/index.html). It details 
measures such as the use of carcass washing systems, chilling or irradiating carcasses, which 
have been shown to have variable effects on reducing Campylobacter contamination.  
 
1.4.2.1 Thermal control of Campylobacter on chicken carcasses 
Chilling has also been researched as a means of reducing Campylobacter 
contamination and this may be a measure more widely acceptable to the consumer than 
others described below, provided that chilling does not induce damage to the surface of the 
carcass. Immersion chilling in water was shown to reduce Campylobacter numbers on 
chickens by 2 log10 CFU/ml of carcass rinse (Northcutt et al, 2008). Previously, Northcutt et 
al (2003) achieved a more modest effect of 1.2 log10 CFU/ml of carcass rinse after chilling in 
dilute sodium hypochlorite. More severe cold treatment such as freezing of naturally 
contaminated carcasses and storage for 31 days at -20 oC reduced Campylobacter by 0.7 to 
2.9 log10 CFU/g (Georgsson et al, 2006). This is further supported by the work of Maziero 
and de Oliveira (2010) who found a decrease of 2.5 log10 in frozen poultry by direct plating. 
However, no difference in recovery of Campylobacter from fresh, chilled or frozen products 
was noted following enrichment cultures, indicating potential long-term survival in food. 
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Historical evidence from Iceland suggests that freezing can be used as a strategy to 
reduce human campylobacteriosis. Following the re-introduction of fresh chicken meat from 
contaminated flocks in 1996, the number of cases of campylobacteriosis rose 7-fold in the 
country by 1999 (Tustin et al, 2011; Fridriksdottir, 2011). Recently, the British Oxygen 
Company (BOC, UK) have described the use of liquid nitrogen for rapid surface chilling to 
decrease carcass contamination with Campylobacter and have demonstrated a 10-fold 
reduction in industry scale trials, without affecting carcass quality or the ability to sell treated 
chickens as fresh produce (BOC, 2015). However, the installation of the system is likely to 
require substantial alterations to the processing lines and significant costs to the 
slaughterhouse and its efficacy may depend on the contaminating strain. 
In addition to chilling, spraying of carcasses with high temperature water can be 
used. However, due to the thermophilic nature of Campylobacter this method is likely to risk 
of damage to the carcass as washes of higher temperatures than for other bacterial pathogens 
may need to be used. Li and Swem (2002) showed that an automated inside-outside washer 
using water at 55 oC only decreased Campylobacter contamination by 0.78log10 and that 
temperatures higher than 60 oC initiated cooking of the carcass and changed its organoleptic 
properties. 
 
1.4.2.2. Chemical control of Campylobacter on chicken carcasses 
A variety of chemical washes for the carcass have been tested, although their use 
may reduce public acceptance of the product. The use of 1 to 3 washers dispensing water 
with 25-35ppm total chlorine was shown to reduce Campylobacter counts by about 0.5 log10 
CFU/ml of whole carcass rinse sample (Bashor et al, 2004). Spraying of carcasses with 
Acidified Sodium Chlorite (ASC) after the aforementioned wash may further reduce 
Campylobacter levels by 1.3 log10 CFU/ml of whole carcass rinse sample (Bashor et al, 
2004). Whyte et al (2001) showed that dipping carcasses in 10% sodium triphosphate (TSP) 
solution, pH12 for 15 seconds followed by a 15s rinse in water reduced Campylobacter 
levels by 1.7 log10 CFU/g of neck skin. In contrast to their use in broiler flocks, in vitro, 
organic acids can nearly eliminate C. jejuni from acidified water within one hour 
(Chaveerach et al, 2002) and as such may be more amenable to use as a topical disinfectant. 
Lactic acid has also been tested for surface decontamination of carcasses and has been 
demonstrated to reduce surface contamination by 1 log10 when a 5% solution was sprayed for 
one minute and by nearly 4 log10 after 7 days of storage at 4 oC when the solution was not 
rinsed off (Chaine et al, 2013). 
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1.4.2.3 Control of Campylobacter on chicken carcasses through irradiation 
Irradiation was advocated in the WHO guidelines but consumers appear reluctant to 
accept such treatment. Whilst public acceptance towards irradiation is increasing in the US, 
in the UK and most of the EU the public still does not widely accept food treated as such 
(reviewed by Wilcock et al, 2004). Yogasundram et al (1989) showed that a dose of 1KGy 
from a Co-60 source complete eliminates C. jejuni from chicken carcasses following 
inoculation at 103 CFU/cm2. Isohanni and Lyhs (2009) describe the use of UV light for the 
reduction of Campylobacter on poultry and obtain more modest reductions of approximately 
0.7 log10 on chicken meat and skin. Furthermore, they show no alteration in organoleptic 
properties of the carcass. While the latter approach may be more acceptable to the consumer, 
the modest decrease achieved means that it would have to be combined with other 
decontamination measures to elicit a significant reduction in carcass contamination. 
 
1.4.2.4. Use of natural antimicrobials for the control of Campylobacter 
More recently, and in line with the public view on the benefits of control of diseases 
using natural products, bacteriophages, bacteriocins and other natural antibacterials have 
been tested. Connerton et al (2011) extensively reviewed bacteriophage therapy for control 
of Campylobacter in poultry and for sanitisation of carcasses post-slaughter. Although trials 
reviewed in the aforementioned paper have proven that bacteriophage therapy is effective in 
both controlling colonisation levels in chickens and on carcasses it is likely that they are 
more suited to the latter application. Extensive use of bacteriophages in live chickens can 
quickly give rise to phage-resistant Campylobacter strains during primary production and it 
would require careful timing before slaughter. α-Endolysins specific to Campylobacter and 
obtained from Campylobacter bacteriophages may also be useful and would act specifically  
on the target rather than other constituents of the microflora. As an alternative to 
bacteriophages, Li (2009) reviewed and advocates the use of bacteriocins (natural or 
artificial anti-bacterial peptides), possibly administered through live commensal vectors, for 
the control of Campylobacter. Such an approach could have the added advantage of 
competitive exclusion through the use of probiotic bacteria such as Lactobacilli (Morishita et 
al, 2000). 
 
1.4.3 Control during retail 
 In addition to controlling Campylobacter contamination on the farm and at 
slaughter, its survival on the final product could be reduced during retail. Control at this level 
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can rely on tightly controlling storage temperature, as at the typical storage temperature of < 
4 oC Campylobacter cannot grow. Additionally, modified atmosphere packaging (MAP) has 
been tested. Due to the microaerophilic nature of Campylobacter, it has been shown that 
MAPs that contain high levels of oxygen (80%) were most effective in inducing a decline in 
Campylobacter on the surface of chicken meat (Meredith et al, 2014). However, these 
conditions increased the multiplication of other spoilage microbes that are not sensitive to 
high oxygen concentrations. The same study reported that a MAP containing 40:30:30 
CO2:O2:N2 offered the best balance between decreased Campylobacter survival and 
decreased growth of spoilage microbes. 
 Another measure that has been tested during retail would be the application of 
certain marinades containing naturally occurring antimicrobials. For example, Zakariene et 
al (2015) show that a thyme-based marinade can decrease numbers of C. jejuni on fresh 
chicken wings by 1log10 and Isohanni et al (2010) show that white and red wine used can 
induce a similar decrease on chicken meat if marinated for 48h. The use of marinades on 
fresh chicken meat could be combined with the use of ready-to-cook bags that allow whole 
chickens to be roasted without the need to remove the product from packaging before 
cooking. 
 
1.4.4. Control at consumer level 
 Lastly, a reduction in human campylobacteriosis can be achieved by consumer 
education. A survey published earlier this year in the USA (Kosa et al, 2015) indicated that 
consumer practices are generally unsafe and they increase the risk of campylobacteriosis. 
The study reported that 70% of consumers still wash poultry meat or carcasses before 
cooking, a practice now shown to be unsafe due to the likelihood of splashing contaminated 
water on surfaces surrounding the sink. In addition, only 17% of consumers were found to 
correctly store fresh poultry in the refrigerator and only 11% thaw frozen poultry correctly. 
 In the UK, the FSA has recently started a consumer education campaign as part of 
their Acting on Campylobacter Together (ACT) Campaign. It provides advice to consumers 
(FSA, 2015b), including not to wash raw chicken, to wash used utensils, to cover and chill 
raw chicken and to cook chicken thoroughly.  
Whilst each of the control measures discussed in the above sections can decrease 
contamination of poultry with Campylobacter and the risk of contracting this bacterium, it is 
likely that efficient control of Campylobacter will require a combination of measures. 
Recognising this, the Campylobacter Joint Working Group has been formed in the UK, 
including members such as The British Poultry Council, DEFRA, FSA, NFU, The British 
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Retail Consortium and research organisations. Some of the priorities identified by this group 
(outlined at http://www.campylobacter.org.uk) include evaluation of biosecurity measures, 
financial incentives for Campylobacter-free produce, improved advice to consumers and 
testing of steam, electrolysed water and ultrasound treatments. The Campylobacter Joint 
Working Group recognises that an effective vaccine could be a valuable additional tool for 
control of this pathogen in broilers but it also recognises that this is a long-term measure as 
significant additional research is needed (FSA, 2010a). 
 
1.5 Vaccines against Campylobacter in poultry 
In light of the studies above, it is evident that many measures for control of 
Campylobacter give modest results, are not widely acceptable to the public or are not easy to 
implement on the scale of modern broiler production (FSA, 2009b). As such, effective 
vaccines for control of Campylobacter in broilers are desirable as they would allow control 
of this problem at source. The “UK Research and Innovation Strategy for Campylobacter in 
the Food Chain” for 2010-2015 (FSA, 2010a) recognises the need for an effective vaccine in 
poultry. Moreover, it recognises a need to improve knowledge of the nature of the immune 
responses conferring protection against colonisation by C. jejuni in chickens. Research to 
date into vaccines for control of this pathogen in poultry is reviewed in this section. Tables 
1.1. to 1.4 summarise the literature found in PubMed when searching for “Campylobacter 
(and) vaccines”. Owing to variation in almost every parameter between different studies 
direct comparison of the protective effect of candidate vaccines is not possible. 
 
1.5.1 Whole cell live vaccines 
 The use of whole cell live vaccines, attenuated through various strategies was one of 
the earliest forms of vaccination. The vaccine against smallpox was the first to be used and 
its safety and efficiency led to this disease becoming the first and only human disease to be 
eradicated world-wide, in 1980 (WHO; http://www.who.int/csr/disease/smallpox/en/). Live 
vaccines have also been used successfully in animals, including for the control of food-borne 
zoonoses. In late 1990’s, non-typhoidal human salmonellosis acquired from poultry and eggs 
was the main food-borne zoonosis (DEFRA, 2015). The introduction of live-attenuated 
vaccines against Salmonella in layer birds, in conjunction with biosecurity measures, 
successfully brought under control this problem as salmonellosis decreased by over 60% 
between 1997 and 2000 (Cogan and Humphrey, 2003). Studies that focused on the use of 
live C. jejuni strains as vaccines are summarised in Table 1.1. 
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Table 1.1 Summary of studies reporting the use of whole cell live vaccines against Campylobacter 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Humoral responses Evidence of protection 
Abimiku et al, 
1989 
Mouse; 
model of 
transfer 
of 
immunity 
to 
progeny 
Whole cell heat-
killed (65 or 100 
oC) or formalin-
fixed (0.5% for 2 
days) compared 
to live vaccine 
Oral or IP 
0.2ml (both IP 
and oral) of 
either: 
inactivated 
cultures at 5, 10 
or 50 
International 
Opacity Units 
(I.O.U); 50 µg; 
live culture at 5 
I.O.U. 
None 
Once weekly 
for 4 weeks; 
10e9 CFU for 
the live 
vaccine 
Progeny 
challenges at 4-
6 days old with 
10e7 CFU 
IgG induced by all vaccinations, 
but lower in the live vaccine 
group; IgA and IgM were 
undetectable; Bactericidal activity 
of serum and milk did not 
correlate with protection. 
IP route: 65 oC heat-killed 
vaccines as protective as 
formalin-fixed (~65% 
protection); 100 oC killed non-
protective; live vaccine 
conferred 100% protection. 
Oral route: live vaccine only 
tested - ~25% protection. IP 
live vaccine protection against 
heterologous challenge highly 
variable (0-75%). Protection 
expressed as reduction in 
numbers colonised. 
Guerry et al, 
1994 
Rabbit 
∆recA C. jejuni 
81-176 or WT 
Oral 10e10 CFU N/A 
Age not 
specified; 1-2 
kg 
Challenged one 
month after 
vaccination via 
the removable 
intestinal tie 
adult rabbit 
diarrhoea 
(RITARD) 
procedure; 
10e4 per animal 
Not determined 
Reduced duration of 
colonisation in the RITARD 
model from 7 days for non-
vaccinated animals to 1.5 days 
for animals vaccinated with 
either ∆recA C. jejuni 81-176 
or WT. 
Rollwagen et 
al, 1993 
Mouse  
Sonicated whole 
cell vaccine; 
compared to live 
vaccine 
Oral 
50, 100 or 300 
µg  of 
sonicated whole 
C. coli cells; 
compared to  
10e9 CFU of 
live cells 
Delivered 
with or 
without 25µg 
of heat-labile 
enterotoxin 
(HLE) of E. 
coli 
Once weekly 
for three 
weeks 
10e9 CFU/bird 
around 4 weeks 
post-
vaccination 
Detected IgA in intestinal lavage 
of all adjuvated groups. In groups 
receiving sonicated vaccines, the 
highest titre was in the highest 
dose (equal to the group 
receiving the live vaccine). Lower 
induction in nonadjuvated 
groups. 
Only adjuvated vaccines 
tested. Sonicated vaccine 
decreased colonisation by 60% 
in homologous challenge. 
Complete protection against 
homologous challenge from 12 
days post-infection by the live 
vaccine. No protection in 
heterologous challenge 
Ziprin et al, 
2002 
Chicken 
A combination of 
equal numbers of 
individual ∆dnaJ, 
∆cadF, ∆ciaB 
and ∆pldA of C. 
jejuni F38011 
IM alone or 
with oral 
gavage 
Each strain at 
10e9 CFU/ml; 
0.1ml IM and 
1ml orally 
With or 
without Ribi's 
Adjuvant R-
700 
5th day of 
hatch 
11th day of 
hatch 
Not undertaken 
No decreases in caecal 
Campylobacter colonisation 
observed 
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While the use of live non-attenuated vaccines appears to provide protection against 
colonisation in murine models, there are unlikely to be usable in chickens as Campylobacter 
naturally persists long-term in the avian intestines. In contrast to studies undertaken in 
rabbits as a model of human disease (Guerry et al, 1994), vaccination of chickens with live 
C. jejuni strains with defined attenuating mutations (Ziprin et al, 2002) did not induce 
protection against colonisation. Secondly, the immune response to experimental 
Campylobacter infection of chickens is mainly against flagellin (Cawthraw et al, 1994) 
making such a response likely to allow immune evasion through variable flagellin 
glycosylation (as reviewed by Szymanski et al, 2003) and potentially limit the use of live 
vaccines against heterologous strains. Lastly, if considered for use in humans or transmitted 
through the food chain, such vaccines pose an increased risk of inducing the development of 
GBS and RA in vaccinated patients compared to subunit vaccines and also pose a risk of 
causing disease if transmitted to immunocompromised patients.   
 
1.5.2 Whole cell inactivated vaccines 
 A second category of vaccines that have been tested, mostly in early studies, is 
whole cell inactivated vaccines. The literature available on the use of these vaccines against 
Campyobacter is summarised in Table 1.2.  
In mice, the studies undertaken suggest that protection using whole cell inactivated 
or lysed vaccines is less than that conferred by live whole cell vaccines (Abimiku et al, 1989; 
Rollwagen et al, 1993). This could be due to the failure of inactivated bacteria to stimulate 
the immune response as efficiently as live bacteria, suggested by studies describing 
improved seroconversion and protection using adjuvated inactivated whole-cell vaccines, 
compared to the same vaccines used without adjuvants (Rollwagen et al, 1993; Baqar et al, 
1995). Furthermore, as for live vaccines, there is a lack of protection conferred against 
heterologous challenge (Rollwagen et al, 1993; Dolby and Newell, 1986). 
In chickens, only one study reported a reduction of 2log10 CFU of C. jejuni per g of 
caecal counts upon administration of inactivated Campylobacter (Widders et al, 1996), but 
this is unlikely to be sufficient for wide field use of these vaccines and the inadequate 
description of the study design makes confirmation of such findings difficult. Other studies 
reported no protection (Okamura et al, 2012) or reductions of 2log10 CFU/g of caecal 
contents, but which were not statistically significant (Rice et al, 1997), most likely due to the 
study being inadequately powered through the use of only three animals per group per time-
point.  
Interestingly, Hermans et al (2014) succeeded in passively immunising chickens by  
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Table 1.2 Summary of studies reporting the use of whole-cell inactivated vaccines against Campylobacter 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge dose 
and time 
Humoral responses Evidence of protection 
Abimiku et 
al, 1989 
See Table 1.1 
Baqar et al, 
1995 
Mouse 
1:1 mixture of heat 
(60 ˚C) and formalin 
(0.02M) killed C. 
jejuni 81-176 
Oral 
10e5, 10e7 or 
10e9 CFU 
With or 
without 25µg 
HLE  
6 to 8 weeks 
of age; three 
doses at 48 
hour intervals 
4 weeks post-
vaccination; 10e8 
CFU 
All groups apart from highest 
dose with no adjuvant 
produced intestinal secretory 
IgA with lowest titre in the 
highest dose group (with or 
without adjuvant); All groups 
seroconverted and had 
similar levels of serum IgA 
and IgG 
All adjuvated doses induced 
protection (60%-100% 
reduction in number 
colonised at day 10 after 
challenge). Only the highest 
dose non-adjuvated vaccine 
induced protection. 
Dolby and 
Newell, 
1986 
Mouse; 
vaccination 
of dams and 
evaluation of 
transfer of 
immunity to 
pups 
Whole cell heat-
killed (65 or 100 ˚C) 
or outer membrane 
preparation 
IP 
0.2ml of cultures 
at 10 or 50 
I.O.U; 50 µg of 
outer membrane 
preparation 
None 
Once weekly 
for 4 weeks 
Progeny 
challenged at 4-6 
days after birth 
Detected IgY against 
flagellar antigens 
The 65 ˚C-killed whole cell 
vaccine protected progeny 
against homologous 
challenge; no protection by 
the 100 ˚C-killed vaccine or 
against heterologous 
challenge; Higher protection 
with higher dose vaccine; 
Outer membrane protein 
vaccine was non-protective. 
Hermans et 
al, 2014 
Chicken; 
passive 
immunisation 
study using a 
seeder 
challenge 
model 
Whole-cell lysate 
(WCL)  compared 
to hydrophobic 
protein fraction 
Layers: IM 
Layers: 50 µg of 
whole cell-lysate 
or 25 µg of 
hydrophobic 
fraction; 
Progeny: fed 5% 
egg yolk (from 
vaccinated 
layers) in feed 
Layers: 1:1 
mixture with 
Freunds' 
Complete 
Adjuvant; 
Progeny: N/A 
Layers: First 
vaccine at 19 
weeks; 
boosters at 
21, 23 and 25 
weeks; 
Progeny: 
feeding 
started at 6 
days of age 
Layers: N/A; 
Progeny: seeder 
birds challenged 
with 10e4 at 10 
days of age, all 
birds PMed at 13 
days of age 
Layers: C. jejuni specific IgY 
detected in egg yolk but not 
in white; IgA and IgM 
undetectable 
Layers: N/A; Progeny: WCL 
decreased colonisation of 
seeder birds by 5 log10 and 
abolished transmission to 
sentinels; Hydrophobic 
fraction decrease overall 
colonisation by 5 log10 but 
did not abolish transmission 
to sentinel birds 
Okamura et 
al, 2012 
Japanese 
Jidori 
chickens 
Whole cell 
inactivated 
(formalin-killed) 
SC 
Approx. 10e8 
CFU/bird 
Oil or 
aluminium 
hydroxide 
gels 
Day of hatch 
and 37 days 
old 
10e7 CFU   IgY induced 
No reduction in caecal 
colonisation or spleen/liver 
count 
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Table 1.2 Continued 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge dose 
and time 
Serology Evidence of protection 
Rice et al, 
1997 
Broiler 
chickens 
 
Whole cell 
inactivated 
(formalin-killed) 
 
Oral 
 
10e9 CFU/bird 
 
None days 2 and 8 
Challenged at day 
2 with seeder 
birds that received 
10e4 CFU/bird 
 
IgA detected 
 
No reduction at 17 days of 
age 
25 µg of HLT 
per dose per 
bird 
Days 2, 9 and 
16 
2 log10 CFU/g reduction at 
46 days but only three birds 
used so not statistically 
significant 
50 µg HLT 
per dose per 
bird 
Days 2, 4 and 
6 
0.5 log10 CFU/g reduction at 
31 days but not significant 
and no reduction at 50 days 
Rollwagen 
et al, 1993 
See Table 1.1. 
Widders et 
al, 1996 
Chicken 
Killed whole cells 
(KWC); keyhole 
limpet haemocyanin 
(KLH) used as a 
model antigen 
SC, IP or 
Oral 
Unknown Unknown 
Vaccinated 
with KLH on 
day of hatch 
or at 24 days 
old; 
Vaccinated 
with KWC C. 
jejuni at days 
16 and 26 
post-hatch 
Unknown 
Only 5/13 birds responded 
to KLH when vaccinated on 
day of hatch; 10/11 
responses if vaccinated at 
24-days old. No IgA or IgM 
induction by KWC vaccine. 
Induction of serum IgY 
observed with KWC vaccine 
and intestinal secreted IgY 
correlated with protection. 
Reduction of 2log10 CFU/g 
observed in the KWC 
vaccinated group. 
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feeding young chicks yolk from eggs laid by hens vaccinated with a whole cell lysate of C. 
jejuni. In a seeder challenge model, this study showed decreases of 5log10 CFU of C. jejuni 
per g of caecal contents in the birds that were directly challenged and abolition of 
transmission to sentinel birds. However, the model used a low challenge dose of 104 CFU/ 
bird and this may have contributed to the high level of protection observed. Nevertheless, 
this model of challenge may mimic natural infection more closely. This study and the study 
of Dolby and Newell (1986) showing protection of mouse pups following vaccination of 
dams suggests that vaccines against Campylobacter in poultry could be used through 
immunisation of laying hens and passive transfer to the chicks, similarly to the use of 
vaccines against Salmonella, however, the possibility of this method of immunisation is yet 
to have been demonstrated experimentally in chickens.  Studies using recently described Ig 
heavy chain deficient transgenic chickens (Schusser et al, 2014) will help to formally 
establish the relevance of antibody in protection. 
 
1.5.3. Subunit vaccines 
 A third category of vaccines that have been tested against Campylobacter are 
recombinant subunit vaccines and the studies describing the use of such vaccines are 
summarised in Table 1.3.  
As the flagellum was shown early in Campylobacter research to be vital for 
intestinal colonisation, early studies focused on using this subunit as a vaccine. While 
protection was observed using this subunit in both chicken (Khoury and Meinersmann, 2011)  
and mouse models (Lee et al, 1999), it was observed in a dose-dependent manner and in 
chickens it only achieved protection of the majority of vaccinated animals when doses as 
high as 1mg of recombinant antigen per animal were used. A recombinant vaccine reliant on 
high amounts of purified protein would be expensive to administer on a wide scale to the 
broiler industry and would, most likely, preclude its field use. Other studies that showed high 
level protection utilising other recombinant antigens have the same drawback: Neal-
McKinney et al (2014) used 250 μg of recombinant FlpA to induce a 3.5 log10 reduction in 
CFU/g of caecal contents in chickens, Du et al (2008) used 200 μg of 6xHis-Peb1A to 
induce near complete clearance in mice and Islam et al (2010) had to use 300 μg of GST-
PorA to induce clearance of C. jejuni infection in mice. Other studies using lower amounts of 
recombinant antigens reported lower levels of protection, e.g. Buckley et al (2010) induced a 
reduction of 2 log10 CFU C. jejuni/g caecal contents following vaccination with 14 μg of 
6xHis-CjaA, however, the lack of dose titration experiments in each of these studies and 
their highly variable design does not allow the contribution of specific factors to be assessed. 
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Table 1.3 Summary of studies using recombinant antigens as vaccines against Campylobacter 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Antigen-specific humoral 
responses 
Evidence of protection 
Annamalai et 
al (2013) 
Chicken 
 Outer membrane 
proteins 
Oral or SC  
25, 125 or 
250 µg for 
oral vaccines, 
125 µg only 
for s.c. 
With or without poly-
lactide-co-glycolide 
encapsulated 
nanoparticles 
Days 7 and 
21 
Challenged at 
35 days with 
10e8 CFU/bird 
Detected induction of serum 
and caecal IgY and IgA in the 
SC vaccinated group 
Protective effect observed only 
with SC vaccine to below the 
detectable limit by plating 
Baqar et al, 
2008 
Mice 
FlaC, FspA1 and 
FspA2; all as 
6xHis fusions; 
flaC and fspA1 
cloned from C. 
jejuni 81-176; 
fspA2 cloned from 
C. jejuni GG8486. 
Intranasal 
5, 25 or 100 
µg 
Each dose delivered 
with or without 1 µg of 
LTR192G 
Thee 
vaccinations, 
two weeks 
apart 
Intra-nasally 
with 3x10e9 
CFU, 28 days 
after last 
vaccine dose; 
with either the 
C. jejuni 
GG8486 
homologous 
strain or C. 
jejuni 81-176 
heterologous 
strain; only the 
100 μg groups 
were 
challenged 
No serum IgG or IgA induced 
by FlaC alone at 5 and 25 µg 
but induced at 100µg and in all 
groups with adjuvant. No 
faecal IgA with any non-
adjuvated dose; increasing 
response with 25 and 100 µg 
adjuvated doses. FspA1 
induced IgG and IgA in all 
vaccinated groups; dose-
response effect if non-
adjuvated. FspA2 did not 
induce IgG and IgA with 5 and 
25 µg non-adjuvated doses; it 
induced IgG and IgA 
responses in a dose-
dependent manner in all doses 
when adjuvated. 
Protection was only tested in the 
highest dose vaccine groups. 
Efficacy given as reduction in 
clinical score. FlaC did not 
provide protection against either 
challenge. FspA2 had lower 
protective efficacy (38%) than 
FspA1 (64%) in homologous 
challenge. FspA1 had 31% 
protective efficacy against 
heterologous challenge. No 
protection against heterologous 
challenge observed with FspA2. 
Buckley et al 
2010 
Chicken 6His-CjaA SC injection 14 µg/bird TiterMax 
1 and 14 
days or 15 
and 29 days 
10e7 CFU at 
day 28 post-
hatch 
IgY and bile IgA induced 
1log10 CFU/g reduction at week 3 
and about 2log10 at week 4 post-
challenge (across 2 biological 
replicates, each with 3 birds per 
interval); no difference between 
the two vaccination times 
Du et al, 
2008 
Mouse 6XHis-Peb1A IM or SC 
25, 50 or 100 
µg mentioned 
in M&Ms 
Mentioned as 
CFA/IFA but not which 
or if both and no dose 
mentioned 
Mice were 7-
9 weeks of 
age; 
vaccinated 4 
times at 1 
weeks 
intervals 
Oral challenge 
with C. jejuni 
81-176; time of 
challenge not 
mentioned 
IgG induced in groups 
vaccinated with 50, 100 and 
200 µg, both IM and SC; 
30% survival at 7 days in control 
group, 50% in the 50µg group 
and 85% in the 100 and 200 µg 
groups; no reduction in clinical 
score in the 50µg group, 70% 
reduction in clinical score in the 
other groups 
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Table 1.3 Continued 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Antigen-specific humoral 
responses 
Evidence of protection 
Islam et al, 
2010 
Mouse GST-PorA Oral 
300 µg per 
bird in 300 µl 
volume 
5 µg of HLT 
Age of first 
vaccination 
not 
mentioned; 
vaccinated 
twice 1 week 
apart 
Challenged 3 
weeks after 
second 
vaccination. 
Given 10e9 
CFU 
The vaccines induced 
significant antibody increases 
(given as an average of serum 
and intestinal IgA, IgM and 
IgY) 
Homologous strain did not 
colonise mice. Variable levels of 
protection against three 
heterologous strains (reduction 
by 50-75% in numbers colonised) 
Khoury and 
Meinersmann 
(2011) 
Chicken Flagellin 
Given orally 
or IM 
250, 500, 750 
or 1000 µg 
per bird for 
oral vaccine 
and 250 or 
1000 for IM 
Fused to HLT, given 
in 4M urea 
2 and 4 
weeks of age 
Challenged at 3 
weeks with 2e8 
CFU/bird 
Both regimens induced 
secretory intestinal IgA; 1mg 
oral dose significantly more 
Three challenge trials run with 
the 1000µg dose - in each trial 
vaccination reduced colonisation 
to approximately half but only 
half of the birds were colonised in 
the control groups 
Lee et al, 
1999 
Mouse 
MBP-FlaA from C. 
jejuni 81-176 
Intranasal or 
oral 
3, 6, 12, 25, 
50 µg 
Each dose delivered 
with or without 5 µg of 
HLT 
6-8 weeks 
old; first dose 
at 7 days 
post-housing, 
second dose 
7 days later 
Homologous 
challenge. 
Intranasally with 
2x10e9 CFU, 
26 days after 
second 
vaccination. 
Also orally 
challenged with 
10e10, 10e9 
and 10e8 CFU. 
Intranasal challenge: Serum 
IgG and intestinal lavage IgA 
were induced in a dose-
dependent manner. Adjuvated 
vaccines induced significantly 
higher titers than non-
adjuvated vaccines for each 
dose. 
Oral challenge: not determined 
Dose-dependent protection 
induced, with approximately 80% 
efficacy in protection against 
clinical symptoms and reduction 
in number of animals colonised 
for the highest dose group, when 
delivered with the adjuvant. Only 
half the efficacy when delivered 
without adjuvant. 
Oral challenge: protection with all 
doses at 7 days but complete 
protection only with the 10e8 
dose. 
Neal-
McKinney et 
al, 2014. 
Chicken 
A combination of 
GST-tagged 
90mers of FlpA, 
CadF and FlaA 
(1ry vaccination) 
and 6xHis-tagged 
entire length 
antigens (2ry 
vaccination), 
individually or a 
combination of 
the three. Cloned 
from C. jejuni 
F38011 
IM, in the 
pectorals 
240 μg of 
GST-tagged 
90mer for first 
immunisation. 
240 μg of full 
length protein 
for second 
immunisation 
80 μg of each 
protein for the 
trivalent 
vaccine 
Montanide ISA 70VG 
(30% antigen, 70% 
adjuvant) 
First 
vaccination at 
6 days of 
age. Booster 
at 16 days of 
age. 
Challenged at 
20 days of age 
with 2x10e8 
CFU/ bird with 
homologous 
strain. 
All vaccines induced serum 
IgY. No differences noted 
between groups. For the FlpA-
vaccinated group, no 
correlation between serum IgY 
induction and caecal 
Campylobacter counts was 
observed in individual birds. 
Reported as reductions in 
median caecal counts with no 
statistical tests: 3 log10 CFU/g 
reduction with the FlpA and 
trivalent vaccines. If mean is 
calculated and t-test used 
pairwise with Bonferonni 
Correction: approx. 3.6 log10 
CFU/g reduction with the trivalent 
and 2.5 log10 reduction with FlpA; 
CadF reduction not significant; 
trivalent vaccine not a statistical 
improvement over FlpA alone. 
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Table 1.3 Continued 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Antigen-specific humoral 
responses 
Evidence of protection 
Paul et al, 
2014 
Chicken 
6xHis-tagged 
CadF, FlpA, PorA, 
FlaA, CmeC, 
Peb1A, JlpA. 
Individually or all 
together 
IM for layers 
Oral for C. 
jejuni-
challenged 
chicks 
Layers: 100 
μg of each 
protein 
C. jejuni-
challenged 
chicks: 
feeding 10% 
(w/w) egg 
yolk powder 
from above 
layers 
Layers: 0.5ml 
Freund’s Complete 
Adjuvant (FCA) 
Chicks: N/A 
Layers: 35 
weeks of age 
C. jejuni-
challenged 
chicks: 
feeding from 
2 days of age 
Layers: None 
Chicks: 
challenged at 2 
days of age 
with 10e8 CFU, 
with 
concomitant 
feeding of 
hyperimmune 
egg yolk 
powder 
IgY induction measured in egg 
yolk. 
No decreases were observed in 
groups treated with hyperimmune 
yolk from hens vaccinated with 
individual or the combination of 
antigens. 
Prokhorova et 
al, 2006 
Mouse 
8 surface-
expressed 
proteins identified 
through MS; 
6xHis-tagged, 
cloned from C. 
jejuni ML53 
SC 
1, 5, 10 and 
25 µg/mouse 
of each 
protein 
100 µg Alum  
Age of mice 
not 
mentioned; 
Vaccinated of 
days 0, 14 
and 28 of 
experiment 
2.5-5x10e8 
CFU of C. jejuni 
ML1 or ML53 
Serum antibody titres (isotype 
not mentioned) determined by 
Western Blot; not seen in the 1 
µg group.  
Only mice with high antibody 
titres (not defined) from each 
dose were challenged. Claimed 
that two proteins decreased 
faecal shedding but animals 
vaccinated with different doses 
were included in the same group 
and a t-test was inappropriately 
used to test multiple treatment 
groups and time-points. 
Zeng et al, 
2010 
Chicken 6xHis-CmeC Oral gavage 
50 and 200 
µg 
Modified heat labile E. 
coli enterotoxin (10 or 
70 µg); groups with 
and groups without 
7 and 21 
days 
10e6 or 10e5 at 
day 35 post-
hatch 
IgY and IgA induced only by 
high dose CmeC plus high 
dose mLT 
No protection seen for up to 12 
days post-infection 
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In passive immunisation studies using CadF, FlpA, PorA, FlaA, CmeC, Peb1A and JlpA as 
recombinant subunit antigens singly or in combination, feeding of 10% (w/w) egg yolk 
powder from hyperimmune layers to broilers did not induce protection against  homologous 
challenge when fed either prophylactically or as treatment (Paul et al, 2014). These findings 
are in contrast to those of Hermans et al (2014) using inactivated whole cell vaccines to 
immunise laying hens. Antibodies against a limited spectrum of antigens may not be able to 
neutralise bacteria as efficiently as antibodies against whole cells, however the differences in 
study design could also account for the discrepancy between the studies. For example, Paul 
et al (2014) used a direct challenge model, giving 108 CFU of the challenge strain to each 
bird whereas Hermans et al (2014) used a low dose seeder challenge model. 
In view of above, it is likely that an effective vaccine would have to be vectored to 
have economic benefits on a wide scale in the field. Vectoring in an attenuated heterologous 
bacterial strain that does not cause pathology in chickens or humans would have the added 
advantage of potential ease of administration via the oral route. Furthermore, an oral vaccine 
would also avoid potential reactions at the site of injection due to adjuvants, which could 
increase the number of carcasses condemned as unfit for human consumption. Depending on 
the choice of vector it may also simultaneously protect against other avian or zoonotic 
pathogens. 
 
1.5.4. Subunit vectored vaccines 
 Recognising the potential benefits of a vectored subunit vaccine over a purified 
recombinant antigen, studies have also focused on vectored vaccines against Campylobacter 
and such studies are described in Table 1.4. The majority of this research has used attenuated 
S. Typhimurium vectors, with the exception of one study describing vectoring of CjaA in 
Eimeria tenella and reduction of caecal colonisation in chicken by approximately 10-fold 
(Clark et al, 2012) and of a study that described a similar reduction in chickens by vectoring 
FlaA in a naked DNA vector that induces expression and antigen presentation in the host 
(Huang et al, 2010). 
 Despite the potential benefits of low production costs and ease of administration the 
majority of the vectored vaccines tested so far have only elicited reductions of 2log10 CFU in 
caecal Campylobacter counts in chickens and the only study reporting the use of such 
vaccines in mice failed to induce protection (Sizemore et al, 2006). Vectoring 
Campylobacter antigens in live bacterial vectors has the potential advantage of inducing an 
immune response more likely to mimic natural infection compared to the parenteral 
administration of recombinant antigens alone. However, the disadvantage may be that  
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Table 1.4 Summary of studies describing vectored subunit vaccines against Campylobacter  
Reference 
Animal 
model 
Campylobacter 
antigen used 
Vector 
Localisation 
within 
vector 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Ag-specific 
humoral 
responses 
Evidence of 
protection 
Buckley et al, 
2010 
  
  
  
Chicken 
 
CjaA 
 
Live 
attenuated 
Salmonella - 
aroA mutant 
Cytoplasmic 
Oral 
 
1e7 
CFU/bird 
 
TiterMax 
 
1 and 14 
days 
10e7 CFU at 
day 28 post-
hatch 
 
IgY and bile IgA 
induced 
 
1.4 log10 CFU/g 
reduction at weeks 3 
and 4 post-challenge 
(across 6 biological 
replicates - 18 birds in 
total per time interval) 
Live 
attenuated 
Salmonella - 
aroA mutant 
Cytoplasmic – 
expression 
from low copy 
plasmid 
Given at 1, 4 
or 8 days 
post-hatch as 
primary 
vaccination 
and two 
weeks later 
as secondary 
Decreases induced at 
week 3 post hatch by 
the 1day group (only 
statistical significance) 
and at week 4 by the 
1 and 4 day group - 
the latter two likely not 
significant due to 
insufficient bird 
numbers 
WT and live 
attenuated 
Salmonella 
mutants - 
aroA, fliM, 
spaS, ssaU  
Cytoplasmic - 
expression 
from low copy 
plasmid 
Given at 1 
and 14 days 
post-hatch 
1.5 log10 CFU/g 
reduction with ΔaroA 
and a further 1.5log10 
reduction with WT, 
ΔspaS and ΔssaU; 
ΔssaU; more invasive 
WT strain induced 
better protection 
CjaA, Peb1A, 
GlnH, ChuA 
Live 
attenuated 
Salmonella - 
aroA mutant 
Cytoplasmic - 
expression 
from low copy 
plasmid 
Given at 1 
and 14 days 
post-hatch 
Only CjaA and Peb1A 
induced 1.8 and 1.5 
log10 CFU/g reductions 
Clark et al, 
2012 
Chicken CjaA 
Eimeria 
tenella 
Intracellular Oral 
300 
sporozoites 
once or 
successive 
infections of 
100, 500, 
3000 or 
5000  
None 
days 1, 3, 7 
and 20 
10e5 CFU/bird 
Serum IgY 
induction shown 
by Western 
blotting 
Both vaccination 
regimens induced 
0.8log10 CFU/g 
reduction 
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Table 1.4 Continued 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Vector 
Localisation 
within 
vector 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Ag-specific 
humoral 
responses 
Evidence of 
protection 
Huang et al, 
2010 
Chicken FlaA  
pCAGGS 
conjugated to 
chitosan as 
DNA vaccine 
Transgenic 
expression in 
nasopharynx 
and upper 
trachea 
Intranasal 
75 μg in 
each nostril 
None  
Days 1, 15 
and 29 
day 42 with 5e7 
IgY and IgA 
induced 
2log10 CFU/g 
reduction in caecal 
counts 
Laniewski et 
al, 2012 
Chicken CjaD  
Live 
attenuated 
Salmonella; 
balanced 
lethal system 
using 
pYA3341 
Asd+ plasmid  
cytoplasm Oral 
10e8 
CFU/bird 
None 
1 and 21 
days 
10e6 at day 28 
post-hatch with 
heterologous 
strain collected 
off chicken 
carcasses 
IgY and IgA 
induced 
0.8 log10 CFU/g 
statistically significant 
at week 1; 0.5 log10, 
CFU/g but not 
significant at week 2; 
used 5 birds per time 
point per group 
Laniewski et 
al, 2014a 
Chicken CjaA 
Salmonella 
Typhimurium 
Inner 
membrane/ 
periplasm 
(demonstrated 
by cellular 
fractionation of 
Salmonella 
vector) 
Oral 
10e8 
CFU/bird 
None 
Days 1 and 
14 
Challenged at 
28 days with 
10e5 CFU/bird 
Detected serum 
IgY and caecal 
IgA. FACS 
analysis - 
induction of B 
cell responses 
but lack of T 
cell responses 
No protection 
observed 
Laniewski et 
al, 2014b 
Chicken CjaD 
Salmonella 
Typhimurium 
Inner 
membrane/ 
periplasm(dem
onstrated by 
cellular 
fractionation of 
Salmonella 
vector) 
Oral 
10e8 
CFU/bird 
None 
Days 1 and 
14 
Challenged at 
28 days with 
10e6 CFU/bird 
IgA induced 
Reduced colonisation 
by 1log10 CFU/g week 
1 after challenge 
(significant) and 0.5 
log10 CFU/g two 
weeks after 
challenged (non-
significant) 
Layton et al, 
2011 
Chicken 
CjaD, CjaA, 
ACE393 
Live 
Salmonella, 
attenuated 
Outer 
membrane, 
within LamB 
Oral 
10e8 
CFU/bird 
CD154 
On day of 
hatch 
day 21, with 
1e7 CFU 
IgY and IgA 
induced 
Day 32: all three 
decreased caecal 
Campylobacter 
counts; CjaD reduced 
by 6log10 CFU/g 
(below limit detectable 
by qPCR) 
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Table 1.4 Continued 
Reference 
Animal 
model 
Campylobacter 
antigen used 
Vector 
Localisation 
within 
vector 
Route of 
vaccination 
Dose of 
vaccine 
Adjuvants 
Time of 
vaccination 
Challenge 
dose and 
time 
Ag-specific 
humoral 
responses 
Evidence of 
protection 
Sizemore et 
al, 2006 
Mouse 
Peb1A fom C. 
jejuni MGN4735 
Salmonella 
Typhimurium; 
expressed 
from 
pYA3342 (a 
pBR-based 
Asd+ 
plasmid) 
Cytoplasmic; 
expressed at 
high level 
Oral 
1-2.5 10e8 
CFU/mouse 
None 
Days 1 and 
12 of 
experiments; 
female 
BALB/c mice, 
7-9 weeks old 
Challenged with 
C. jejuni 81-
176;  
IgG induced 
against vector 
and Peb1A in 
100% of 
animals; no IgA 
detected 
against the 
vector or Peb1A 
No protection 
observed - no 
reduction in bacterial 
loads or intensity of 
clinical symptoms 
  
Mouse 
Peb1A fom C. 
jejuni MGN4735 
Salmonella 
Typhimurium; 
expressed 
from an 
arabinose 
regulated 
runaway 
plasmid, 
Asd+-based 
Cytolasmic; 
expressed at 
lower level 
than above 
Oral 
1-2.5 10e8 
CFU/mouse 
None 
Days 1 and 
12 of 
experiments; 
female 
BALB/c mice, 
7-9 weeks old 
Challenged with 
C. jejuni 81-
176;  
IgG induced 
against vector 
and Peb1A in 
90% of animals; 
no IgA detected 
against the 
vector or Peb1A 
No protection 
observed - no 
reduction in bacterial 
loads of intensity of 
clinical symptoms 
  
Mouse 
Peb1A fom C. 
jejuni MGN4735 
Salmonella 
Typhimurium; 
expressed 
from as an 
Hly fusion in 
an Asd+ -
based 
plasmid, pUC 
ori 
Extracellular 
secretion; low 
level secretion 
Oral 
1-2.5 10e8 
CFU/mouse 
None 
Days 1 and 
12 of 
experiments; 
female 
BALB/c mice, 
7-9 weeks old 
Challenged with 
C. jejuni 81-
176;  
IgG induced 
against vector 
in all animals 
and against 
Peb1A in 20% 
of animals; no 
IgA detected 
against the 
vector or Peb1A 
No protection 
observed - no 
reduction in bacterial 
loads of intensity of 
clinical symptoms 
Wyszynska 
et al, 2004 
Chicken CjaA 
Live 
attenuated 
Salmonella 
Cytoplasmic – 
expressed 
from high copy 
number 
plasmid 
Oral 
10e8 
CFU/bird 
None 
1 day and 14 
days post-
hatch 
2x10e8 CFU at 
day 28 in 
PBS/gelatine - 
heterologous 
challenge with 
broiler carcass 
isolated strain 
IgY and IgA 
induced 
About 6log10 CFU/g 
reduction but other 
authors have been 
unable to replicate the 
results, albeit using 
vectors with different 
properties 
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antigens and epitopes from the vector may become immunodominant over the 
Campylobacter antigen(s) used and reduce the immune response to it. One study that 
reported a 6log10 reduction in CFU of C. jejuni per g of caecal contents in chickens (Layton  
et al, 2011) presented the antigen (CjaD) on the surface of the bacterium, in tandem with the 
immunostimulatory molecule CD154 (CD40 ligand). This may have resulted in an enhanced 
binding of the antigen-CD154 doublet to antigen-presenting cells and enhanced activation of 
other immune cells (macrophages and/or T-cell independent B cell activation), however, the 
effects of using this immunostimulatory molecule in the vaccine were not compared to a 
vaccine that vectored CjaD alone. Another study reported a 6 log10 CFU/g reduction 
(Wyszynska et al, 2005) using vectored CjaA, however the results were not replicated by 
other independent studies. Buckley et al (2010) obtained a 1.4 log10 reduction in CFU/g of 
caecal contents using the same vectored antigen and Laniewski et al (2014a) did not observe 
protection using CjaA, albeit the properties of the Salmonella vectors were different in these 
two later studies. 
Further knowledge of the nature of the immune response induced by protective 
vectored vaccines or mounted by chickens that are naturally resistant to colonisation would 
allow the rational development of vaccines that induce the appropriate type(s) of immune 
response more strongly.  
 
1.5.5 Other strategies for immunisation of chickens 
 In addition to the studies described above, glycoconjugate vaccines have been tested 
in models of human campylobacteriosis. Monteiro et al (2009) reported significant reduction 
in clinical scores in mice following vaccination with a capsular polysaccharide conjugated to 
a mutant diphtheria toxin. No studies using glycoconjugate vaccines in chickens have been 
reported to date. However, the characterisation of the PglB enzyme from C. jejuni and its 
ability to glycosylate carrier proteins in recombinant E. coli strains (Cuccui and Wren, 2013) 
opens the door to cost-effective production of glycoconjugate vaccines for use in chickens. 
Another reported strategy was similar to the studies investigating the passive transfer 
of immunity though feeding of anti-Campylobacter antibodies to chickens, however, in this 
case, the antibodies were generated in a llama (Riazi et al, 2013). Following inoculation of 
the llama with a C. jejuni flagella, two flagella-specific single-domain antibodies were 
selected and pentamerised. When 1mg of the pentamer was fed daily to two-day-old chicks 
challenged with 108 CFU C. jejuni, the caecal colonisation levels were decreased by 2.5 log10 
CFU C. jejuni/g. The study showed that the pentamer was able to bind flagella, agglutinate 
bacteria and inhibit motility in soft agar, providing a likely explanation for the observed 
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decrease in colonisation. Even though potentially useful, such antibodies are likely to be 
expensive to produce on a suitable scale for field use. 
 
 
1.6 Aims of this study 
This study aimed to refine a previously described live-attenuated Salmonella-
vectored vaccine against Campylobacter in poultry, based on the Campylobacter antigen 
CjaA (Buckley et al, 2010), through vectoring this antigen in PoulVac® E. coli, an attenuated 
avian pathogenic E. coli vaccine. The effect of codon-optimisation of protein expression 
from the PoulVac E. coli was also assessed. 
In addition, this study also aimed to evaluate novel Campylobacter antigens as 
recombinant subunit vaccine candidates in chickens. This required the rational selection, 
cloning, purification and testing of candidate antigens in chicken vaccination and challenge 
models. Where protection was observed, we also sought to define the nature, magnitude and 
timing of avian immune responses and to associate them with protection. The capacity of 
induced antibodies to recognise their Campylobacter targets was also investigated. 
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2. Materials and Methods 
2.1 Bacterial strains and plasmids 
The bacterial strains used in this study are detailed below: 
 E. coli XL1 Blue (Stratagene, USA) was used for molecular cloning and plasmid 
propagation and maintenance. Genotype: ΔrecA1 ΔendA1 ΔgyrA96 Δthi-1 ΔhsdR17 
ΔsupE44 ΔrelA1 Δlac [F´ proAB lacIqZ∆M15 Tn10 (Tetr)]. 
 E. coli Rosetta (DE3) pLysS (Novagen, Germany) was used for protein expression 
as it contains additional tRNA genes that overcome rare codons in E. coli and allow 
universal expression. Genotype: F- ompT hsdSB(rB- mB-) gal dcm (DE3) pLysSRARE 
(CamR). 
 The C. jejuni M1 strain (Grant et al, 2005) was used as a source of DNA for cloning 
of Campylobacter antigens and as a model strain in the challenge and vaccination 
studies conducted in chickens. This was chosen in order to permit comparison with 
previous studies published in our group (Buckley et al, 2010).  
 The C. jejuni 11168H strain (Karlyshev et al, 2001) was used as a model organism 
for the study of cj0424 and as a heterologous challenge for Campylobacter antigens 
cloned from the M1 strain. This strain was chosen for testing of the role of cj0424 in 
colonisation as it is the only commonly used laboratory strain that contains this gene. 
 PoulVac EC®, an O78 strain of APEC that carries a ΔaroA mutation (La Ragione et 
al, 2013), originating from an intact vaccine vial received from Zoetis, was used for 
construction of live-attenuated vectored vaccines. 
 ST4/74 strain of S. Typhimurium that carries the ΔaroA attenuating mutation was 
also used for the construction of live-attenuated vectored vaccines and has been 
described previously (Buckley et al, 2010). 
The plasmids used for cloning in this study were:  
 pTECH2 (Khan et al, 1994) for the expression of Campylobacter antigens in live-
attenuated Salmonella or APEC vaccines (Figure 2.1). Genotype: E1 origin of 
replication giving 15-20 copies per cell; under the control of a nirB promoter 
activated by growth under anaerobic conditions; ampicillin resistance gene for 
selection; multiple cloning site (MCS) at 3’ end of tetC. 
 pGEX-4T1 (GE Lifesciences, UK) for the cloning and expression of Campylobacter 
antigens as fusions to the C-terminus of GST; these were utilised as recombinant 
purified anti-Campylobacter vaccines. Genotype: origin of replication from pBR322 
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giving approximately 50 copies/cell; tac promoter for chemical induction; contains a 
lacIq gene to control basal level of expression; ampicillin resistance gene for 
selection; MCS at 3’ end of gst. 
 pMal-p2X (New England Biolabs [NEB], UK) for the cloning and expression of 
Campylobacter antigens as fusions to the C-terminus of MBP; these were utilised as 
recombinant purified proteins in ELISAs measuring humoral responses following 
vaccination. Genotype: origin of replication from pBR322 giving approximately 50 
copies/cell; also contains an M13 origin of replication; tac promoter for chemical 
induction; contains a lacIq gene to control basal level of expression; ampicillin 
resistance gene for selection; multiple cloning site (MCS) at 3’ end of malE. 
The plasmids constructed in this study are given in Table 2.1. Bacterial strains produced 
in this study included E. coli XL1 Blue and E. coli Rosetta strains containing each of the 
pGEX-4T1 plasmid constructs given in Table 2.1 and E. coli XL1 strains containing each of 
the pMal-p2X plasmid constructs given in Table 2.1. Further strains constructed included 
PoulVac® E. coli containing the empty pTECH2 plasmid and both of the pTECH2-cjaA 
constructs given in Table 2.1 below and S. Typhimurium ST4/74 strains containing the 
empty pTECH2 and the pTECH2-cjaA constructs. 
 
  
                             
Figure 2.1 Map of the pTECH2 plasmid. Genes encoding Campylobacter antigens were 
cloned 3’ of tetC as in-frame fusions in the MCS using the BamHI and HindIII enzymes. 
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Table 2.1. Plasmids constructed in this study. 
Plasmid Description 
pTECH2-cjaA C. jejuni M1 cjaA fused 3' to tetC in pTECH2 
pTECH2-cjaAc.o. C. jejuni M1 cjaA codon optimised for expression in E. coli fused 3' to tetC in 
pTECH2 
pGEX-4T1-cjaA C. jejuni M1 cjaA fused 3’ to gst in pGEX-4T1 
pGEX-4T1-tetC tetC gene from pTECH2 fused 3' to gst  in pGEX-4T1 
pGEX-4T1-fliD C. jejuni M1 fliD fused 3’ to gst in pGEX-4T1 
pGEX-4T1-fspA C. jejuni M1 fspA fused 3’ to gst in pGEX-4T1 
pGEX-4T1-sodB C. jejuni M1 sodB fused 3’ to gst in pGEX-4T1 
pGEX-4T1-porA C. jejuni M1 porA fused 3’ to gst in pGEX-4T1 
pGEX-4T1-(PorAL7*) C. jejuni M1 loop7 of PorA fused 3’ to gst in pGEX-4T1 
pGEX-4T1-tpx C. jejuni M1 tpx fused 3’ to gst in pGEX-4T1 
pGEX-4T1-accD C. jejuni M1 accD fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cmeC C. jejuni M1 cmeC fused 3’ to gst in pGEX-4T1 
pGEX-4T1-flgE2 C. jejuni M1 flgE2 fused 3’ to gst in pGEX-4T1 
pGEX-4T1-flgk C. jejuni M1 flgK fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cj0214 C. jejuni M1 cj0124 fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cj0125 C. jejuni M1 cj0125 fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cj0126 C. jejuni M1 cj0126 fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cadF C. jejuni M1 cadF fused 3’ to gst in pGEX-4T1 
pGEX-4T1-flpA C. jejuni M1 flpA fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cj0586 C. jejuni M1 cj0586 fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cjaC C. jejuni M1 cjaC fused 3’ to gst in pGEX-4T1 
pGEX-4T1-flgL C. jejuni M1 flgL fused 3’ to gst in pGEX-4T1 
pGEX-4T1-cjaD C. jejuni M1 cjaD fused 3’ to gst in pGEX-4T1 
pGEX-4T1-ggt C. jejuni M1 ggt fused 3’ to gst in pGEX-4T1 
pMAL-p2X-cjaA C. jejuni M1 cjaA fused 3’ to malE in pMal-p2X 
pMAL-p2X-fliD C. jejuni M1 fliD fused 3’ to malE in pMal-p2X 
pMAL-p2X-fspA C. jejuni M1 fspA fused 3’ to malE in pMal-p2X 
pMAL-p2X-sodB C. jejuni M1 sodB fused 3’ to malE pMal-p2X 
pMAL-p2X-porA C. jejuni M1 porA fused 3’ to malE in pMal-p2X 
pMAL-p2X-(PorAL7*) C. jejuni M1 loop7 of PorA fused 3’ to malE in pMal-p2X 
pMAL-p2X-tpx C. jejuni M1 tpx fused 3’ to malE in pMal-p2X 
pMAL-p2X-accD C. jejuni M1 accD fused 3’ to malE  in pMal-p2X 
pMAL-p2X-cmeC C. jejuni M1 cmeC fused 3’ to malE in pMal-p2X 
pMAL-p2X-flgE2 C. jejuni M1 flgE2 fused 3’ to malE in pMal-p2X 
pMAL-p2X-flgK C. jejuni M1 flgK fused 3’ to malE in pMal-p2X 
pMAL-p2X-cj0214 C. jejuni M1 cj0124 fused 3’ to malE in pMal-p2X 
pMAL-p2X-cj0126 C. jejuni M1 cj0126 fused 3’ to malE in pMal-p2X 
pMAL-p2X-cadF C. jejuni M1 cadF fused 3’ to malE in pMal-p2X 
pMAL-p2X-flpA C. jejuni M1 flpA fused 3’ to malE in pMal-p2X 
pMAL-p2X-cj0586 C. jejuni M1 cj0586 fused 3’ to malE in pMal-p2X 
pMAL-p2X-cjaC C. jejuni M1 cjaC fused 3’ to malE in pMal-p2X 
pMAL-p2X-flgL C. jejuni M1 flgL fused 3’ to malE in pMal-p2X 
pMAL-p2X-cjaD C. jejuni M1 cjaD fused 3’ to malE in pMal-p2X 
pMAL-p2X-ggt C. jejuni M1 ggt fused 3’ to malE in pMal-p2X 
 
* Base pairs 897 to 1020 of porA encoding for protein residues 299 to 340 were cloned. 
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2.2 Culture conditions 
E. coli and Salmonella were grown in Luria Bertani (LB; Oxoid, UK) broth or agar 
at 37 ˚C, unless otherwise indicated, with shaking at 200 rpm for liquid cultures. C. jejuni 
was grown on modified charcoal cephoperazone deoxycholate agar (mCCDA; Oxoid, UK) 
or in Mueller-Hinton Broth (MH; Oxoid, UK), at 37 ˚C in a microaerophilic workstation 
(Don Whitley Scientific, UK) in a low oxygen atmosphere (5% O2, 5% CO2 and 90% N2). 
Liquid cultures of Campylobacter were grown with shaking at 400 rpm using a table top 
shaker (IKA, Germany) under low oxygen conditions as above. Antibiotics were used at the 
final concentrations of 100µg/ml ampicillin, 50µg/ml kanamycin, 20µg/ml nalidixic acid and 
34 µg/ml chloramphenicol where appropriate. 
 
2.3 DNA manipulation 
2.3.1 Plasmid DNA extraction 
Plasmid DNA was extracted from bacterial strains using the QiaPrep Spin Miniprep 
Kit (Qiagen, UK) or the Qiagen Plasmid Midi Kit, following the manufacturer’s instructions. 
The Qiagen kits works by selectively binding different sizes of DNA in high salt solutions to 
silica membranes, followed by washing and elution of the DNA of interest in low salt 
solutions or water. 
 
2.3.2 Genomic DNA extraction 
Genomic DNA (gDNA) was extracted using the Wizard Genomic DNA Purification 
Kit (Promega, UK), following the manufacturer’s instructions. The kit works by lysing the 
cells, eliminating proteins via precipitation in salt, eliminating RNA via RNase digestion and 
then concentrating and washing high molecular weight DNA by isopropanol precipitation. 
 
2.3.3 DNA purification  
PCR products were purified using the QIAquick PCR (Qiagen) purification kit and 
gel extraction of PCR amplicons using the QIAquick Gel Extraction Kit (Qiagen), according 
to the manufacturer’s instructions. Elutions were in 50 µl of water. This kit works on the 
same principles that the plasmid DNA extraction kit uses. 
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2.4 Polymerase chain reaction 
Diagnostic polymerase chain reactions (PCRs) were run using the Taq DNA 
Polymerase (Invitrogen), in a reaction of 25µl or 50 µl final volume comprising of the 
following: 0.2mM each dNTP, 1.5mM MgCl2, 0.5µM each primer, 0.05% (v/v) buffer W1 
(included in the kit), PCR buffer without MgCl2 diluted 10-fold and 1-2µl of template DNA 
solution (containing various amounts of template DNA) or bacterial suspensions in water, at 
various concentrations. The cycling conditions were as follows: 
 Initial denaturation for 45s at 94 oC 
 Thirty cycles of denaturation for 45s at 94 oC, annealing for 30s at 55 oC and 
extension for 90s at 72 oC  
 Final extension for 10 minutes at 72 oC 
 Holding of the reaction at 4 oC until use. 
 
Agarose gel electrophoresis was undertaken in 1% (w/v) agarose gels, with 1:10,000 dilution 
of SybrSafe (Invitrogen, UK) and run at 80-100V for 45-90 minutes. 
 
 
2.5 DNA Quantitation 
DNA quantity and concentration were measured using a Nanodrop 1000 machine 
(Thermo, UK). This was done according to the manufacturer’s instructions, by adding 1 µl 
of the DNA sample to the pedestal of the machine. 
 
 
2.6 Codon optimisation 
Codon optimisation of C. jejuni cjaA for expression in E. coli was carried out by 
Dundee Cell Products (Dundee, UK) in order to assess whether it would offer increased 
expression via the pTECH2 plasmid in the APEC vector. In the process of codon 
optimisation, codons of a heterologous gene that are rarely used in the host in which the gene 
is to be expressed are replaced with highly used synonymous codons. The codon-optimised 
variant of cjaA was synthesised de novo and inserted into the pBluescript plasmid. The-
codon optimised sequence of cjaA will be referred to as cjaAc.o. and was verified by double-
stranded dideoxy chain-termination sequencing by the manufacturer. The sequence of the 
codon-optimised variant in alignment with the wild-type gene is given in Section 3.2. 
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2.7 Molecular cloning 
2.7.1 PCRs for molecular cloning 
PCR amplicons for cloning were obtained using Phusion proof-reading polymerase 
(Finnzymes, Finland), with reactions containing reagents as directed by the manufacturer’s 
instructions. Cycling conditions were either as above (Section 2.4) or used a two-stage 
cycling step in the PCR protocol if the melting temperature (Tm) of the primers was above 72 
oC. The two-step protocol was as above but missed the annealing stage during the cycling 
step. Primer sequences used for amplification of genes for cloning are given in Sections 3.2 
and 4.2. 
 
2.7.2 Restriction enzyme digests 
All DNA digestion reactions contained the following: 1µl of each restriction enzyme 
supplied by NEB and containing 20 units (U) for BamHI and SalI or 10 U for NotI, 2 µl of 
an appropriate React buffer, 0.2 µl of acetylated bovine serum albumin (BSA), between 1 µl 
and 16.8 µl of DNA in water containing a maximum of 1.5 µg of DNA and water to a total 
of 20 µl. All DNA digestion reactions were incubated at 37 ˚C for 2h. For cloning of the 
Campylobacter antigens into the pGEX-4T1 and the pMal-p2X plasmids, 10 U (in 1µl) of 
calf intestinal phosphatase (CIP; NEB, UK) was added to the digestion reactions of the 
plasmids during the last hour of incubation. Digest reactions were passed through a PCR 
purification column to remove enzymes and obtain DNA eluted in water. 
 
2.7.3 Ligation 
All ligations reactions contained the following: 2 U (in 1 µl) of T4 DNA Ligase 
(Promega, UK), 1 µl of T4 DNA ligase buffer (Promega), DNA insert and vector in ratios of 
3:1, 1:1 or 1:3 (up to a total volume of 8 µl and a total amount of DNA vector of 100 ng) and 
water to 10 µl. The reactions were incubated overnight on ice in water and for a following 
hour at room temperature (RT) the following morning, before being transformed into an 
appropriate bacterial strain. 
 
2.7.4 Transformation of bacterial cells 
Plasmid transformations into chemically-competent E. coli XL1 were done 
according to the manufacturer’s instructions. A fast version of the electroporation protocol 
(Choi et al, 2006) was used for electroporation into the E. coli Rosetta strain or the APEC or 
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Salmonella strains for construction of live-attenuated vaccines. For this, the cells of 6 ml of 
overnight culture of the strain to be used were collected by centrifugation in a 1.5ml 
microcentrifuge tube at 16,060 g for 5 minutes. The cells were washed twice in 1 ml 20% 
(w/v) sucrose in water and re-suspended in a final volume of 100 µl of 20% sucrose (w/v). 
Finally, 50 µl of the cells were mixed with 1 µl of DNA containing between 100ng and 1 µg 
of DNA and pulsed in a 0.1 cm cuvette (BioRad) at 2.5kV, 25mF, 200 Ω using the 
GenePulser machine (Biorad). Immediately, 450 µl of super optimal broth with catabolite 
repression (SOC; Oxoid) warmed at 37 ˚C was added and the cells were then incubated for 
1h at 37 ˚C with shaking at 200 rpm before being plated on the appropriate selective media 
and incubated at 37 ˚C for 18-24h. 
 
 
2.8 DNA sequencing 
Sequencing of plasmid DNA or PCR amplicons was performed using the dideoxy 
chain-termination (Sanger) method and was contracted to Dundee DNA Sequencing and 
Services (University of Dundee, UK), to Source Bioscience (Nottingham, UK) or to GATC 
Biotech (Germany) and the samples were prepared according to their instructions. DNA 
sequences were analysed in Lasergene 10 (DNASTAR). Chromatograms were manually 
trimmed at the 5’ and 3’ end to good signal. The sequence obtained using the reverse primer 
was reverse complemented and a contig was formed between this and the sequence obtained 
from the forward primer. The consensus sequence was aligned in Clustal W2 with the 
expected sequence extracted from the C. jejuni M1 genome available in the Nucleotide 
database of the National Centre for Biotechnology Information (NCBI). 
 
 
2.9 Bacterial growth curves 
Bacterial growth curves were measured in order to determine whether the 
introduction of the pTECH2 plasmids had an inhibitory effect on the growth of the parent 
strains. For these assays overnight cultures were diluted 1:10,000 in LB and 100 microliters 
of this dilution added to a 96 well-plate in triplicate. A further 10-fold dilution of this culture 
(10-5) was plated on selective media for retrospective enumeration of viable bacteria in the 
inoculum. The 96 well plate was incubated at 37 ˚C with shaking every 30 minutes, followed 
by an OD595 reading, using a Multiskan Ascent spectrophotometer (Thermo Scientific). This 
cycle was continued for 18 hours. 
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2.10 Cell invasion assays 
Cell invasion and proliferation assays were used to assess whether the introduction 
of the pTECH2 plasmid in the PoulVac® E. coli and Salmonella strains had an inhibitory 
effect on the invasiveness and net intracellular survival of the parent strains. These assays 
were done in HeLa cells (ACTC CCL-2), which were grown and maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) with 200mM L-glutamine (Life Technologies, UK), in 
appropriately sized tissue culture flasks (Corning, USA). Cells were passaged when they 
reached 90% confluence by treatment with 3ml of 0.5% (w/v) trypsin-EDTA solution in PBS 
(Life Technologies) for 5 minutes followed by inactivation with an equal volume of heat-
inactivated bovine serum (HIBS). The cells were then pelleted by centrifugation at 400g for 
5 minutes and washed in Hank’s balanced salt solution (HBSS, Invitrogen, UK). The cells 
were then pelleted as above, the supernatant discarded and the cells seeded in a tissue culture 
flask of increased size and incubated as above. 
The invasion and proliferation assays were undertaken in 24 well tissue culture 
plates (Corning) that were seeded with 5x105 HeLa cells 24 hours before infection. Cells 
were incubated and maintained in the media described above. Before infection, the 
supernatant was removed and the cells were washed in HBSS once. Bacterial cultures were 
prepared by inoculation of a 10ml volume of LB medium from an overnight culture and 
grown to a minimum OD600nm of 0.5. These cultures were then diluted 1:15 in DMEM and a 
1ml volume was added to each well to give a multiplicity of infection (MOI) of 50. Inocula 
were determined by retrospective plating of serial ten-fold dilutions. The 24 wells plates 
were then incubated as above for 1 hour and at the end of the incubation period 1ml of 100 
µg/ml gentamicin (Invitrogen, UK) in DMEM was added to each well and incubated for a 
further hour. At the end of the incubation period, the HeLa cells were lysed in 0.1% (w/v) 
sodium-deoxycholate (Thermo, UK) and 10-fold serial dilutions in PBS plated on LB agar. 
 
 
2.11 Protein expression and purification 
2.11.1 Purification of GST and GST-fusion proteins 
Before large scale purification of recombinant GST-tagged Campylobacter antigens 
to be used in vaccination trials, small scale induction and purification studies were 
performed to assess the ease of purification of each protein (solubility, yield, purity, 
expression of truncated variants and ease of elution were taken into consideration) and the 
likelihood of successful large scale preparation. For these, cultures of 25ml of the E. coli 
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Rosetta cells containing the GST–Campylobacter antigen fusion constructs were inoculated 
at a 1:100 dilution from a stationary phase overnight LB culture with antibiotics as 
appropriate and incubated for 3h, with shaking at 200 rpm, at either 28 ˚C or 37 ˚C and 
induced with either 0.1 mM or 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG, Thermo 
Scientifc, UK). Following induction, the cultures were incubated for a further 3h at either 28 
˚C or 37 ˚C and then bacterial cells were harvested by centrifugation for 15 minutes at 
3200g. Bacterial pellets were lysed in 5ml/g wet cell paste of BugBuster MasterMix 
(Novagen, UK) and the lysates centrifuged at 3200g for 10 minutes to pellet the insoluble 
fraction. GST fusion proteins were purified from the supernatant using glutathione sepharose 
beads (GE Healthcare, UK), in batch format, following the manufacturer’s recommended 
protocol. Bound GST fusion proteins were eluted for one hour (50mM TrisHCl, 40mM 
glutathione pH 8), in a volume double that of the beads.  Beads were eluted three times and 
fusion protein-containing eluates confirmed by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) as described below. Only antigens for which purification of 
sufficient quantities within these conditions was possible were taken forward to be purified 
in larger quantities and tested as anti-Campylobacter vaccines in chickens. 
For large scale vaccine production, individual cultures of 500ml to 2 litres of the E. 
coli Rosetta cells containing the GST-tagged Campylobacter antigen of interest were grown 
as described above for small scale protein inductions. For poorly soluble antigens, multiple 2 
litre cultures, up to a total of 6 litres of culture, were each grown in 5 litre flasks. Bacterial 
cells were harvested by centrifugation in a KR4i ultracentrifuge (Thermo, UK) at 15,075g 
for 15 minutes. Protein purification was in batch format, on glutathione sepharose beads, as 
described above. 
 
2.11.2 Purification of MBP-fusion proteins 
Each of the Campylobacter antigens tested as a recombinant GST-tagged anti-
Campylobacter vaccine was also purified as an MBP-tagged recombinant protein in order to 
be used in ELISAs measuring the humoral responses induced by vaccination. This approach 
was chosen in order to avoid detection of antibodies against the GST fraction of the 
recombinant purified vaccines. Their purification was run in batch format, as described for 
the large scale production of the GST-tagged proteins above. However, the pMal-p2X 
constructs were expressed in the E. coli XL1 Blue cells in which they were originally cloned. 
This approach was chosen as the quantities of purified recombinant protein required for 
ELISAs were smaller than those required for vaccination and sufficient expression was 
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obtained in this strain. Conditions for incubation temperature and IPTG concentration were 
as described for the GST-tagged constructs. 
 
2.11.3 6xHis-tagged protein purification 
A 6xHis-tagged CjaA recombinant protein was purified in order to be tested in 
parallel with GST-CjaA, as used in previous studies utilising 6xHis-CjaA (Buckley et al, 
2010). The culture and induction conditions were as described for the large scale purification 
of GST-CjaA and purification was run in batch format utilising Ni-NTA His-Bind resin 
(Novagen, UK), according to the manufacturer’s recommended protocol. 
 
 
2.12 Protein quantitation 
Protein quantitation of the GST-fused Campylobacter antigens was done using the 
Bradford Assay, using the QuickStartTM Bradford 1x dye reagent (Biorad) and the 2mg/ml 
liquid BSA standard (Biorad), following the manufacturer’s instructions for the 96-well plate 
microassay protocol. This measurement assay works on the basis of a colorimetric change 
induced by the binding of Coomassie brilliant blue G250 dye to primarily basic and aromatic 
amino acid residues. This method was chosen for the GST-fused antigens as the method used 
for quantitation of the MBP-fusion constructs is inaccurate in the presence of the glutathione 
present in the elution buffer for the GST-tagged proteins. 
Quantitation of the 6xHis- and MBP-tagged antigens was via the Direct Detect 
system (Merck-Millipore, USA), following manufacturer’s instruction. This system works 
by directly measuring protein amounts in a set volume of 2µl by measuring the absorbance 
of infrared light of amide bonds present in proteins. 
 
 
2.13 SDS-PAGE 
Protein preparations were separated via SDS-PAGE on 10% Mini-TGX gels 
(Biorad, UK), ran in SDS buffer (Scientific Laboratory Supplies [SLS], UK) in a Protean 
Tetra Mini cell (Biorad, UK). All gels were run at 300V for 18 minutes. The Dual Colour 
Precision Plus protein standards (Biorad, UK) were used to estimate the molecular weight of 
separated proteins. 
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Gels were stained either with Coomassie stain, using the Biosafe Coomassie stain 
(Biorad, UK), according to the manufacturer’s instructions or silver stained using the Pierce 
Silver Stain Kit (Thermo, UK), following manufacturer’s instructions. 
 
 
2.14 Western blotting 
For Western blotting, SDS-PAGE gels were transferred to polyvinylidene fluoride  
PVDF membrane using the TransBlot Turbo system and transfer packs (Biorad, UK), 
following the manufacturer’s recommended conditions for rapid transfer (up to 25V, 2.5 A, 
3min). Membranes were blocked for one hour, at room temperature, in 5% (w/v) BSA in 
phosphate-buffered saline (PBS) containing 0.01% (w/v) Tween-20 (PBS-T). Membranes 
were washed three times in PBS-T for 15 minutes each and then incubated for one hour with 
the primary antibody diluted in PBS-T. Washing was performed for 15 minutes once, 
followed by three washes of 5 minutes each. Membranes were then incubated for 1 hour with 
secondary antibody diluted in PBS-T containing 1% (w/v) non-fat dry milk powder (Blotto, 
Santa-Cruz, USA). Blots were washed as above and developed using Clarity enhanced 
chemiluminescence (ECL) (BioRad, UK) and autoradiography (Amersham Hyperfilm ECL, 
GE Lifesciences, UK). The ECL substrate was allowed to incubate on the membrane for 5 
minutes. Table 2.2 lists the antibodies used in this study. 
 
Table 2.1 Antibodies used in this study. 
Manufacturer 
Batch 
number 
Type of 
antibody 
Antigen 
recognised 
Species 
raised in 
Isotype Procedure used in 
Dilution 
used at 
Sigma Aldrich 
051M48
87 
Secondary: HRP 
conjugated 
Chicken 
IgY 
Rabbit Polyclonal 
Westen blotting; 
ELISA 
1:3,000 
for both 
Santa Cruz K1903 Primary GST Rabbit 
Polyclonal 
IgG 
Western blot 1:10,000 
AbD Serotec 010312 
Secondary: HRP 
conjugated 
Chicken 
IgA 
Goat 
Polyclonal 
IgG 
ELISA 1:10,000 
Abcam 
GR1102
83-1 
Secondary: 
Alexa Fluor® 488 
conjugated 
Chicken 
IgY 
Goat 
Polyclonal 
IgG 
Immunofluorescence 
(IF) 
1:500 
AbD Serotec 1006 Primary 
Tetanus 
exotoxin 
Goat 
Polyclonal 
IgG 
Western blotting 1:10,000 
Sigma Aldrich 
1212156
A 
Secondary: HRP 
conjugated 
Rabbit IgG Goat Polyclonal Western blotting 1:10,000 
AbCam  Primary MBP Rabbit IgG1 Western blotting 1:10,000 
This study N/A Primary SodB Chicken 
Polyclonal 
IgY 
IF 1:500 
This study N/A Primary FliD Chicken 
Polyclonal 
IgY 
IF 1:500 
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2.15 Vaccination trials 
2.15.1 Experimental animals 
All procedures were conducted under Home Office PPL 60-4420, according to the 
requirements of the Animal (Scientific Procedures) Act 1986, and with the approval of the 
local ethical review committee (Moredun Research Institute (MRI), Edinburgh, UK). 
Institutional guidelines of the MRI for the care of animals and for animal procedures were 
also followed. A total of 800 White Leghorn chickens, obtained on the day of hatch from the 
National Avian Research Facility (NARF) at The Roslin Institute (Edinburgh, UK) were 
used. Eggs were incubated and hatched under specified pathogen-free conditions either at 
MRI or at the NARF and transported to the MRI on the day of hatch. Animals were housed 
in groups of up to 20 birds, in colony cages of 1.5 m2, in a single room (up to 6 cages per 
room). The birds were on wire mesh floors, partially covered with cardboard to provide 
support for young birds. Groups were of mixed sex and were wing-tagged for individual 
identification following assignment to a cage. Water was given ad libitum and the feed 
consisted of a fine-ground starter vegetable-protein-based sterile irradiated feed for the first 
two weeks of life and (DBM Ltd., UK). The birds were then weaned on a grower pellet diet 
for the remainder of the experiment (DBM Ltd). Birds were sourced from Campylobacter-
free layer flocks and confirmed to be free of Campylobacter by plating of cloacal swabs on 
mCCDA, followed by microaerophilic incubation. 
 
2.15.2 Experimental design 
To maintain consistency in experimental design with previous vaccination trials 
undertaken by our laboratory, the vaccination and challenge protocol described in Buckley et 
al (2010) was followed. Briefly, between 12 and 24 birds were used per experiment per 
group. A mechanical dispenser and high accuracy syringes (Hamilton-Bonaduz, Switzerland) 
were used for both vaccinations and challenge to deliver an accurate dose. Vaccination was 
subcutaneous on each side of the thorax, in a volume of 50 µl per side. At each vaccination, 
the antigen preparations were mixed in a 1:1 ratio with TiterMax Gold (Sigma-Aldrich, UK) 
and each bird received 4.3x10-10 moles of entire recombinant protein. Birds were given the 
primary vaccination on the day of hatch and a booster 14 days later. 
Birds were challenged at 28 days post hatch (dph) through oral gavage, with c. 107 
CFU of C. jejuni M1 or 11168H per bird, in a volume of 50 µl. Challenge cultures were 
prepared by first streaking the M1 strain on mCCDA and then, following incubation as 
described above, inoculating single colonies into MH broth and incubating the liquid cultures 
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for 24 hours. The liquid cultures were then standardised to an OD600 of 0.15, corresponding 
to 2x109 CFU/ml. They were confirmed to have spiral morphology and rapid motility and 
then diluted a further 10-fold in PBS to a final working concentration of 2x108 CFU/ml. 
Starting one week after challenge, between 4 and 6 birds were removed at weekly 
intervals for Campylobacter enumeration and at the same time samples of blood and bile 
were collected for the measurement of humoral responses at post-mortem examination. 
Blood was collected through cardiac puncture after the death of the birds and stored at 4 ˚C 
overnight to allow coagulation. The following morning blood cells were pelleted by 
centrifugation at 3200g for 10 minutes. Serum was collected and stored at -80 ˚C until use. A 
schematic representation of the time-course of the vaccination and challenge experiments is 
given in Figure 2.2. 
 
2.15.3 Assessment of caecal colonisation 
Enumeration of caecal Campylobacter was performed by weighing 1g of caecal 
contents for each of the samples available and diluting this 1:10 with 9ml of Bolton Broth 
(Oxoid, UK) containing Bolton Broth selective supplement (Oxoid, UK). From this, a further 
six 10-fold serial dilutions in PBS were made in 48 well plates, in a total volume of 1ml for 
each dilution. From each dilution, 100µl was plated on mCCDA plates, which were 
incubated in a microaerophilic atmosphere for 48 hours, as described above. The 10-1 
dilution in Bolton Broth was incubated for 24 hours as described above, following which it 
was plated by streaking with a 10 µl sterile plastic loop on mCCDA plates, which was then 
incubated for 48 hours as described above. Colonies were counted on each of the mCCDA 
plates and only counts between 10 and 400 were used in calculating an average CFU/ml of 
caecal contents. Given a 1 gram sample, the theoretical limit of detection was 100 CFU/g by 
direct plating and 1 CFU/g following enrichment culture. 
 
2.15.4 ELISAs 
ELISAs were performed to measure antigen-specific serum IgY and secretory bile 
IgA (sIgA) against each of the recombinant antigens tested as vaccine candidates. The assays 
were done essentially as previously described by Buckley et al (2010), however, no blocking 
step was used for the measurement of serum IgY. Plates were coated with an appropriate 
amount of antigen diluted in carbonate-bicarbonate buffer in a total volume of 100 µl in each 
well and incubated at 37 ˚C for 1h. They were then washed five times in PBS containing 
0.1% (w/v) Tween-20 (PBS-T) by submerging the plate in solution, flicking the liquid out of  
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the wells, inverting and tapping on paper. One hundred µl of serum or bile samples diluted in 
PBS-T were then added to each well, using an appropriate dilution for each antigen and the 
plates were incubated at 37 ˚C for 1h. Plates were then washed as described above, 100 µl of 
secondary antibody added to each well and then incubated at 37 ˚C for 1h. Secondary 
antibodies were an HRP-conjugated rabbit anti-chicken IgY antibody (Sigma, UK) used at a 
1:3000 dilution to detect bound serum IgY or an HRP-conjugated goat anti-chicken IgA 
antibody (AbD Serotec, UK) used at a 1:10,000 dilution to detect bound sIgA. Coating 
conditions and dilutions of the samples were optimised for each antigen using chequerboard 
analyses for IgY and sIgA individually. Chequerboard analyses are used to determine 
appropriate antigen coating concentration and sample dilution to ensure the readings are 
obtained within the linear range of the assay. For this, ELISAs with three-fold serial 
dilutions of representative samples were performed on halving concentrations of coating 
antigen. Plates were developed using tetramethylbenzidine (TMB) substrate (Biolegend, 
UK), for five minutes, as described by the manufacturer, reactions stopped by addition of 1M 
sulphuric acid and then absorbance was measured at 450nm on a Multiskan Ascent plate 
reader (Thermo, UK). 
 
 
2.16 Immunofluorescent staining of C. jejuni cells 
Assessment of subcellular localisation of SodB within C. jejuni cells was carried out 
by immunofluorescent staining of whole Campylobacter cells. Serum from GST-SodB-
vaccinated chickens collected before challenge was used as primary antibody. Poly-L-lysine 
treated glass cover slips were coated with 500 µl of an overnight culture of C. jejuni 11168H, 
and fixed in 4% (w/v) paraformaldehyde for 30 minutes. Cover slips were washed three 
times with 1ml of PBS. Where indicated, cells were permeabilised with 10% (v/v) Triton X-
100 for 30 minutes and non-specific sites blocked for 30 minutes in 0.5% (w/v) bovine 
serum albumin (BSA) in PBS (BSA-PBS). Cover slips were as above. Pooled serum form 
GST-SodB vaccinated birds was applied at 1:500 in BSA-PBS and a goat anti-chicken IgY 
conjugated to AlexaFluor-488 secondary antibody (Abcam, UK) was used for detection at a 
1:500 dilution in BSA-PBS. Cover slips were as above after incubation with each of the 
primary and secondary antibodies. Cover slips were dipped in water once to remove salts in 
PBS and then mounted on glass slides using Prolong Gold (Life Technologies), according to 
manufacturer’s directions. Images were captured using fluorescent and light microscopy on a 
DML microscope (Leica, Germany). 
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2.17 Generation of subcellular fractions of C. jejuni 
Subcellular fractions of C. jejuni 11168H were generated by Halah Al-Haideri, 
University of Sheffield.  For the preparation of the periplasmic fraction, an osmotic shock 
procedure was used. C. jejuni 11168H cultures in early stationary phase were harvested by 
centrifugation (8,000g, 10 min, 4 °C) and resuspended in 20 ml buffer containing 20% (w/v) 
sucrose, 30 mM Tris-HCl pH8, 1mM EDTA (STE) and incubated with gentle shaking for 30 
min. The cells were pelleted by centrifugation at 10,000g, for 10 min at room temperature 
and then re-suspended in 10 ml ice-cold 10 mM Tris-HCl pH8. Following incubation with 
gentle shaking (20 rpm, 2 hr, 4°C), cells were pelleted by centrifugation at 15,000g for 25 
min at 4 °C, and the supernatant containing the periplasmic proteins was carefully removed 
and stored at -20 °C. 
To prepare the inner and outer membrane fractions, C. jejuni 11168H cells were 
cultured to early stationary phase and harvested by centrifugation (15,000g, 20 min, 4 °C) 
then re-suspended in 10 ml 10 mM HEPES pH 7.4. The cells were broken by sonication with 
6 x 15 sec pulses at an amplitude of 16 microns using a Soniprep 150 ultrasonic disintegrator 
(SANYO) and then pelleted by centrifugation (15,000g, 20 min, 4°C) to remove unbroken 
cells and debris. The supernatant was carefully transferred to a pre-cooled tube. In order to 
isolate the outer and inner membrane, total membranes were first pelleted by 
ultracentrifugation (100,000g, 1 hr, 4 °C) in a Ti70.1 rotor (Beckman Coulter, UK) and the 
pellet washed twice with 5 ml of 10 mM HEPES pH 7.4. The membrane pellet was finally 
re-suspended in 1 ml 10 mM HEPES pH 7.4. To solubilise the inner membrane, an equal 
volume of 2% (v/v) Sarcosyl (Sodium N-Lauryl sarcosinate) dissolved in 10 mM HEPES 
buffer was added with gentle mixing. Following incubation at 37 ˚C for 30 min, the mixture 
was pelleted by centrifugation (15,000g, 30 min, 4 °C). The supernatant (solubilized inner 
membrane) was collected and stored at -20 °C and the outer membrane pellets were 
resuspended in 10 mM HEPES buffer pH 7.4, washed and re-pelleted twice. Finally, the 
pellet was resuspended and dispersed in 0.5-1 ml of 10 mM HEPES buffer pH 7.4 and stored 
at -20 °C. 
The purity of the fractions was demonstrated by Halah Al-Haideri through Western 
blotting with αCapA (an outer membrane auto-transported adhesin, Ashgar et al, 2007) or 
αMfrA (a periplasmic fumarate reductase subunit associated with an inner membrane 
complex, Guccione et al, 2010). 
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2.18 Model for testing the effect of C. jejuni mutations in Galleria 
mellonella 
A model to assess bacterial virulence in wax moth (Galleria mellonella) larvae was 
developed in order to assess whether cj0424 may play a role in colonisation or virulence. 
The model has been reported to detect the attenuating effect of mutations in factors known to 
influence virulence in mammalian models and chicken colonisation (Champion et al, 2010). 
For this model, the C. jejuni 11168H wild-type, Δcj0424 mutant and a Δcj0424::cj0424 
complemented strain provided by Halah Al-Haideri were inoculated on mCCDA by 
streaking with a 10 µl sterile plastic loop. After incubation of the plates for 48 hours, 
multiple liquid cultures of each strain were inoculated in MH broth and grown for 24 hours 
as described above. In contrast to the vaccination experiments, liquid cultures were 
inoculated using a sweep of multiple colonies from the mCCDA plates. At the end of this 
incubation period, each culture was assessed visually, under an inverted light microscope, at 
400x magnification, for morphology and motility of the C. jejuni cells. Only the three 
cultures with the most similar morphology and motility were taken forward to be tested in 
wax moth larvae. 
For testing in wax moth larvae, cultures of each strain were standardised to an OD600 
of 0.15 and then diluted a further 10-fold in PBS. For each culture, 10 larvae were injected 
with 10 µl each, on the caudo-dorsal aspect, using a LT1200 syringe (Hamilton-Bonaduz, 
Switzerland). Each larva received a total dose of c. 106 CFU of C. jejuni determined by 
retrospective plating of serial ten-fold dilutions of inocula on mCCDA. Larvae were then 
incubated microaerophilically, in inverted 90mm Petri dishes, on a disc of filter paper. The 
number of live/dead larvae was recorded for each of the groups at three hour intervals and 
differences in the survival of each of the groups assessed as detailed below. 
 
2.19 Model for testing the effects of C. jejuni mutations in chickens 
A model of Campylobacter challenge and persistence was developed in chickens in 
order to assess the effect of the Δcj0424 mutation on the colonisation potential of C. jejuni 
11168H. These experiments were run under the same Home Office project and personal 
licence as described above for the vaccination experiments. Ethical approval was obtained 
from the MRI. White Leghorn eggs were sourced from and incubated in the NARF as 
described above. When hatched, day-old chicks were transferred to MRI and grown under 
SPF conditions as described above, in groups of 20 birds. Cultures of the three C. jejuni 
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11168H strains described in the wax moth larvae model were prepared as described above. 
Cultures of identical motility and morphology were used to separately challenge each of the 
birds by oral gavage with 50 µl of culture diluted in PBS containing 108, 106 or 104 CFU. 
Each group received only one of the three strains utilised. Caeca were collected from 4-6 
birds at post-mortem examination at weekly intervals for three weeks following challenge. 
Campylobacter numbers present in caecal contents were determined by plating serial 
dilutions on mCCDA as described above for the vaccination experiments. 
 
 
2.20 Statistical analysis 
All statistical analyses were performed using Minitab 17 (Minitab, UK), with the 
exception of the survival curves for the Galleria mellonella model, which were done in 
Prism 6 (GraphPad, USA). 
Individual caecal Campylobacter counts were logarithmically transformed and the 
arithmetic mean was calculated. Significant reductions compared to control groups were 
determined using post-hoc Dunnet tests following fitting of a third order hierarchical general 
linear model (GLM) that took into account interactions between experiment, time of 
collection and treatment group. A separate model was fitted for each of the datasets 
presented subsequently. 
As the main purpose of serum IgY measurement was to demonstrate successful 
vaccine delivery, only significant inductions in each vaccine group relative to control birds 
were assessed, without comparisons between different treatment groups. Significant changes 
in serum IgY were determined through a two-tailed Student’s t-test on the raw OD450nm data.  
Antigen-specific fold changes in OD450 of serum IgY in individual birds were 
calculated by dividing the OD450 measures in each vaccinated bird by the average of the 
GST-vaccinated control group calculated at each sampling time-point. Correlations between 
serum IgY levels and caecal Campylobacter counts in individual birds were assessed by 
fitting of a linear regression to the data. P values of ≤ 0.05 were considered significant. 
Differences in survival curves of Galleria melonella were assessed using the 
Survival Analysis function in Prism 6. The logrank test was utilised and p values ≤ 0.05 were 
considered significant. 
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3. Live vectored vaccines for the control of 
Campylobacter in poultry 
 
3.1 Introduction 
3.1.1 The use of CjaA in vectored vaccines against Campylobacter in poultry 
 Vaccines for the control of Campylobacter, including subunit vaccines vectored in 
attenuated bacterial strains were discussed in Section 1.5. Previous research within our 
laboratory described the use of attenuated S. Typhimurium strains vectoring CjaA as 
vaccines for the control of Campylobacter infection in poultry (Buckley et al, 2010). The 
study describes the use of ∆aroA S. Typhimurium 4/74 carrying a pTECH2 plasmid that 
expressed CjaA as a fusion to the C-fragment of tetanus toxin (TetC), under the control of 
the nirB promoter, which is believed to be induced in vivo by anaerobic conditions. 
Following oral vaccination of Light Sussex birds with 107 CFU of the vaccine per bird, a 
reduction of approximately 1.5log10 CFU C. jejuni/g in caecal colonisation of the 
homologous C. jejuni M1 strain was observed at 48 and 56 days post-hatch. While the 
protection was statistically significant, it reflected six biological replicates, each using 3 
birds per group per time-point and variation was observed between trials. Furthermore, 
protection was observed late in the life of commercially reared birds as most broilers are 
slaughtered around 6 weeks of age. 
 The same study investigated the use of different attenuating mutations and reported 
that strains of Salmonella with different mutations vary in the protection induced when 
vectoring CjaA. S. Typhimurium attenuated through ∆spaS or ∆ssaU induced significantly 
larger decreases in caecal Campylobacter loads (approximately 3.5log10 CFU/g) compared to 
the ∆aroA attenuated strain (approximately 1.5log10 CFU/g when tested in parallel, similar to 
the initial experiment across six biological replicates). This was observed across two 
biological replicates, each using 3 birds per time point per group. In Salmonella, spaS and 
ssaU encode components of the Salmonella pathogenicity island (SPI) 1 and 2 Type III 
secretion systems respectively and they have been shown to be important for colonisation of 
the chicken gut and systemic disease depending on the serovar and age of bird at inoculation. 
In S. Typhimurium, which causes age-dependent systemic disease in chickens with only the 
very young being affected, both SPI-1 and SPI-2 secretion systems are important in day old 
chicks as mutants in both aforementioned genes showed reduced gut colonisation in chickens 
and reduced clinical signs (Jones et al, 2007). Dieye et al (2009) showed that SPI-1 is 
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essential for spleen and gut colonisation of week-old chicks by S. Typhimurium but a SPI-2 
mutant was only defective in colonisation of the spleen. In contrast, in S. Gallinarum, which 
causes overt pathology and clinical signs in chickens of all ages, only SPI-2 appears to be 
essential for virulence and colonisation as only the ∆ssaU mutant had a severely attenuated 
phenotype (Jones et al, 2001). 
 Other independent reports describe the use of CjaA-based vaccines for control of 
Campylobacter infection in chickens. Wyszynska et al (2004) reported a 6log10 CFU/g 
reduction in caecal colonisation following vaccination of chickens with 108 CFU of an asdA 
balanced-lethal system attenuated S. Typhimurium χ3987, vectoring CjaA from the high copy 
number plasmid PYA334. The reductions were observed at days 3 to 12 following challenge 
with 108 CFU of C. jejuni 72Dz/92 strain carrying a plasmid conferring chloramphenicol 
resistance. Another study reports a more modest reduction of 2log10 CFU/g when vectoring 
CjaA in a ∆aroA mutant of S. Typhimurium that constitutively expressed a 35aa fragment of 
CjaA on the surface of the bacterium, from a chromosomal insertion of the cjaA fragment in 
a region of the lamB gene that gives rise to surface expressed protein (Layton et al., 2010). 
Interestingly, the vector strain presented the CjaA fragment in concert with a 10aa fragment 
of CD145, predicted to contain the binding motif for activation of CD40, though the 
requirement for this modification in protection was not tested. In addition to the above 
studies demonstrating the successful use of CjaA in bacterial vectors, one study reported a 
1log10 CFU/g reduction in caecal Campylobacter numbers following vaccination of chickens 
with transgenic Eimeria tenella expressing CjaA (Clark et al, 2012). Properties of the vector 
system are evidently significant as the same authors that claimed a 6 log10 CFU/g reduction 
in caecal colonisation after vaccination of chickens with S. Typhimurium ΔaroA expressing 
CjaA (Wyszynksa et al, 2005) later observed no protection when using a different strain for 
delayed regulated expression (Laniewski et al, 2014a). 
 
3.1.2 Avian pathogenic E. coli as vectors for CjaA-based vaccines 
Given the previous research in our group described above and the reports of 
independent groups on the successful use of CjaA in vectored vaccines against 
Campylobacter in poultry, this project initially aimed to construct and test refined bacterial 
vectors expressing this antigen. Towards this aim, we developed and tested a ∆aroA avian 
pathogenic E. coli (APEC) vaccine expressing CjaA. 
APEC are a group of highly heterogeneous bacteria (reviewed by Guabiraba and 
Schouler, 2015) that cause a complex of respiratory and systemic diseases generically named 
avian collibacilosis with clinical signs including airsacullitis, polyserositis, perihepatitis, 
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pericarditis, septicaemia and other mainly extra-intestinal presentations (reviewed by Dho-
Moulin and Fairbrother, 1999). Dziva and Stevens (2008) discuss the various virulence 
factors present in APEC, but emphasise that these factors do not universally occur in all 
APEC, which suggests disease is likely to be induced through different molecular 
mechanisms by highly different strains. In view of the pathogenic potential of APEC, we 
hypothesised that strains engineered to express CjaA may induce improved protection 
against C. jejuni given that more invasive strains of Salmonella were shown to provide better 
protection (Buckley et al, 2010). 
Furthermore, using an APEC-based vaccine would allow poultry farmers to control 
both collibacillosis and Campylobacter colonisation concomitantly. This could potentially 
act as a financial incentive to control a seemingly innocuous infection in chickens due to 
reduced mortality and improved productivity conferred by vaccination against APEC. A 
further advantage of using APEC as a vector is that there is a genetically modified ∆aroA 
APEC vaccine licensed for use in poultry in Europe and the United States. This vaccine is 
marketed by Zoetis as PoulVac® E. coli and La Ragione et al (2013) showed that vaccinated 
birds did not show mortality when challenged with the wild-type fully virulent APEC 
O78:H9 strain and that the signs of collibacilosis were reduced from 100% in non-vaccinated 
bird to approximately 40% of vaccinated birds. The associated patent also claims 
heterologous protection against serogroup O1 and O2 strains. Using PoulVac® E. coli as a 
vector creates a precedent for the licensing of genetically modified APEC-based vaccines for 
field use and may have the added advantage of ease of commercialisation and reduced 
development costs for Zoetis. Other advantages of using PoulVac® E. coli are its ease of use 
and safety. The vaccine is typically delivered as a spray directed at the heads of the birds on 
the day of hatch and the safety profile of this vaccine has been determined during its 
licensing. Although it can colonise the gut of chickens it does not cause clinical signs in 
vaccinated birds (La Ragione et al, 2013). Lastly, the vaccine has been shown to be 
protective against collibacilosis in turkeys and as such may allow the concomitant control of 
Campylobacter in other commercially important birds. Our laboratory has been studying the 
immune responses induced by PoulVac® E. coli in turkeys and chickens and their association 
with protection (Sadeyen et al, 2015a; Sadeyen et al, 2015b). 
Lastly, APEC may pose a lower risk of zoonosis than attenuated Salmonella 
vaccines. Even though they have been shown to contain many of the virulence associated 
genes found in human uropathogenic E. coli (UPEC) strains (Rodriguez-Siek et al¸ 2005) 
and human neonatal meningitis strains (Johnson et al, 2012), the latter study also showed 
that APEC have a markedly lower potential of causing systemic disease and meningitis in 
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murine models of this disease. In contrast, Nolan et al (2010) found serogroup O18 strains of 
APEC and neonatal meningitis E. coli (NMEC) to have a similar disease outcome in a rat 
model of human disease. As such, the potential of APEC to cause human disease remains to 
be elucidated.  
 
 
3.2 Materials and Methods 
 This section will specifically describe the construction, validation and testing of S. 
Typhimurium and APEC-based attenuated vaccines vectoring CjaA, using the general 
methods described in Section 2. 
 
3.2.1. Construction of Salmonella vectored vaccines 
 The ∆aroA S. Typhiumurium 4/74-based vaccine strains described previously by 
Buckley et al (2010) served as positive controls in the vaccination and challenge experiments 
testing the APEC-based vaccines. To construct the pTECH2-cjaA plasmid, the cjaA gene 
was amplified from C. jejuni M1 using the primers given in Table 3.1 and ligated into 
pTECH2 following digestion of both the insert and plasmid with BamHI and HindIII. 
Ligation reactions were transformed into chemically-competent E. coli XL1 cells and 
individual colonies screened for positive clones via a colony PCR, using the pTECH2seq primer 
forward and the pTECH2seq primer reverse (Table 3.1). At the time of screening, each colony was 
also re-streaked on LB agar supplemented with ampicillin and incubated for a further 8h, 
followed by a second round of diagnostic PCR. Clones positive in both PCR rounds were 
inoculated into liquid media and grown overnight. Plasmid DNA was extracted from each 
liquid culture and validated through sequencing by Dundee DNA Sequencing and Services. 
The ∆aroA Salmonella Typhimurium ST4/74 strain (Buckley et al, 2010) was 
transformed through the fast electroporation method with validated the pTECH2 or 
pTECH2-cjaA plasmids. Following electroporation, individual colonies were re-streaked on 
LB agar containing ampicillin and nalidixic acid (the parent ∆aroA S. Typhiumurium 4/74 
strain is nalidixic resistant) and the colonies that grew were screened by PCR for the 
presence of the expected plasmid. The presence of the ∆aroA mutation in S. Typhimurium 
ST4/74 vaccines was confirmed via PCR using the primers ∆aroA-STfwd and ∆aroA-STrev 
(Table 3.1). Colonies that were confirmed positive for pTECH2 and pTECH2-cjaA were 
inoculated in 10ml of LB broth and incubated overnight. The following day, they were 
stored in 16.6% (v/v) glycerol at -70 oC until further use. In addition, these liquid broth 
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cultures were used to extract plasmid DNA from each strain and plasmids validated via a 
restriction enzyme digest utilising the BamHI and NotI emzymes (data not shown). 
 
3.2.2 Construction of APEC vectored vaccines 
3.2.2.1 Codon optimisation of cjaA 
 Due to C. jejuni cjaA containing 20% of codons that are rarely used in E. coli, we 
tested whether codon optimisation increases the expression level of CjaA within the APEC-
based vaccines. Codon optimisation was undertaken by Dundee DNA and Sequencing 
Services, using a table of codon usage for APEC based on codons used in highly expressed 
genes. The codon optimised variant was synthesised de novo with the BamHI and NotI 
restriction enzyme recognition sequences at the 5’ and 3’ ends. The newly synthesised gene 
was introduced in pBluescript to be used as a vector for propagation of the construct. Figure 
3.1 shows the sequence of the codon optimised cjaA compared to the wild-type variant. 
 
3.2.2.2 Cloning of wild-type and codon optimised cjaA into the expression vector 
and transformation into the vaccine strain  
 The APEC strain used for the construction of these vaccines originated from an 
intact vial of PoulVac® E. coli received directly from Zoetis. This vial was reconstituted 
according to the manufacturer’s recommendations and cells were stored in 16.6% (v/v) 
glycerol at -70 oC both in their original reconstituted form and after two passages (growth on 
LB agar plates with subsequent inoculation of a single colony into LB broth). The passaged 
culture originating from a single colony was used for the construction of the APEC vaccines 
vectoring CjaA. 
 To create the pTECH2 plasmids vectoring codon optimised cjaA (denoted hereafter 
as pTECH2-cjaAc.o.), the pBluescript plasmid containing the codon optimised variant of cjaA 
was transformed into E. coli XL1 for propagation and amplification. This strain was grown 
and cjaAc.o. was digested from extracted plasmid DNA using BamHI and NotI. The digested 
product was ligated into pTECH2 digested with the same enzymes and the ligation 
transformed into E. coli XL1. Validation of the transformants was undertaken as described 
above for the construction of pTECH2-cjaA, including double strand sequencing of the 
insert. 
The pTECH2, pTECH2-cjaA and pTECH2-cjaAc.o. plasmids were electroporated 
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Wild-type_cjaA            ATGAAAAAAATACTTCTAAGTGTTTTAACGGCCTTTGTTGTAGTAGTATTGGCTGCTTGT 60 
Codon_optimised_cjaA      ATGAAGAAAATCCTGCTGAGCGTCCTGACAGCGTTTGTCGTGGTGGTGCTGGCAGCTTGC 60 
                          ***** ***** ** ** ** **  * ** ** ***** ** ** **  **** *****  
 
Wild-type_cjaA            GGAGGAAATTCTGACTCTAAAACTTTAAATTCTCTTGATAAGATCAAGCAAAATGGAGTT 120 
Codon_optimised_cjaA      GGCGGGAATAGCGACAGCAAGACTCTGAATAGTCTGGATAAGATCAAACAAAACGGCGTG 120 
                          ** ** ***   ***   ** *** * ***  *** *********** ***** ** **  
 
Wild-type_cjaA            ATTAGGATTGGGGTATTTGGCGATAAACCACCTTTTGGTTATGTGGATGAAAAAGGAAAC 180 
Codon_optimised_cjaA      ATTCGTATCGGTGTGTTCGGTGACAAACCTCCGTTCGGGTATGTGGACGAGAAAGGTAAT 180 
                          *** * ** ** ** ** ** ** ***** ** ** ** ******** ** ***** **  
 
Wild-type_cjaA            AATCAAGGCTATGATATAGCTTTAGCTAAACGCATAGCAAAAGAACTTTTTGGCGATGAA 240 
Codon_optimised_cjaA      AACCAAGGCTATGACATTGCCCTGGCCAAGCGCATCGCGAAAGAACTGTTTGGGGATGAA 240 
                          ** *********** ** **  * ** ** ***** ** ******** ***** ****** 
 
Wild-type_cjaA            AATAAGGTGCAATTTGTTCTTGTTGAAGCTGCAAATAGGGTTGAGTTTTTAAAATCAAAT 300 
Codon_optimised_cjaA      AATAAAGTACAGTTTGTGCTGGTAGAAGCTGCCAACCGTGTCGAGTTCCTGAAAAGCAAT 300 
                          ***** ** ** ***** ** ** ******** **  * ** *****  * ***   *** 
 
Wild-type_cjaA            AAAGTAGATATTATTTTGGCTAATTTTACTCAAACTCCGCAAAGAGCCGAGCAGGTTGAT 360 
Codon_optimised_cjaA      AAAGTGGACATCATCCTGGCAAATTTCACGCAGACGCCGCAACGCGCCGAACAGGTTGAC 360 
                          ***** ** ** **  **** ***** ** ** ** ****** * ***** ********  
 
Wild-type_cjaA            TTTTGCTTGCCTTATATGAAGGTAGCTTTAGGCGTAGCTGTACCAAAGGATAGTAATATA 420 
Codon_optimised_cjaA      TTCTGTCTGCCGTATATGAAAGTTGCGCTGGGTGTTGCTGTGCCAAAGGACAGCAATATC 420 
                          ** **  **** ******** ** **  * ** ** ***** ******** ** *****  
 
Wild-type_cjaA            ACTAGCGTAGAAGATTTAAAAGATAAAACCTTGCTTTTAAACAAAGGCACAACAGCAGAT 480 
Codon_optimised_cjaA      ACGAGTGTTGAAGACCTGAAAGACAAAACGCTGCTGCTGAACAAAGGGACCACTGCCGAT 480 
                          ** ** ** *****  * ***** *****  ****  * ******** ** ** ** *** 
 
Wild-type_cjaA            GCGTATTTTACGCAAAATTATCCTGATATTAAAACTTTAAAATACGATCAAAATACCGAA 540 
Codon_optimised_cjaA      GCATACTTTACCCAGAACTATCCGGACATTAAGACCCTGAAATACGACCAGAACACAGAA 540 
                          ** ** ***** ** ** ***** ** ***** **  * ******** ** ** ** *** 
 
Wild-type_cjaA            ACTTTTGCCGCTTTGATGGATAAAAGAGGCGATGCTTTAAGTCATGATAATACCTTGCTT 600 
Codon_optimised_cjaA      ACCTTTGCGGCACTGATGGATAAACGCGGCGATGCACTGAGTCATGATAACACCCTGCTG 600 
                          ** ***** **  *********** * ********  * *********** *** ****  
 
Wild-type_cjaA            TTTGCTTGGGTGAAAGATCATCCTGATTTTAAAATGGCTATCAAAGAGTTAGGCAACAAA 660 
Codon_optimised_cjaA      TTTGCGTGGGTCAAAGATCACCCGGATTTCAAAATGGCGATTAAAGAACTGGGTAACAAA 660 
                          ***** ***** ******** ** ***** ******** ** *****  * ** ****** 
 
Wild-type_cjaA            GATGTTATCGCACCAGCAGTTAAAAAAGGCGATAAAGAACTTAAAGAATTTATCGATAAT 720 
Codon_optimised_cjaA      GATGTAATTGCCCCAGCGGTAAAGAAAGGTGATAAAGAGCTGAAAGAGTTTATTGATAAC 720 
                          ***** ** ** ***** ** ** ***** ******** ** ***** ***** *****  
 
Wild-type_cjaA            TTGATCATTAAACTAGGCCAAGAGCAGTTTTTTCACAAGGCTTATGATGAAACTTTAAAA 780 
Codon_optimised_cjaA      CTGATTATTAAACTGGGCCAGGAACAGTTCTTTCATAAAGCGTACGATGAAACCCTGAAG 780 
                           **** ******** ***** ** ***** ***** ** ** ** ********  * **  
 
Wild-type_cjaA            GCTCATTTTGGAGATGATGTTAAGGCTGATGATGTAGTGATTGAAGGTGGAAAAATTTAA 840 
Codon_optimised_cjaA      GCGCACTTCGGCGATGATGTTAAGGCTGATGATGTGGTTATTGAGGGCGGCAAGATCTAA 840 
                          ** ** ** ** *********************** ** ***** ** ** ** ** *** 
 
 
 
Figure 3.1 Alignment of the codon optimised variant of cjaA with the wild-type variant. The alignment 
was performed in ClustalW2. The nucleotide sequence of codon-optimised CjaA in pTECH2 was confirmed to 
be as presented (data not shown) 
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into PoulVac® E. coli and transformed colonies validated as described above for the 
Salmonella vaccines. The primers used for the validation of the ∆aroA mutation in the parent  
and vaccine strains are given in Table 3.1. The pTECH2 diagnostic primers were used to 
ensure each vaccine contained the expected plasmid. 
 
Table 3.1 Primers used for cloning and validation of the Salmonella- and APEC- based 
vaccines vectoring CjaA. Underlined sequence represent recognition sites of enzymes used 
for cloning. 
Primer Sequence (5’ to 3’) 
 
Primers for cloning of cjaA into pTECH2 
cjaAfwd CCCCCCGGATCCATGAAAAAAATA 
cjaArev CCCCCCAAGCTTTTAAATTTTTCCACCTTCAATC 
 
Diagnostic primers 
pTECH2 seq primer forward GGTTGCGACTGGTACTTCGT 
pTECH2 seq primer reverse TTACCGCCTTTGAGTGAGCT 
∆aroA-STfwd CCGATTGAAGGGGTAAAAGC 
∆aroA-STrev GCCACCGCCAGTAGTAATGA 
∆aroA-APECfwd TTGAGTTCGAACGTCGTCAC 
∆aroA-APECrev ATACCCCACAAGGTCCGAAA 
 
3.2.3. Assessment of antigen expression from the live vectored vaccines  
 The TetC-CjaA and TetC antigens were expressed in the Salmonella and APEC 
vectors from the pTECH2 plasmid, which contains the nirB promoter reported to be induced 
by anaerobic conditions, but found in this study to express under aerobic conditions also. 
Expression of CjaA from the vaccines described above was assessed through Western 
blotting of aerobic and anaerobic cultures. For this, the vaccine strains were streaked on LB 
agar for individual colonies from glycerol stocks and a single colony was inoculated either in 
6ml of LB broth in a 20ml universal or in 7 ml of LB broth in a 7ml universal. The cultures 
were incubated at 32 oC for 16 hours, either with the lid loosened in the case of the 20ml 
universals or with the lid tightly closed in the case of the 7ml universals, to create aerobic 
and anerobic growth conditions respectively. The following day, 1 ml of each culture was 
pelleted by centrifugation at 16,060 g for 5 minutes and the pellet lysed in 100 µl of 
BugBuster. An equal volume of Sample Treatment Buffer (STB) was added to each tube and 
20 µl of each sample resolved by SDS-PAGE and transferred to PVDF membrane. A 
Western blot using an anti-TetC antibody (AbCam, UK) used at a 1:10,000 dilution was run 
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to assess expression of TetC or the TetC-CjaA fusion from the pTECH2 and pTECH2-cjaA 
plamids. 
 
3.2.4. Comparison of growth curves, invasion and replication of the vaccine strains 
and the parent strains 
 In order to demonstrate that the introduction of the pTECH2 plasmids did not lead to 
attenuation of the APEC strains used as vectors, their growth curves, invasion and replication 
phenotypes were tested in vitro. Growth curves were determined for each vaccine strain 
using the method described in Section 2.10 and compared to that of the parent strain. The 
invasion and net replication profiles of each of the constructed strains were compared to that 
of the parent strain through the use of a gentamicin protection assay, which was run as 
described in Section 2.11. The retention of the endogenous plasmids of PoulVac® E. coli 
following introduction of the pTECH2 plasmids was also tested. For this, the parent 
PoulVac® E. coli and each of the vaccine strains were grown overnight in LB broth. Five ml 
of culture were pelleted by centrifugation at 16,060 g for 5 minutes and plasmid DNA 
extracted from each of the strains. One µg of each DNA preparation was run on a 1% 
agarose gel at 100V for one hour to assess the plasmids present within each preparation. As 
the use of S. Typhimurium successfully vectoring heterologous Campylobacter antigens 
from the pTECH2 plasmid has been described in the literature previously (Buckley et al, 
2010; Pogonka et al, 2003; Somner et al, 1999), no such tests were run for the Salmonella-
vectored vaccines. 
 
3.2.5. Testing of the above vaccines in chickens 
 Once the expression of TetC and TetC-CjaA from the Salmonella and APEC 
vectored vaccines was confirmed, they were tested for their protective efficacy against 
homologous challenge in chickens. CjaA-vectoring vaccines were tested in parallel with 
vectors containing the empty pTECH2 plasmid and with a PBS only group. Two vaccination 
and challenge trials were run using the protocol described in Section 2. Subcutaneous 
vaccination was used to ensure delivery of a standard inoculum. Each trial used between 2 
and 5 birds per group per time-point. All of the groups were housed within the same room in 
the first experiment, whilst in the second experiment control groups (vaccinated with PBS or 
with the empty vectors) were housed in a separate room. This was due to low level 
transmission of the vaccine strains to the control groups during the first trial as a result of 
one bird being erroneously returned to a wrong cage after they escaped their cage during 
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feeding. This error occurred due to the birds not being wing-tagged during the first 
experiment by a member of Moredun Animal Services. Subsequent experiments used double 
wing-tagging to avoid such errors. 
 
3.2.6. Dissemination and persistence of the live-vectored vaccines 
 To assess the dissemination of the vaccines following subcutaneous delivery, liver 
and spleen samples were collected at three days after each vaccination from two birds in 
each group. The entire spleen and the central lobe of the liver were sampled for each bird. 
These were weighed, diluted 1:10 (w/v) in PBS and homogenised using 7mm stainless steel 
beads in 2ml SafeLock® tubes (Eppendorf, UK) in the TissueLyser® II machine (Qiagen, 
UK). Samples were homogenised twice, at 25Hz, for two minutes, with the block being 
turned between runs in order to ensure equal path length for all samples. Three further 10-
fold dilutions of these homogenates were made and 100 µl of each dilution were plated on 
MacConkey agar plates containing ampicillin. Also, 1ml of the original culture was 
inoculated into 10ml of LB broth with ampicillin as an enrichment culture. To assess 
persistence of the vaccines, the first three serial dilutions used for enumeration of 
Campylobacter in caecal contents were also plated on MacConkey agar supplemented with 
ampicillin. 
 
3.2.7. Measurement of serum IgY responses induced by vaccination 
3.2.7.1 Production of the coating antigen to be used in ELISAs 
 In order to measure antigen-specific humoral responses in vaccinated birds, TetC 
and CjaA were purified as GST-tagged recombinant proteins, expressed from the pGEX-4T1 
plasmid. The tetC gene was amplified from the pTECH2 plasmid using the primers 
described in Table 3.2 and digested with BamHI and NotI restriction enzymes. The cjaAc.o. 
gene was digested with the same restriction enzymes from pTECH2-cjaAc.o.. Both genes 
were separately ligated in pGEX-4T1 digested with BamHI and NotI. Ligations were 
transformed into E. coli XL1 and 100 µl plated onto LB agar with ampicillin. After 
overnight incubation, individual colonies were inoculated on LB agar with ampicillin and 
screened for the expected insert by PCR, using the primers described in Table 3.2. Positive 
colonies were inoculated in 10ml of LB broth with ampicillin and verified by PCR a second 
time. Cultures from colonies positive for both PCRs were chosen for plasmid DNA 
extraction. Plasmids were validated by sequencing on both strands at Dundee DNA and 
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Sequencing Services and correct plasmids were electroporated into E. coli Rosetta using the 
fast electroporation method. 
 GST-TetC and GST-CjaA were purified from E. coli Rosetta as described in Section 
2.11.1, using 500ml cultures. The purity of each of the preparations was assessed via a 
Western blot using a mouse monoclonal IgG1 anti-GST antibody (Santa-Cruz Biotech, 
USA), at a 1:10,000 dilution. Before use in ELISAs, protein concentration in each 
preparation was assessed using the QuickStart Bradford Assay (Biorad, UK). 
 
Table 3.2 Primers used in construction and validation of the pGEX-4T1 plasmids 
expressing TetC and CjaA as recombinant GST-tagged proteins. Underlined sequences 
represent the recognition sites for restriction enzymes used during cloning. 
Primer   Sequence (5'-3') 
 
Primers for cjaA and tetC cloning into pGEX-4T1 
pGEX-4T1-tetCfwd CCGGCCGGATCCCTGATGAAAAACCTTGATTGTTG 
pGEX-4T1-tetCrev GGGGCCGCGGCCGCGTCGTTGGTCCAACCTTCAT 
 
Diagnostic primers for the pGEX-4T1 plasmids 
pGEXfwd GGGCTGGCAAGCCACGTTTGGTG 
pGEXrev  CCGGGAGCTGCATGTGTCAGAGG 
 
 
3.2.7.2 Measurement of serum IgY responses by ELISAs  
 Antigen-specific serum IgY and bile secretory IgA (sIgA) induction against CjaA 
and TetC were measured by ELISAs using the GST-TetC and GST-CjaA preparations 
described above as coating antigens. Chequerboard analyses were run for serum and bile for 
each antigen separately to determine appropriate coating concentrations and sample dilution. 
For coating ELISA plates, GST-CjaA was used at a concentration of 0.5 µg/ml and GST-
TetC was used at a concentration of 1 µg/ml for measurement of both serum and bile 
humoral responses.  
For birds vaccinated during the first experiment only, induction of serum IgY against 
CjaA was measured by determining titres of antibodies for each bird. For this, 3-fold serial 
dilutions were used for each serum sample and the titre was calculated as the dilution of 
serum which would give the OD450nm reading corresponding to the point half way between 
the high and low plateaus. 
For subsequent experiments, serum and bile antibody induction due to vaccination 
was determined through the use of a single sample dilution that fell within the linear range of 
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typical curves obtained in chequerboard analyses. To assess CjaA-specific induction, sera 
and bile were diluted 1:500 and to assess TetC-specific induction they were diluted 1:250. 
To assess induction of antibodies induced specifically by vaccination, fold-changes in serum 
IgY compared to the PBS-control group were calculated for each treatment group. At each 
sampling interval, these were expressed as average fold-change in OD450nm reading of 
individual birds, obtained by dividing the OD450nm for individual vaccinated birds to the 
average OD450nm of the PBS-injected control group at that particular sampling interval. 
 
 
3.3 Results 
3.3.1 Construction of the live attenuated vaccines vectoring CjaA 
 Sequencing of the pTECH2-cjaA and pTECH2-cjaAc.o. plasmids demonstrated them 
to have the expected sequence (as shown in Figure 3.1). The validated plasmids pTECH2-
cjaA and pTECH2 were transformed into the ∆aroA S. Typhimurium ST4/74 strain. The 
pTECH2-cjaA, pTECH2-cjaAc.o. and the pECTH2 plasmids were transformed into the ∆aroA 
PoulVac® E. coli strain received from Zoetis. Each vaccine strain was validated by PCR with 
the pTECH2(seq primer forward) and the pTECH2(seq primer reverse) primers flanking the cloning site and 
found to contain the expected plasmids (Figure 3.2, panels A and C). Each vaccine also 
contained the 100bp deletion in the aroA gene, as demonstrated by PCR using the primers 
given in Table 3.1 (Figure 3.2, panels B and D). 
 
3.3.2. Demonstration of antigen expression in the vaccine strains constructed 
 Following validation of each of the vaccine strain genotypes as described above, the 
expression of TetC or TetC-CjaA from the constructed strains was demonstrated via Western 
blot analysis of total protein from aerobic and anaerobic cultures, using an anti-TetC 
antibody. All vaccine strains expressed the expected antigens under both aerobic and 
anerobic conditions (Figure 3.3). No increase in antigen expression was observed under 
anaerobic conditions and no improvement in expression was conferred by codon 
optimisation of cjaA. 
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3.3.3 Phenotypic validation of the PoulVac® E. coli vaccine strains 
3.3.3.1 Growth curves 
 Growth curves were determined in order to assess whether the introduction of the 
heterologous expression plasmid impaired the growth of the PoulVac® E. coli strain. Under 
aerobic conditions in rich medium (LB broth), none of the pTECH2-containing vaccine 
strains exhibited decreased growth compared to the parent strain not containing the pTECH2 
plasmid (Figure 3.4). 
 
Figure 3.2. Validation of S. Typhimurium 4/74 and PoulVac® E. coli-based live 
attenuated anti-Campylobacter vaccines. A. pTECH2 and pTECH2-cjaA constructs in S. 
Typhimurium ST4/74 ∆aroA vaccines. Expected size of the PCR products are: 450bp for 
pTECH2; 1290bp for pTECH2-cjaA and pTECH2-cjaAc.o. B. Validation of the ∆aroA 
attenuating mutation in S. Typhimurium vaccines – the mutation was made through the 
replacement of aroA with the aph cassette from pACYC177 (1122bp). Expected size of 
wild-type aroA amplicon is 1468bp. C. pTECH2, pTECH2-cjaA and pTECH2-cjaAc.o. 
constructs in the PoulVac® E. coli vectored vaccines. Expected size of the PCR products are 
as for panel A. D. Validation of the ∆aroA attenuating mutation in the PoulVac® E. coli 
vaccines – the mutation was made through the deletion of a 100bp region of the gene. 
Expected size of wild-type aroA amplicon is 1591bp. 
 
650bp 
500bp 
400bp 
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Figure 3.3. Expression of TetC and TetC-CjaA in the live attenuated anti-
Campylobacter vaccines. A. Expression of TetC and TetC-CjaA in the ∆aroA S. 
Typhimurium vaccines under aerobic (1) and anaerobic conditions (2). B. Expression of 
TetC and TetC-CjaA in the ∆aroA PoulVac® E. coli vaccines under aerobic (1) and 
anaerobic conditions (2). CjaA and CjaAc.o. were tested in the same Western blot and the 
separation between them denotes the removal of a lane testing another antigen not described 
in this study. Arrows indicate the expected size of the antigen in each construct: TetC 55kD, 
TetC-CjaA 90kD. All cultures were standardised to the OD450nm of the culture with the lowest 
reading and the lysate of 1 ml of each culture was used. 
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Figure 3.4. Growth curves of the PoulVac® E. coli-based anti-Campylobacter vaccines. 
Growth curves were determined in triplicate for each of three biological replicates by 
growing in 96 well plates at 37 ˚C degrees with shaking every 30 minutes, followed by 
automatic measurement of OD600nm after each shaking. Data presented are the average of all 
replicates. 
 
 
3.3.3.2. Cellular invasion and net replication in vitro 
 In order to further validate that the introduction of the heterologous expression 
vector did not alter the phenotype of the vaccine strains compared to their parent strain, a cell 
invasion and proliferation assay was run. This assay is more likely to be relevant to in vivo 
growth conditions than growth in rich medium. Using HeLa cells, no differences in 
invasiveness and net replication were noted between the vaccine and the parent strains in the 
case of the PoulVac® E. coli vectored vaccines (Figure 3.5). The wild-type S.Typhimurium 
ST4/74 strain was also tested in this assay but it is not shown in the figure due to a much 
higher level of the inoculum being recovered (3% mean recovery across three replicates). 
 
3.3.3.3. pTECH2 plasmid compatibility in PoulVac® E. coli 
 The retention of the endogenous plasmids in PoulVac® E. coli was assessed by 
agarose gel electrophoresis of plasmid DNA extractions from each of the vaccines strains 
and the parent strain. The plasmid species that were present in the parent strain were also 
present in all of the vaccine strains (data not shown). 
cjaAc.o. 
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Figure 3.5 Invasion and net replication of the PoulVac® E. coli strains in HeLa cells. 
The data represents the average of three biological replicates, each run in triplicate. Bacteria 
were allowed to invade for 1 hour and the HeLa cells incubated in the presence of 
gentamicin for a further hour before being lysed. The error bars represent the SEM. 
 
 
3.3.4. In vivo testing of the live attenuated vaccines vectoring CjaA 
3.3.4.1 Safety profile of the vaccines 
 In each treatment group, a minimum of 32 White Leghorn birds were vaccinated 
subcutaneously on the day of hatch and at 14 dph with 107 CFU of the vaccine strains across 
the two experiments run. The subcutaneous route of vaccination was chosen for reliability of 
delivery and due to a single study run previously had suggested that the S. Typhimurium 
4/74 ΔaroA vaccine vectoring CjaA was more protective when given via this route than 
when administered orally (unpublished data cited in Buckley et al, 2010) None of the 
vaccinated birds exhibited clinical signs typical of salmonellosis or colibacilosis following 
vaccination. 
 
3.3.4.2 Protection against caecal colonisation 
 The live attenuated Salmonella and APEC vaccines vectoring TetC-CjaA were 
tested for their protective efficacy against homologous challenge with the C. jejuni M1 strain 
in chickens in two independent experiments. A third order hierarchical general linear (R2 = 
0.48) model taking into account the time of sampling, treatment group and experiment was 
fitted to the average data of the two experiments. Post-hoc Dunnet’s tests indicated a 
significant difference between the group vaccinated with S. Typhimurium ST4/74 ΔaroA 
vectoring CjaA and the PBS-injected group (p = 0.016) when considering the entire course 
of colonisation.  However, the course of colonisation in this group was not significantly 
cjaAc.o. 
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different to the empty Salmonella vector (p = 0.7) and neither was there a difference between 
the empty Salmonella group and the PBS-injected group (p = 0.2). Furthermore, post-hoc 
Dunnet’s test taking into account treatment group and time of vaccination could not 
distinguish individual time points that were significantly different. As such, it can be 
concluded that overall no reduction in caecal colonisation was observed with either of the 
vaccines when compared to vaccines expressing TetC only or with a PBS-injected control 
group (Figure 3.6C). Data obtained in individual replicates is shown in Panels A and B of 
Figure 3.6. 
 
3.3.4.3 Recovery of the vaccine strains from liver, spleen and gut 
During the first experiment, three birds were sampled at post-mortem examination 
three days after the first vaccination to assess the invasion of the vaccine strains and 
dissemination to the liver and spleen. No birds were culled for this purpose after the second 
vaccination due to poor hatching rates and fewer birds than originally planned being 
available for the experiment. During the second experiment, three birds were culled for post-
mortem examination three days following each vaccination. In each vaccination experiment, 
both the Salmonella and the APEC strains were recovered from the liver and spleen of 
vaccinated birds.  
Bacterial recovery from vaccinated birds, averaged across both experiments, is given 
in Figure 3.7. No statistically significant differences between primary vaccination and 
booster or between vaccine strains were observed.  
To investigate the duration of colonisation of the gut by the vaccine strains, the first 
serial dilution used for assessment of Campylobacter colonisation was streaked onto 
MacConkey agar supplemented with ampicillin. While not quantified, this demonstrated the 
presence of the vaccine in the gut of vaccinated birds strains throughout the duration of the 
study (data not shown), raising concern that if the vaccines were ever used as described they 
may persist to the point of entry into the food chain. 
 
3.3.5 Induction of humoral responses following vaccination 
3.3.5.1 Production of GST-tagged recombinant CjaA and TetC 
In order to develop ELISAs to measure humoral responses induced by vaccination, 
TetC and CjaA were cloned into pGEX-4T1 and expressed as recombinant GST-tagged 
proteins. In small scale preliminary experiments testing induction conditions, CjaA 
expression gave the optimal balance of quantity and solubility when induced at 28 oC with 
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0.1 mM IPTG, while TetC produce soluble protein when expressed at 37 oC with 1 mM 
IPTG (data not shown). Under these conditions, larger scale purifications of GST-TetC and 
 
   
 
 
 
Figure 3.6. Protective efficacy of the live vaccines vectoring CjaA against caecal 
colonisation by the homologous C. jejuni M1 strain. A. Colonisation kinetics during the 
first vaccination and challenge experiment. B. Colonisation kinetics within the second 
vaccination and challenge experiment. C. Average colonisation kinetics from both 
vaccination and challenge experiments. In all panels, data is given as average of log-
transformed caecal C. jejuni M1 counts in vaccinated birds. Caecal C. jejuni counts were 
determined through serial dilution of caecal contents collected at post-mortem examination. 
Between 3 and 6 birds were sampled at each time-point in each group. Error bars represent 
the standard error of the mean (SEM). Between time-points, lines infer the course of 
colonisation and should not be interpreted as longitudinal caecal counts. 
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Figure 3.7. Dissemination of the vaccine strains to liver (A) and spleen (B) at three days 
after each vaccination. Data is given as average of log-transformed bacterial counts per 
gram of tissue in each organ. Error bars represent SEM. In total, between 4 and 6 birds were 
sampled at primary vaccination and 3 birds were sampled at the time of the booster. The 
entire spleen was collected and as such the limit of detection for this organ was 1 CFU/g. 
 
 
GST-CjaA were run. The final protein preparations used in ELISAs resolved through SDS-
PAGE are shown in Figure 3.8A. The purity of the preparations and the identity of the bands 
observed through Coomassie staining were assessed by a Western blot using an anti-GST 
antibody. This highlighted the presence of GST-only truncations in both the GST-TetC and 
the GST-CjaA preparations (Figure 3.8B). Passage of the protein preparation through a 
concentrator column with a molecular weight cut-off of 50kD did not eliminate the presence 
of the GST only truncation (Figure 3.8B). 
 
A. 
B. 
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Figure 3.8. Purification of GST-CjaA and GST-TetC for use in ELISAs measuring 
antigen-specific humoral responses. A. Coomassie stain of SDS-PAGE resolved GST-
TetC and GST-CjaA protein preparations. Black arrows indicate the expected size of each of 
the constructs (GST: 25kD, GST-CjaA: 50kD and GST-TetC: 75kD). B. Purity of the protein 
preparations in panel A indicated by a Western blot with an anti-GST antibody. 1 and 2 are 
the same protein preparation before and after passage through a concentrator column with a 
50kD molecular cut-off. White arrow heads indicate the expected size of each of the 
constructs. Red arrows indicate truncation of the constructs with a size equal to that of GST 
alone that reacts with an anti-GST antibody. 
 
 
3.3.5.2 Induction of serum IgY within the first vaccination trial 
 Humoral immune responses to vaccination were determined in order to establish that 
the lack of protection against caecal colonisation by Campylobacter was not due to failure to 
adequately deliver the vaccines. Antigen-specific serum IgY induction was measured by 
ELISA using the GST-TetC and GST-CjaA coating antigens described above. The average 
titre obtained in each vaccinated group at each sampling point is given in Figure 3.9A. 
Significant inductions of antigen-specific serum IgY were observed only in the group that 
received S. Typhimurium ST4/74 ΔaroA vectoring CjaA, at 42 (p = 0.01) and 48 (p = 0.02) 
dph. In order to reduce work for subsequent experiments, vaccine-specific induction of 
serum IgY against CjaA was also calculated as fold-change in OD450 of each treatment group 
compared to the control PBS-injected group using a single reading within the linear range of 
the assay. The data is shown in Figure 3.9B. Significant changes were calculated on the raw 
OD450nm and are observed at the same time-points as in panel A. Additional time-points of 
significant induction are observed compared to both the PBS-injected controls and the empty 
vector controls. These are due to the smaller range of values for OD450nm compared to titres 
and as such lower variability of the data obtained in this way. The data suggest that 
vaccination with Salmonella ST4/74 ΔaroA vectoring TetC-CjaA induced a more stable  
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Figure 3.9. Induction of CjaA-specific serum IgY in the first vaccination experiment.  
A. Specific anti-CjaA serum IgY induction expressed as titre, calculated as the dilution 
required to give an absorbance reading half-way between the maximum and minimum 
absorbance obtained in a three-fold serial dilution. Error bars repent the SEM. Significant 
changes are denoted by * (p < 0.05). 
B. Specific anti-CjaA serum IgY induction due to vaccination expressed as fold change in 
OD450nm of individual vaccinated birds over the average OD450nm of the PBS-injected control 
group. Only one reading in the linear range was used for each bird. Error bars represent the 
SEM. Significant changes are changes are denoted by * (p < 0.05) and ** for (p < 0.01) and 
brackets indicate differences to the empty vector control groups. 
C. Validation of ELISAs measuring CjaA-specific serum IgY through Western blotting. The 
Western blot shows the reactivity to GST-CjaA of sera collected from one bird at each time-
point from the Salmonella vectoring CjaA vaccine group during the first vaccination 
experiment. Lanes 1 to 6 represent individual birds at the following time-points: (1) 
challenge; (2) to (5) weeks 1, 2, 3 and 4 post-challenge. The OD450nm given below the lanes 
are the reading obtained in ELISAs. The lower reactive band is a GST truncation, the middle 
band is the GST-CjaA species (red arrowhead) and the top band is likely to be GST-CjaA 
dimer as GST can dimerise. 
* * 
C. 
* 
* 
** 
* 
** * * 
* 
 
85 
 
serum IgY response compared to vectoring in PoulVac® E. coli, as evidenced by significant 
induction induced by the latter vaccine only at 56 dph and stable induction of the former 
throughout the study. However, no significant difference was found between these groups. 
While a marked induction in serum IgY against CjaA was observed in the PoulVac® E. coli 
vectored group at 35 dph, this was not statistically significant due to high variation in the 
data observed at this time-point. 
 Validation of the specificity of the developed ELISA was undertaken through 
Western blotting. The GST-CjaA preparation was probed with sera containing different 
antibody levels obtained at different time-points, using a multi-lane block. Bound serum IgY 
was detected with the same anti-chicken IgY HRP-conjugated antibody that was used in the 
ELISA, used at the same dilution. The reactivity of each serum sample towards GST-CjaA is 
shown in Figure 3.9C and the intensity of the specific reactivity obtained through Western 
blotting varies in line with the OD450nm obtained in ELISAs. 
 
3.3.5.3 Induction of CjaA-specific bile sIgA in the first vaccination trial 
 The induction of CjaA-specific bile sIgA during the first vaccination trial was 
determined as fold-change in OD450nm in each treatment group over the PBS-injected control 
group. This was done in order to assess whether vaccination induced other antibody types 
than serum IgY alone. The average fold-change in each treatment group is shown in Figure 
3.10. Due to variable availability of samples (certain birds had no bile in the gall bladder), 
statistical significance could not be assessed at all time-points for all groups. Within the 
groups and time-points at which it was possible to assess statistical significance, no 
significant changes in bile IgA were found. 
 
3.3.5.4 Induction of TetC-specific humoral responses in the first vaccination trial 
 Induction of TetC-specific serum IgY and bile sIgA was determined in vaccinated 
birds as fold changes in OD450nm over the control group, as described above. Figure 3.11 
shows the average fold-changes in TetC-specific antibodies in both serum (Panel A) and bile 
(Panel B). No significant induction of bile IgA was observed against TetC in any of the 
vaccinated groups. Significant induction of TetC antibodies were detected in the group 
vaccinated with S. Typhimurium 4/74 ΔaroA vectoring empty pTECH2 at 35 (p = 0.01) and 
42 (p = 0.03) dph and in the group vaccinated with PoulVac® E. coli vectoring pTECH2-
cjaA at 35 dph (p = 0.0008). 
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Figure 3.10. Induction of CjaA-specific bile sIgA in vaccinated birds within the first 
experiment. Data is expressed as average fold-change in OD450nm over PBS only vaccinated 
birds. Error bars represent the SEM. 
 
 
Figure 3.11. TetC-specific antibody inductions in within the first experiment. A. TetC 
specific serum IgY expressed as fold-change in OD450nm over PBS vaccinated birds. B. TetC 
specific bile sIgA expressed as fold-change in OD450nm over PBS vaccinated birds. Error bars 
represent the SEM. Significant inductions are denoted by * (p < 0.05) and *** (p < 0.001) 
and are superimposed on the time-points at which they were observed. 
* 
* 
*** 
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3.3.5.5. Induction of CjaA-specific serum IgY in the second vaccination trial 
 In order to assess whether the vaccines were delivered successfully in the second 
vaccination experiment, induction of serum IgY was determined as fold increase in OD450nm 
in vaccinated birds compared to the PBS-injected control group. However, loss of sample 
labelling during storage resulted in approximately half of the samples being discarded. As 
such, the majority of time points had either missing data or a single value and statistical 
significance could not be assessed. Out of the time-points at which statistical significance 
was assessed, there was a significant 2.7 fold increase in the group vaccinated with S. 
Typhimurium ST4/74 ΔaroA vectoring CjaA (p = 0.006) at 3 weeks post-challenge and a 
1.5-fold increase in the group vaccinated with the PoulVac® E. coli vectoring CjaA vaccine 
(p = 0.01) at 2 weeks post-challenge. These may indicate successful delivery of the vaccine 
although caution should be exercised in interpretation of these results in view of the missing 
data. 
 
 
3.4 Discussion 
 Vaccines vectoring CjaA as a TetC fusion in ∆aroA S. Typhimurium 4/74 and ∆aroA 
APEC O78:H9 (PoulVac® E. coli) were constructed and shown to express the TetC-CjaA 
fusion from pTECH2, under the control of the nirB promoter. The nirB gene of E. coli 
encodes an NADH-dependent nitrite reductase and its promoter was described initially in E. 
coli by Jayaraman et al (1987). Furthermore, it was shown that the promoter is partially 
induced by anaerobic conditions, through the action of the FNR protein, but that optimal 
activation required the addition of nitrite to the culture medium. Jayaraman et al (1988) 
mapped the nucleotide sequences of the promoter region required for induction by anaerobic 
conditions and by nitrite. Expression of TetC in E. coli driven by the nirB promoter and its 
induction by anaerobic conditions, with an increase in TetC of approximately two orders of 
magnitude, was demonstrated by Oxer et al (1991). The nirB promoter was also used for 
plasmid-driven expression of TetC in a ∆aroA ∆aroD S. Typhimurium (Chatfield et al, 
1992), with stable expression and propagation of the plasmid in mice vaccinated with this 
strain. 
 In contrast to the tight regulation of the nirB promoter claimed by Oxer et al (1991) 
in E. coli and by Chatfield et al (1992) in Salmonella, all of the vaccines constructed in this 
study expressed the TetC and TetC-CjaA antigens at a similar level under both the aerobic 
and anaerobic culture conditions used here. Both this study and the studies described above 
used the same method of induction – completely filling 7ml bijoux and tightening the lid. 
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However, the difference in oxygen availability within the two culture conditions was not 
assessed. Alternatively, addition of nitrite to the culture medium may be required for 
maximal induction that may allow a difference to be observed between culture conditions. 
This may mimic natural infection conditions as it has been shown that the nirB promoter can 
induce high levels of expression following Salmonella invasion in macrophages (Everest et 
al, 1995), which use nitrite production (Iyengar et al, 1987) as a defence mechanism against 
bacterial pathogens, including Campylobacter (Iovine et al, 2008).  
 In the case of the APEC-based vaccines, codon optimisation of cjaA did not appear 
to increase TetC-CjaA expression. While codon optimisation has been shown to generally 
confer increased in vitro expression over native genes, there is no universally accepted 
method of codon optimisation and particular methods may not be broadly applicable as some 
genes appear refractory to improved expression following codon optimisation (Burgess-
Brown et al, 2008). This could be the case with cjaA expression and suboptimal codon 
optimisation may account for the premature termination (Goldman et al, 1995) observed 
within this study and also reported by Buckley et al (2010). Furthermore, it has been shown 
that, at least in yeast, the codon usage bias may vary with the phase of growth and codon 
optimisation may have to take this into account (Lanza et al, 2014). This aspect is not widely 
studied for individual bacteria and is not a factor that most codon optimisation programmes 
take into account. Another aspect that could contribute to the lack of improvement in TetC-
CjaA expression is that the tetC gene was not codon optimised. Given that the antigen 
expressed was a continuous fusion of CjaA to TetC, with TetC being translated first, it is 
possible that the expression of TetC acted as a limiting factor. Lastly, it is possible that even 
though not observed in vitro, codon optimisation of cjaA conferred an expression advantage 
in vivo. While it was attempted to grow the vaccine strains in minimal medium supplemented 
with aromatic amino acids and assess antigen expression, the level of growth was too low to 
detect the antigen through a Western blot (data not shown). 
When tested in vivo, although both of the attenuated Salmonella and APEC 
vectoring TetC-CjaA vaccines induced significant increases in CjaA-specific serum and bile 
IgA in vaccinated White Leghorn birds, neither of the vaccines induced protection against 
caecal colonisation by the homologous C. jejuni M1 strain. A number of deviations from the 
study design reported by Buckley et al (2010) could have accounted for this difference. 
Firstly, the breed of chickens used in this study was White Leghorn and it is possible that the 
nature and timing of immune responses in this breed differs compared to the Light Sussex 
birds used previously. Secondly, it is possible that through running only two biological 
replicates with a total of 8-10 birds per time-point, this study was underpowered. The 
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previous study reported data from six replicates with a total of 18 birds per time-point to 
yield a statistically significant reduction of 1.4log10 CFU/g. Individual caecal Campylobacter 
counts from the previous trials were not available to assess the variance in those experiments 
and calculate sample sizes for the current experiments that would ensure adequate statistical 
power. In addition, subcutaneous vaccination was used in this study while the study reported 
by Buckley et al (2010) used oral vaccination. This approach was chosen as a single 
experiment previously carried out using subcutaneous delivery of the live-attenuated 
Salmonella vaccines resulted in improved protection (Anthony Buckley, unpublished data). 
It is possible that oral vaccination may induce a local immune response more appropriate for 
clearing of the infection and delivery of the vaccines developed within this trial by a 
different route may result in protection. Lastly, while the previous experiments report that 
the Salmonella vaccine strain was cleared from the intestines of vaccinated birds by 38 dph, 
in the current experiments all vaccine strains were detected throughout the experiment. The 
long-term presence of the live Salmonella or APEC within the birds, even though attenuated, 
may have dominated the immune response at the later time-point in the experiment and 
decreased the magnitude of the immune response towards Campylobacter. Additionally, it 
has been shown that the presence of lesions consistent with E. coli infections in broilers is a 
significant risk for factor Campylobacter infection (Bull et al, 2008; FSA, 2015b) although 
mechanisms behind this effect have not yet been elucidated. 
In spite of the absence of protection, the induction of CjaA-specific serum IgY was 
detected in both groups vaccinated with Salmonella ST4/47 ΔaroA or PoulVac® E. coli 
vectoring TetC-CjaA. Using a single OD450nm reading within the linear range of the assay (as 
determined through chequerboard analysis) proved to be a more sensitive method of 
detection than the use of titres. Due to the high variability in bird to bird response to 
vaccination, the lower range of the OD450nm measurements compared to titres resulted in less 
overall variation and an increased power of the assay. Using this method, significant 
increases were detected compared to both the PBS-only vaccinated group and the empty 
vector control groups. While the data also suggest a more stable induction of antigen-specific 
antibody by the Salmonella vectored CjaA vaccines, with higher inductions of serum IgY at 
the time of challenge, no significant differences were observed between these groups. 
Assessment of differences between these groups would likely require the use of a higher 
number of birds per time-point due to high variability of the response to vaccination 
observed in individual birds. 
To assess the safety of the live-attenuated vaccines in vaccinated birds, the 
experimental animals were monitored for clinical signs throughout the duration of the 
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experiment. None of the vaccinated birds showed clinical signs following vaccination, 
however, a small number of birds died unexpectedly. These birds did not exhibit gross organ 
pathology at post-mortem examination and the cause of death was unidentified. In addition, 
three birds from each vaccinated group were culled three days after each vaccination. 
Bacteria were recovered at low levels from the spleen and liver in the majority of the birds. 
Recovery of the Salmonella vaccine strain from these organs was also observed within the 
previous studies undertaken in our group. In line with efficient attenuation of both the 
Salmonella and the APEC vaccine, none of the birds culled throughout the duration of the 
study exhibited gross internal pathology. However, no detailed histopathology was 
undertaken and organ invasion of the vaccine strains was not measured longitudinally within 
these experiments. Even though subcutaneous vaccination was used, these findings are in 
line with those described by La Ragione et al (2013) for PoulVac® E. coli and by Buckley et 
al (2010) for the S. Typhimurium vaccines using oral delivery. 
To assess the risk of vaccine transmission to the consumer, vaccine presence within 
the gut was assessed at each of the time-points used in this study. In contrast to the findings 
of Buckley et al (2010), which reported clearance of the vaccine strain at 38 dph after oral 
vaccination, both the Salmonella and the APEC vaccine strains were recovered from the 
caecal contents of the vaccinated birds throughout the duration of this study. The presence of 
the vector strains within the caeca of vaccinated birds at time of slaughter poses the risk of 
carcass contamination with these vaccines and the transmission of these vaccines to 
consumers should the products not be handled or cooked appropriately. These findings are in 
line with experiments carried out during PoulVac® E. coli’s European Medicines Agency 
(EMA) licensing procedures that describe the persistence of the vaccine strain in cloacal 
swabs of vaccinated birds for 4 weeks following vaccination through coarse spray (EMA, 
2012). While a risk of transmission to consumers was highlighted by the EMA, they also 
deemed that due to the safety and stability profiles of this vaccine, no withdrawal period 
needed to be imposed. The position taken by the EMA indicates that, provided the safety and 
stability of a genetically modified vaccine can be clearly proven, there is scope for their use 
within the food chain even though they may persist in the animal at the point of 
consumption. 
In order to develop ELISAs for the measurement of serum IgY and bile sIgA, the 
TetC and CjaA proteins were cloned into the pGEX-4T1 vector and expressed as GST-
tagged recombinant proteins. Western blotting with an anti-GST antibody indicated the 
presence of GST only truncations. As discussed above for the expression of TetC-CjaA 
within the vaccine strains, it is possible that rare codons in the heterologous genes for TetC 
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and CjaA resulted in premature termination of translation (Goldman et al, 1995). The 
presence of the GST only truncation after passage through a concentrator column with a 
molecular weight cut-off of 50kD may to be associated with the ability of GST to dimerise 
(Fabrini et al, 2009), resulting in complexes with a molecular weight of 50kD. 
Using the GST-CjaA and GST-TetC protein preparations described above, the 
inductions of CjaA- and TetC-specific antibodies in serum and bile was measured through 
ELISAs. Significant induction of antigen-specific serum IgY in both vaccination trials 
indicate that the vaccines were delivered successfully in both experiments. The patterns of 
induction of CjaA-specific serum IgY and sIgA following vaccination with the Salmonella-
based vaccine in the first experiment were similar to that described by Buckley et al (2010), 
albeit a different line of bird and route of delivery were used. Within both these experiments 
and the previously reported ones the peak of serum IgY levels did not correspond with any 
reduction in caecal C. jejuni levels: the peak in OD450nm reading was at 49dph, whereas in 
previous trials significant reductions were observed at 56dph (Buckley et al, 2010). 
However, this measure takes into account the total antibody induction due to both 
vaccination and challenge. If vaccination-specific induction is calculated as fold-change in 
CjaA-specific antibodies compared to Campylobacter challenged but non-vaccinated birds, 
the largest fold-change in serum IgY was observed from 42 days onwards and in bile sIgA at 
56 dph, which was the time when significant reduction in caecal Campylobacter colonisation 
were observed within the previous experiments (Buckley et al, 2010). Similar inductions of 
antigen-specific bile sIgA were observed in CjaA-vaccinated birds, whether they were 
vectored in Salmonella or APEC. However, the fold-increase compared to control birds was 
approximately an order of magnitude lower than the increase observed for serum IgY. 
Furthermore, the levels of Campylobacter in the caeca of individual birds did not correlate 
with antibody induction for either antibody in those birds (data not shown). 
In conclusion, whilst no protection was observed with either of the vectors 
expressing CjaA, both vaccines induced humoral immune responses. This study 
demonstrated induction of immunity through the use of APEC vaccines vectoring 
heterologous antigens. As such, the possibility of using APEC as a vector for vaccines 
against Campylobacter remains open but further studies are needed to optimise the vaccine. 
Due to the lack of a protective effect observed with CjaA-based vaccines the rest of the work 
described in this thesis focused on the search for an antigen or a combination of antigens that 
may confer improved magnitude or replicability of protection. 
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4. Production of recombinant subunit vaccines 
 
4.1 Introduction 
 The previous chapter described that whilst both the Salmonella and APEC attenuated 
live vaccines vectoring CjaA induced antigen-specific humoral responses, they did not 
reduce caecal colonisation by C. jejuni. Furthermore, the Salmonella-based vaccine 
vectoring CjaA exhibited a variable protective effect in previous studies in our group 
(Buckley et al, 2010). Lastly, low level cross-transmission of the live vaccine strains 
between different treatment groups was observed within the first vaccination and challenge 
experiment. Due to these limitations, further development of live vectored vaccines would 
have required a high number of replicates to test each condition, becoming labour and 
resource intensive for a doctoral project. 
As such, the remainder of this project focused on the search for an antigen or 
combination of antigens that could confer improved protection against C. jejuni colonisation 
over CjaA. Towards this aim, novel antigens were tested as recombinant subunit vaccines in 
order to avoid the cross-contamination risk posed by using live vectored vaccines. Rational 
antigen selection has gained more ground in recent years: a search for “rational (and) vaccine 
development” in PubMed returned 11 articles for the year 1994, 23 articles for the year 2004 
and 80 articles for the year 2014, highlighting the recent focus on this aspect of vaccine 
development. Morefield (2011) points out that in light of rapidly evolving diseases, such as 
avian influenza, the traditional empirical approach to vaccine development would be too 
slow to allow adequate responses in the face of new strains. In addition, Rueckert and 
Guzman (2012) review rational development approaches for subunit recombinant vaccines 
and highlight that in their view a rational approach is not only desirable but necessary for the 
delivery of tailored vaccines in a cost and time-effective manner for pathogens for which the 
traditional empirical approach has failed to date. De Gregorio and Rappuoli (2014) also 
review rational vaccine development but focus on recent technological developments that 
can aid this approach. One such approach is reverse vaccinology, which mines genome 
sequence data to identify potential vaccine candidates which are then tested for their 
protective efficacy as recombinant subunit vaccines. This approach was successfully used for 
the production of a vaccine against Neisseria meningitidis group B: Pizza et al (2000) 
identified candidate antigens from whole genome sequencing data and subsequent rational 
development of the vaccine led to a recently licensed commercial product (Bai et al, 2011). 
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In view of above, the approach of informed antigen selection was adopted for this 
project. A literature survey was carried out to select candidate antigens to be tested as 
purified recombinant subunit vaccines against Campylobacter in poultry. Promising 
candidate antigens were selected from original research articles describing evidence of a role 
in colonisation in vivo in chickens, evidence of efficacy as an anti-Campylobacter vaccine in 
an animal model of vaccination or evidence of the antigen being recognised by antibodies 
during primary infection or by maternal antibodies. The antigens identified and the studies 
describing them are summarised in Table 4.1.  
Following identification of the above vaccine candidates, other characteristics of the 
antigens were assessed in order to decide whether they would be likely to constitute an 
effective vaccine. These characteristics included the presence of the antigen in strains that 
commonly infect humans and chickens and the sequence conservation of the antigen within 
these strains. An antigen with high sequence conservation and that is present within the 
majority of field isolates would increase the likelihood of adequate cross-protection. 
Furthermore, hydrophobicity was assessed as a predictor of ease of purification of 
recombinant proteins. Lastly, while consideration was given to the subcellular localisation 
(as shown in Table 4.1), antigens were not restricted to surface-expressed proteins as the 
exclusive role of neutralising antibodies in vaccine-mediated protection against 
Campylobacter has not been demonstrated and recombinant vaccines utilising antigens that 
may not be surface exposed have given promising results (e.g. CjaA, SodB in Helicobacter 
pylori). Gene identity within the annotated C. jejuni M1 genome, gene size, protein 
molecular weight and protein sequence conservation within full-length entries available on 
NCBI are given for each antigen in Table 4.2. 
To obtain the information detailed in Table 4.2, the DNA sequences encoding each 
of the antigens was extracted from the genome sequence of C. jejuni M1 available in NCBI’s 
Nucleotide database. To assess antigen conservation, the DNA sequence given in NCBI’s 
gene information was searched against the non-redundant nucleotide collection (nr/nt) in 
NCBI’s Basic Local Alignment Search Tool (BLAST), utilising the blastn function, with C. 
jejuni subsp. jejuni (taxid: 32022) set as the organism. The obtained alignments were 
screened in 20 C. jejuni strains to identify the lowest percentage conservation of the gene 
within available sequences and this score is given in Table 4.2 with the detailed data in 
individual strains provided in Appendix I. Protein molecular weight was estimated using the 
ExPASy ProtParam tool (http://web.expasy.org/protparam). Presence of the identified 
proteins within different C. jejuni strains was not formally assessed. However,  
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Table 4.1. Characteristics of candidate antigens for use as recombinant vaccines against C. jejuni in chickens, identified through a literature search. 
Functional 
group 
Antigen 
name 
Predicted subcellular 
localisation 
Function 
Role of gene in chicken 
colonisation 
Other aspects to support as 
vaccine candidate 
Other comments 
Adhesins 
CadF 
Outer membrane, on 
extracellular surface 
(Konkel et al, 2005) 
Fibronecting binding 
protein (Konkel et al, 
2005) 
Reduced colonisation of chickens 
by a ∆cadF mutant (Flanagan et 
al, 2009) 
Protective as recombinant protein 
against homologous challenge in 
chickens (Neal-McKinney et al, 
2014) 
N/A 
FlpA 
Outer membrane, on 
extracellular surface 
(Konkel et al, 2010) 
Fibronecting binding 
protein (Konkel et al, 
2010) 
Required for maximal host cell 
adherence (Konkel et al, 2010); 
Reduced colonisation of chickens 
by a ∆flpA mutant (Flanagan et 
al, 2009) 
Highly protective as recombinant 
protein against homologous 
challenge in chickens (Neal-
McKinney et al, 2014) 
Heavily glycosylated: a 
glycoprotein of ~250 kD in native 
form (Konkel et al, 2010) 
Hypothetical 
proteins 
(identified in 
OM 
proteomics 
screen at 
MRI) 
Cj0088 
Outer membrane 
(Cj81176_0124 in Watson 
et al, 2014) 
Part of the operon 
cj0088-cj0089 involved 
in synthesis of Cj0089 
(Paek et al, 2012) 
Unknown None at time of writing N/A 
Cj0089 
Outer membrane 
(Cj81176_0125 in Watson 
et al, 2014) 
Possible adhesin (Paek 
et al, 2012) 
Unknown 
Crystal structure resolved: 
immunoglobulin-like ß-sandwich; 
sequence similarity to 
fibronectin/fimbriae protein – also 
contains an immunoglobulin-like 
ß-sandwich (Paek et al, 2012) 
N/A 
Cj0090 
Outer membrane 
(Cj81176_0126 in Watson 
et al, 2014) 
Part of the operon 
cj0088-cj0090 involved 
in synthesis of Cj0089 
(Paek et al, 2012) 
Unknown None at time of writing N/A 
Cj0536 
Outer membrane (Watson 
et al, 2014) 
Unknown Unknown 
Structural prediction with Phyre 2 
(Kelley et al, 2015): 
Transmembrane beta-barrel 
porin-type structure; similar to 
OmpG of E. coli 
May be involved in nutrient 
uptake (possibly larger 
oligosaccharides) as this 
function was suggested for 
OmpG by Subbarao and van der 
Berg (2006) 
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Table 4.1. Continued. 
Functional 
group 
Antigen 
name 
Predicted subcellular 
localisation 
Function 
Role of gene in chicken 
colonisation 
Other aspects to support as 
vaccine candidate 
Other comments 
Outer 
membrane 
proteins 
CjaA 
Periplasm and inner 
membrane (Wyszynska et 
al, 2008) 
The binding component 
of an ABC-type cysteine 
transporter system 
(Mullet et al, 2005) 
Unknown 
Shown to reduce colonisation of 
chickens by C. jejuni by 6log10 
when vectored in an attenuated 
S. Typhimurium vector 
(Wyszynska et al, 2004) 
Later shown to reduce 
colonisation of chickens by C. 
jejuni by 2log10 CFU/g caecal 
contents when vectored in an 
attenuated S. Typhimurium 
vector or given as recombinant 
subunit vaccine (Buckley et al, 
2010) and by 1log10 when 
vectored in Eimeria tenella 
(Clark et al, 2012). 
CjaC 
Anchored to inner 
membrane (Wyszynska et 
al, 2007) 
Histidine binding 
protein, part of ABC-
type transport system 
(Wyszynska et al, 2007) 
Unknown 
Conserved in isolates of three 
serotypes of C. jejuni common in 
human cases (Pawelec et al, 
1988) 
Recognised by maternal 
antibodies transferred in egg 
(Shoaf-Sweeney et al, 2008); 
Also described as OmpH1 
(Pawelec et al, 2000) 
CjaD 
Outer membrane (as 
reviewed in Godlewska et 
al, 2009) 
Interacts with Tol 
proteins (as reviewed in 
Godlewska et al, 2009) 
Failed attempts to obtain a 
mutant (as reviewed in 
Godlewska et al, 2009) 
Shown to reduce colonisation of 
chickens by C. jejuni by 6log10 
when vectored in an attenuated 
S. Typhimurium vector (Layton et 
al, 2011) 
No protection observed in 
another attenuated S. 
Typhimurium vectored vaccine 
(Laniewski et al, 2012) 
PorA 
Outer membrane (Amako 
et al, 1996) 
Forms a porin when 
multimerised; role in 
adhesion to intestinal 
cells (Mahdavi et al, 
2014) 
Could not be deleted but a mutant 
that is not glycosylated has 
reduced chicken colonisation 
potential (Mahdavi et al, 2014) 
GST-PorA protective against 
heterologous colonisation in a 
mouse model (Islam et al, 2010) 
Shown to be O-glycosylated 
(Mahdavi et al, 2014) 
Multidrug 
efflux 
system 
CmeA 
Periplasmic (Lin et al, 
2002) 
Part of CmeABC 
multidrug resistance 
efflux pump (Lin et al, 
2002) 
Increased expression of CmeABC 
in presence of bile salts  (Lin et 
al, 2005) but no direct evidence of 
role in chicken colonisation 
None at time of writing N/A 
 
 
 
 
 
96 
 
Table 4.1. Continued. 
Functional 
group 
Antigen 
name 
Predicted subcellular 
localisation 
Function 
Role of gene in chicken 
colonisation 
Other aspects to support as 
vaccine candidate 
Other comments 
Multidrug 
efflux 
system 
CmeC 
Outer membrane (Zeng et 
al, 2010) 
Part of CmeABC 
multidrug resistance 
efflux pump (Lin et al, 
2002) 
∆cmeC mutant fails to colonise 
chickens when given at 107 CFU 
(Lin et al, 2003) 
Study in chickens showed that it 
induces strong IgA and IgY 
response when given 
subcutaneously but was not 
protective against colonisation 
(Zeng et al, 2010) 
Failure of protection replicated in 
a later study (Neal-McKinney et 
al, 2014) 
Flagellar 
proteins 
FlaA 
On cellular surface 
(Nuijten et al, 1990) 
The major flagellar unit 
(Nuijten et al, 1990) 
FlaA rather than motility is 
required for chicken colonisation 
(Wasenaar et al, 1993) 
Multiple studies showed 
protection using FlaA-based 
vaccines (see Section 1.5) 
Other studies showed no 
protection using FlaA-based 
vaccines (see Section 1.5) 
FlgE2 
On cellular surface 
(Power et al, 1992) 
Flagellar hook protein 
(Power et al, 1992) 
Unknown 
FlgE2 mutant is non-motile and 
does not secrete Cia proteins 
(Konkel et al, 2004) 
Recognised by maternal 
antibodies transferred in egg 
(Shoaf-Sweeney et al, 2008) 
FlgK On cellular surface 
Flagellar junction 
protein 
FlgK is required for motility and 
chicken colonisation (Fernando et 
al, 2007) 
FlgK mutant unable to secrete the 
Cia proteins (Neal-McKinney and 
Konkel, 2012) 
N/A 
FliD 
At end of flagellum 
(shown in Salmonella by 
Yokoseki et al, 1995) 
Flagellar cap protein; 
acts as polymerisation 
template for the filament 
(shown in Salmonella 
by Yokoseki et al, 1995) 
Unknown 
Immunogenic in natural 
Campylobacter infection, with 
high prevalence of FliD specific 
serum IgY in broiler birds (Yeh et 
al, 2014b) 
Mutant has reduced motility in 
vitro (Neal-McKinney and 
Konkel, 2012) 
FspA1 
Extracellular, secreted 
through the flagellum 
(Poly et al, 2007) 
Unknown Unknown 
Immunogenic and protected mice 
against illness after C. jejuni 
challenge (Baqar et al, 2008) 
N/A 
Cellular 
metabolism 
proteins 
GGT 
Periplasmic in E. coli 
(Suzuki et al, 1986) 
Metabolism of 
glutathione and 
glutamine - catalyses 
first step in pathway that 
releases cysteine 
residues from 
glutathione (Tate and 
Meister, 1985) 
Role in persistent colonisation of 
avian gut by C. jejuni (Barnes et 
al, 2007) 
GGT from C. jejuni inhibits 
epithelial cell and lymphocyte 
proliferation but has no 
proapoptotic activity (Floch et al, 
2014) 
Essential role in colonisation of 
gastric mucosa of mice by 
related pathogen H. pylori 
(Chevalier et al, 1999) 
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Table 4.1. Continued 
Functional 
group 
Antigen 
name 
Predicted subcellular 
localisation 
Gene function 
Role of gene in chicken 
colonisation 
Other aspects to support as 
vaccine candidate 
Other comments 
Cellular 
metabolism 
proteins 
SodB 
Outer membrane (Watson 
et al, 2014) 
Basal expression level 
is essential for 
resistance to oxidative 
stress (modelled by 
paraquat stress) 
(Garenaux et al, 2008) 
Reduced colonisation of chickens 
by a ∆sodB C. coli mutant (Purdy 
et al, 1999) 
Recombinant SodB linked to 
Vibrio cholerae toxin is protective 
against H. pylori challenge in a 
murine model (US Pat. No. 
US20010019834) 
Crystal structure of H. pylori 
SodB shows an N-terminal tail 
thought to be involved in 
interaction with outer membrane; 
similar sequence present in C. 
jejuni SodB (Esposito et al, 
2008) 
Tpx 
Periplasmic in E. coli 
(Cha et al, 1995) 
Antioxidant enzyme that 
removes peroxides and 
H2O2 (Cha et al, 1995) 
Unknown None at time of writing 
Found to be upregulated in a gut 
loop model of C. jejuni infection 
in rabbit (Stintzi et al, 2005) 
AccD 
Cytoplasmic 
(http://www.uniprot.org/un
iprot/A7I0T4) 
Component of the 
acetyl coenzyme A 
carboxylase (ACC) 
complex 
(http://www.uniprot.org/
uniprot/A7I0T4) 
Unknown None at time of writing N/A 
Other 
proteins 
Cj0424 Outer membrane 
Resistance to innate 
antimicrobial peptides * 
Unknown 
Mutant is more susceptible in 
vitro to antimicrobial peptides 
from chickens and humans * 
N/A 
 
* At the time of selection, evidence was presented by Halah al Haideri (Prof. David Kelly’s group, University of Sheffield, to indicate a role in defence against 
cationic antimicrobial peptides, including polymixin B, human β-defensin 1, human cathelicidin IL-37 and chicken fowlicidins 1 and 2.
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Table 4.2. Characteristics of the genes and encoded proteins for each of the candidate 
vaccine antigens identified in Table 4.1. 
Functional 
group 
Protein name (and 
abbreviation) 
Gene number in C. 
jejuni M1 (old locus 
tag) 
Size of 
gene (bp) 
Molecular 
weight 
(kD) 
Gene 
conservation 
(min %) 
Adhesin 
Outer membrane 
fibronectin-binding protein 
(CadF) 
(CJM1_1423) 960 36.023 99 
Fibronectin-like protein A 
(FlpA) 
(CJM1_1260) 1236 46.072 97 
Hypothetical 
proteins 
CJ0088 (CJ0124*) 
CJM1_RS00440 
(CJM1_0088) 
1362 51.237 98 
CJ0089 (CJ0125*) 
CJM1_RS00445 
(CJM1_0089) 
369 14.043 98 
CJ0090 (CJ0126*) 
CJM1_RS00450 
(CJM1_0090) 
624 22.446 99 
Cj0536 (CJM1_0536) 930 35.039 98 
Outer 
membrane 
protein 
Campylobacter jejuni 
antigen A (CjaA) 
(CJM1_0957) 840 30.993 97 
Campylobacter jejuni 
antigen C (CjaC) 
(CJM1_0717) 756 27.799 99 
Campylobacter jejuni 
antigen D (CjaD); 
Peptidoglycan-associated 
lipoprotein (Pal); Omp18 
CJM1_RS00560 
(CJM1_0112) 
497 17.828 99 
Major outer membrane 
protein (PorA; MOMP) 
(CJM1_1240) 1275 45.6 83 
Multidrug 
efflux system 
Campylobacter multidrug 
efflux protein A (CmeA) 
CJM1_0345 1104 40.103 97 
Campylobacter multidrug 
efflux protein C (CmeC) 
(CJM1_0343) 1479 55.437 97 
Flagellar-
related 
proteins 
 
Flagellin A (FlaA) 
CJM1_RS06450 
(CJM1_1296) 
1731 59.5290 79 
Flagellar hook protein 
(FlgE2) 
(CJM1_1679) 2073 73.699 84 
Flagellar hook-associated 
protein; junction (FlgK) 
(CJM1_1412) 1827 67.086 98 
Flagellar cap protein 
(FliD) 
CJM1_RS02610 
(CJM1_0523) 
1932 69.921 96 
Flagellar secreted protein 
1 (FspA1) 
(CJM1_0381) 429 16.528 98 
Cellular 
metabolism 
proteins 
Gamma-glutamyl 
transpeptidase (GGT) 
CJM1_RS00190 
(CJM1_0038) 
1671 60.257 99 
Superoxide dismutase 
(SodB) 
CJM1_RS00850 
(CJM1_0171) 
663 24.812 98 
Thiol peroxidase (Tpx) 
CJM1_RS03760 
(CJM1_0755) 
528 18.428 99 
acetyl-coenzyme A 
carboxylase carboxyl 
transferase subunit beta 
(AccD) 
(CJM1_0126) 843 30.951 98 
Antimicrobial 
defence 
Cj0424 (RidL) CJ11168_0424 633 24.198 99 
* Gene numbers in C. jejuni 81-176, where they were identified by Watson et al (2014). 
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the majority of the chosen genes are central metabolic genes or flagellar genes, suggesting 
universal presence. Cj0424 was shown to only be present in under 50% of sequenced strains 
available (data obtained from Halah Al-Haideri).  
This chapter described the cloning and assessment of solubility for all antigens 
described above and large-scale recombinant protein production of a subset of 10 antigens 
chosen due to their higher solubility relative to the other antigens tested.  
 
 
4.2. Materials and methods 
4.2.1 Construction of the E. coli strains for expression of recombinant 
Campylobacter antigens 
4.2.1.1 Cloning of antigens encoding the glutathione-S-transferase fusions 
Each of the selected genes encoding the candidate antigens was separately cloned 
into the pGEX-4T1 plasmid (GE Lifesciences; details given in Section 2.1), under the 
control of an IPTG-inducible promoter, in order to purify the proteins as GST fusions to be 
tested in a vaccination and challenge model in chickens. The genes were amplified from C. 
jejuni M1 genomic DNA using the forward and reverse primers detailed in Table 4.3 using 
the proofreading Phusion DNA polymerase by PCR and were cloned as an in-frame C-
terminal fusion to GST through ligation-dependent cloning, using the BamHI (5’ end) and 
NotI (3’ end) restriction sites. Ligation reactions were transformed into E. coli XL1 Blue and 
individual transformed colonies validated by PCR (using the pGEXfwd and pGEXrev primers 
given in Table 4.3) and double strand sequencing for the presence of the expected construct 
as described in Section 3.2 for the construction of the pTECH2-cjaA plasmid. Sequencing of 
these constructs was contracted to Source Bioscience (UK). Verified plasmids were 
transformed into electrocompetent E. coli Rosetta (genotype given in Section 2.1) using the 
fast electroporation protocol. The empty pGEX-4T1 plasmid was also transformed into the 
Rosetta strain to purify GST that would be used as a negative control during vaccination 
experiments in chickens. Transformed E. coli Rosetta were screened for the presence of a 
correct plasmid by PCR as described for the construction of the pTECH2-cjaA plasmid in 
Section 3.2. 
 
 
 
 
 
100 
 
4.2.1.2 Cloning of antigens cloned as maltose binding protein fusions 
Nine of the GST-tagged recombinant antigens tested in vivo were also cloned into 
pMal-p2X (NEB; details given in Section 2.1) as in-frame fusions to the C-terminus of MBP 
in order to be utilised in ELISAs for the measurement of humoral immune responses induced 
by vaccination. This approach was chosen to avoid detection of antibodies against the GST 
fraction of each recombinant antigen. Genes were re-amplified by PCR with the proof-
reading Phusion DNA polymerase using the same forward primers described above, but with 
different reverse primers described in Table 4.3 and denoted by pMal. These PCR fragments 
were cloned into the BamHI (3’ end) and SalI (5’ end) restriction sites of the pMal-p2X 
plasmid as described above. The same construct validation workflow as utilised for the 
pGEX-4T1 constructs was used, but the pMalfwd and pMalrev primers were used for PCR 
validation. Only pMal-p2X-sodB and pMal-p2x-fliD were transformed in E. coli Rosetta and 
validated as described above. Otherwise, expression of the MBP recombinant proteins for 
purification was performed using E. coli XL1 cells. 
 
4.2.1.3 Cloning of cjaA as a 6xHis fusion 
The cloning of cjaA as a 6xHis-tagged fusion in the pET28b (Novagen, UK) plasmid 
was undertaken for a more direct comparison with previous studies within our group 
(Buckley et al, 2010). This plasmid has an origin of replication from pBR322 giving 
approximately 50 copies/cell and it also contains an f1 origin or replication. The T7 promoter 
allows chemical induction with IPTG and the lacIq gene to control basal level of expression. 
A kanamycin resistance gene is used for selection. The plasmid contains 6xHis tags at both 
the 5’ and 3’ end of the MCS. For this cloning, C. jejuni M1 cjaA gene was digested from 
the pGEX-4T1-cjaA plasmid with the BamHI and NotI restriction enzymes and ligated into 
the pET28b vector digested with the same restriction enzymes to fuse 6xHis residues at the C 
terminus. Plasmid constructs were transformed into E. coli XL1 and a validation workflow 
similar to the one described above for pGEX-4T1 constructs was used. Sequencing-validated 
plasmids were transformed into E. coli Rosetta and the strains validated as described for the 
pGEX-4T1 constructs above. 
 
4.2.2 Assessment of ease of purification of GST-tagged recombinant proteins 
 Following construction of the E. coli Rosetta strain expressing each of the candidate 
antigens described above, small scale inductions and purifications were run to assess the  
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Table 4.3. Primers used for the construction of recombinant Campylobacter antigen 
expression plasmids. Underlined sequences represent sites for restriction enzymes utilised 
in cloning. All sequences are given as 5’ to 3’. 
Primer   Sequence (5'-3') 
Primers for cloning of C. jejuni M1 antigens into pGEX-4T1 
pGEX-4T1-cmeCfwd CGCGCGGGATCCATGAATAAAATAATTTCAAT 
pGEX-4T1-cmeCrev CGCGCGGCGGCCGCCTATTCTCTAAAAGACATAT 
pGEX-4T1-porAfwd CGCGCGGGATCCATGAAACTAGTTAAACTTAG 
pGEX-4T1-porArev CGCGCGGCGGCCGCTTAGAATTTGTAAAGAGCTT 
pGEX-4T1-accDfwd CGCGCGGGATCCATGAATTTTGCAGATATTTT 
pGEX-4T1-accDrev CGCGCGGCGGCCGCTTATTTTCCCTAAAAAATTT 
pGEX-4T1-cadFfwd CGCGCGGGATCCATGAAAAAAATATTCTTATG 
pGEX-4T1-cadFrev CGCGCGGCGGCCGCTTATCTTAAAATAAATTTAG 
pGEX-4T1-flpAfwd CGCGCGGGATCCATGACAACCCACATCTATGA 
pGEX-4T1-flpArev CGCGCGGCGGCCGCTCAAATTTTTTCATTTAAAA 
pGEX-4T1-cj0586fwd CGCGCGGGATCCATGCTAGTAAATAAATTTAA 
pGEX-4T1-cj0586rev CGCGCGGCGGCCGCTTAATAATCGATGATATTTT 
pGEX-4T1-cjaCfwd CGCGCGGGATCCATGAAAAAAATATTAAGCAT 
pGEX-4T1-cjaCrev CGCGCGGCGGCCGCTTATTCTAATTCATATTTTT 
pGEX-4T1-por18fwd CGCGCGGGATCCATGAAAAAAATTCTTTTTAC 
pGEX-4T1-por18rev CGCGCGGCGGCCGCTTATCTTGATAATTTAAATT 
pGEX-4T1-flgE2fwd CGCGCGGGATCCATGATGAGATCACTTTGGTC 
pGEX-4T1-flgE2rev CGCGCGCGGCCGCTTAAGATCCATCATTATTAA 
pGEX-4T1-fspAfwd CGCGCGGGATCCATGCAAATTAACAATTCCTT 
pGEX-4T1-fspArev CGCGCGCGGCCGCTCAAGCTTGTTGGCTTTGGA 
pGEX-4T1-L7,porAfwd CGCGCGGGATCCATGGGTAAAAAAGATAAAACTAC 
pGEX-4T1-L7,porArev CGCGCGCGGCCGCTTAAATATCGCCATTTAGGTTAG 
pGEX-4T1-flgKfwd CGCGCGGGATCCATGGGTATTTTTGGAACATT  
pGEX-4T1-flgKrev CGCGCGCGGCCGCTTAAGATTTAAGCCCTAGTA 
pGEX-4T1-fliDfwd CGCGCGGGATCCATGGCATTTGGTAGTCTATC 
pGEX-4T1-fliDrev CGCGCGCGGCCGCTTAATTATTAGAATTGTTTG 
pGEX-4T1-flgLfwd CGCGCGGGATCCATGAGAATTACAAATAAACT 
pGEX-4T1-flgLrev GCGCGCGCTCGAGTTACATATAATTTAATAAGC 
pGEX-4T1-cj0088fwd CGCGCGGGATCCATGAAGATAAAAGTTGGGTT 
pGEX-4T1-cj0088rev CGCGCGGCGGCCGCTTATTTTTCCATGATAGCAA 
pGEX-4T1-cj0089fwd CGCGCGGGATCCATGAAAAAAAATATTTTATT 
pGEX-4T1-cj0089rev CGCGCGGCGGCCGCTTAATTTTTTGCTTTAATTT 
pGEX-4T1-cj0090fwd CGCGCGGGATCCATGAAAAAAACAAAAATTTT 
pGEX-4T1-cj0090rev CGCGCGGCGGCCGCTTACCAAGTAACTGATTTAC 
pGEX-4T1-tpxfwd CGCGCGGGATCCATGAGTACAGTAAATTTTAA 
pGEX-4T1-tpxrev CGCGCGGCGGCCGCTTAATGGCAACCACAACCAC 
pGEX-4T1-sodBfwd CGCGCGGGATCCATGTTTGAATTAAGAAAATT 
pGEX-4T1-sodBrev CGCGCGGCGGCCGCTTATTTTACAGGGTGAAGTT 
pGEX-4T1-ggtfwd CGCGCGGGATCCATGCGTTATTTAGCTATATT 
pGEX-4T1-ggtrev CGCGCGGCGGCCGCATACAAGAAAAGAATTCTAA 
    
Primers for cloning of C. jejuni antigens in pMAL-p2X 
pMAL-p2X-tpxrev CGCGCGCGCGGTCGACTTAATGGCAACCACAACCAC 
pMAL-p2X-sodBrev CGCGCGCGCGGTCGACTTATTTTACAGGGTGAAGTT 
pMAL-p2X-cj0089rev CGCGCGCGCGGTCGACTTAATTTTTTGCTTTAATTT 
pMAL-p2X-flgE2rev CGCGCGCGCGGTCGACTTAAGATCCATCATTATTAA 
pMAL-p2X-porA-L7rev  CGCGCGCGCGGTCGACTTAAATATCGCCATTTAGGTTAG 
pMAL-p2X-cjaArev CGCGCGCGCGGTCGACTTAGATCTTGCCGCCCTCAATA 
pMAL-p2X-fspArev  CGCGCGCGCGGTCGACTCAAGCTTGTTGGCTTTGGA 
pMAL-p2X-fliDrev CGCGCGCGCGGTCGAC TTAATTATTAGAATTGTT TG 
    
Diagnostic primers   
pGEXfwd GGGCTGGCAAGCCACGTTTGGTG 
pGEXrev CCGGGAGCTGCATGTGTCAGAGG 
pMALfwd GGTCGTCAGACTGTCGATGAAGCC 
M13fwd (for pMALrev) TGTAAAACGACGGCCAGT 
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solubility of each GST-tagged recombinant antigen. These were run as described in Section 
2.11.1 in a total volume of 50 ml LB broth, grown at 37 ºC and induced with 1mM IPTG. 
The antigens that showed poor solubility under these conditions were re-assessed for 
improved yield under growth at 27 ºC and induction with 0.1mM IPTG. To establish whether 
antigens had adequate solubility to ensure that they could be tested in vivo the amount of 
total soluble protein present within the pooled eluates of each of the recombinant proteins 
was measured through a Bradford assay. Only proteins that were estimated to be obtainable 
in sufficient quantity from 6 litres of culture to vaccinate all birds in a group once (between 
264 and 926 μg, depending on molecular weight of the antigen) were tested in vivo. 
 
4.2.3 Production of GST-tagged recombinant subunit vaccines 
The antigens that were deemed to have adequate solubility from the preliminary 
small scale screen were purified in large quantities. For each purification, volumes between 
500 ml and 6 l were grown in LB broth at either 37 ºC or 28 ºC and induced with either 1mM 
or 0.1 mM IPTG. Purification of each protein was undertaken as described in Section 2.11. 
To allow constitution of vaccines in a total volume of 50µl per dose, multiple eluates of each 
protein were passed through Amicon® Ultra (Milipore, UK) centrifugal concentrator 
columns with a molecular weight cut-off of either 30kD or 50kD as appropriate. Final 
protein preparations were quantified through a Bradford assay before use in vivo. 
Each large scale protein preparation was resolved through SDS-PAGE on two 
separate 10% MiniProtean® TGX gels (BioRad). One of the gels was silver stained and the 
other transferred to PVDF membrane and assessed for the purity of the protein preparations 
via a Western blot using an anti-GST mouse IgG1 monoclonal antibody (Santa-Cruz 
Biotechnology, USA) at a 1:10,000 dilution. Bound primary antibody was detected with a 
rabbit anti-mouse HRP-conjugated secondary antibody (Sigma, UK) used at a 1:10,000 
dilution. Western blots were developed as described in section 2.14. 
 
4.2.4 Production of 6xHis-tagged recombinant subunit vaccines 
 Production of 6xHis-CjaA was undertaken from E. coli Rosetta. The E. coli BL21 
strain for expression of 6xHis-Cj0424 from a pET plasmid was constructed by Halah Al 
Haideri (Prof. David Kelly’s group, University of Sheffield). Expression and purification 
was undertaken using Ni-NTA resin affinity chromatography as described in Section 2.11.3. 
Final protein preparations were verified through a Western blot with a mouse IgG anti-6xHis 
antibody (Invitrogen, UK) used at a 1:10,000 dilution and detected with an HRP-conjugated  
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goat-anti mouse IgY antibody (AbD Serotec, UK) used at a 1:10,000 dilution. Final protein 
preparations were quantified through a Bradford assay before being used in vivo. 
 
4.2.5 Production of MBP-tagged recombinant antigens for use in ELISAs 
4.2.5.1 MBP-tagged protein production  
 Production of the MBP-tagged Campylobacter antigens was undertaken in E. coli 
XL1 due to lower amounts of antigen being required for ELISAs compared to the 
vaccination trials. Volumes of LB broth cultures between 500ml and 2 litres were induced 
with either 0.5 mM IPTG (as per manufacturer’s recommendations) or 0.1 mM IPTG at 
either 37 ºC or 28 ºC. Purification was undertaken as described in section 2.11.2 and multiple 
eluates were passed through the same concentrator column. 
 
4.2.5.2 Validation MBP-tagged protein preparations 
Validation of the MBP-fusion antigens was as described for the GST-fusion antigens, 
however the Western blot utilised an anti-MBP mouse IgG2a monoclonal primary antibody 
(NEB, UK) at a 1:10,000 dilution, followed by detection with the same secondary antibody 
as above. Before use in ELISAs, final protein preparations were quantified on the Direct 
Detect® machine (Milipore, UK), following manufacturer’s instructions. 
 
4.2.6 Assessment of the role of Cj0424 in virulence and colonisation 
Strains of C. jejuni 11168H lacking cj0424 or having a double deletion of cj0423-
cj0424 and their complemented strains were constructed by Halah Al Haideri (Prof. David 
Kelly’s group, University of Sheffield). The entire cj0424 gene or cj0423-cj0424 doublet 
were replaced by homologous recombination with a kanamycin resistance gene. The 
complemented strains had pCmetK::cj0424 or pCmetK::cj0424-0423 (pCmetK was 
described by Gaskin et al, 2007) integrated at the cj0046 pseudogene locus, allowing 
selection through chloramphenicol ressitance. 
Initially, the single mutant and its complemented strain were tested for attenuation in 
a model of virulence using wax moth (Galleria mellonella) larvae as described in Section 
2.18. Subsequently, the single mutant was tested in vivo in a chicken model of colonisation, 
as described in Section 2.15, using challenge doses of 106 and 108 CFU/bird. Lastly, the 
double mutant was tested in the chicken model of colonisation using challenge doses of 104 
and 106 CFU/bird. In each experiment, the mutant strains were compared against wild-type 
and complemented control strains. Before each experiment the motility of the three strains 
 
104 
 
used was assessed through a soft agar diffusion test. For this, early stationary phase cultures 
were inoculated in the centre of a Petri dish containing 0.3% (w/v) MH agar using a 10 μl 
plastic loop. Plates were incubated for 24 hours and the diameter of the diffusion zone 
measured.   
 
 
4.3. Results 
4.3.1 Construction of strains for expression of GST-tagged Campylobacter antigens  
 The preparation of gDNA used for antigen cloning is shown in Figure 4.1.A and 
demonstrates the presence of high molecular weight DNA only. All antigens were 
successfully amplified by PCR from gDNA (data not shown), cloned into pGEX-4T1 and 
transformed into E. coli XL1 (data not shown). The cj0089 gene only amplified when the 
PCR reactions contained double the amount of MgCl2 present in the HF Buffer of the 
Phusion polymerase. The BamHI-NotI double digest of the PCR amplicon for sodB and the 
PCR validation of the sodB gene ligated in pGEX-4T1 and transformed in E. coli XL1 are 
given as illustrative examples in Figure 4.1.B and C respectively. Using dideoxy chain 
termination sequencing, all of the plasmids were shown to have the expected sequence (data 
 
Figure 4.1 Construction of the pGEX-4T1-sodB plasmid. A. gDNA extracted from C. 
jejuni M1. B. BamHI and NotI double-digested sodB PCR amplicon (using primers pGEX-
4T1-sodBfwd and pGEX-4T1-sodBrev) from the gDNA preparation shown in panel A. The 
size of the expected product is 669bp. The negative control reaction contains no template 
DNA. C. PCR validation of an E. coli XL1 single colony containing the pGEX-4T1-sodB 
plasmid, using primers pGEXfwd and pGEXrev. The size of the expected product is 867bp. 
The negative control reaction contains E. coli XL1 without the pGEX-4T1 plasmid. 
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not shown). The alignment between the expected and obtained sequence for pGEX-4T1-sodB only is 
given in Figure 4.2 as an illustrative example. 
 
Expected         -------------------------------------------------CTGGCAAGCCA 11 
Observed         TTGATAAGTACTTGAAATCCAGCAAGTATATAGCATGGCCTTTGCAGGGCTGGCAAGCCA 60 
                                                                  *********** 
 
Expected        CGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGTTTG 71 
Observed        CGTTTGGTGGTGGCGACCATCCTCCAAAATCGGATCTGGTTCCGCGTGGATCCATGTTTG 120 
                ************************************************************ 
 
Expected        AATTAAGAAAATTACCTTATGATACCAATGCTTTTGGTGATTTTTTGAGTGCTGAAACTT 131 
Observed        AATTAAGAAAATTACCTTATGATACCAATGCTTTTGGTGATTTTTTGAGTGCTGAAACTT 180 
                ************************************************************ 
 
Expected        TTAGCTATCATCATGGAAAACATCACAATACTTATGTTACAAATCTAAATAATCTTATTA 191 
Observed        TTAGCTATCATCATGGAAAACATCACAATACTTATGTTACAAATCTAAATAATCTTATTA 240 
                ************************************************************ 
 
Expected        AAGATACTGAATTTGCAGGTAAAGATCTTGTAAGTATTATCAAAACTTCAAATGGGGGCG 251 
Observed        AAGATACTGAATTTGCAGGTAAAGATCTTGTAAGTATTATCAAAACTTCAAATGGGGGCG 300 
                ************************************************************ 
 
Expected        TATTTAATAACGCAGCTCAAGTTTATAATCATGATTTTTATTTTGATTGCATTAAGCCAA 311 
Observed        TATTTAATAACGCAGCTCAAGTTTATAATCATGATTTTTATTTTGATTGCATTAAGCCAA 360 
                ************************************************************ 
 
Expected        GTACAGGCTGTGGCTGTGGCGGTTCATGTCAAAGTATAGATGCTAATTTACAAGCGGCAC 371 
Observed        GTACAGGCTGTGGCTGTGGCGGTTCATGTCAAAGTATAGATGCTAATTTACAAGCGGCAC 420 
                ************************************************************ 
 
Expected        TAGAAAAAGAATTTGGATCTTTAGAAAATTTCAAAGCTGAATTCATCAAAGGTGCTACAG 431 
Observed        TAGAAAAAGAATTTGGATCTTTAGAAAATTTCAAAGCTGAATTCATCAAAGGTGCTACAG 480 
                ************************************************************ 
 
Expected        GAGTTTTTGGTTCAGGATGGTTTTGGTTAGTTTATAATACTAAAAATCAAAAACTAGAAT 491 
Observed        GAGTTTTTGGTTCAGGATGGTTTTGGTTAGTTTATAATACTAAAAATCAAAAACTAGAAT 540 
                ************************************************************ 
 
Expected        TTGTAGGTACTTCAAACGCAGCTACACCAATTACTGAAGATAAAGTTCCTTTGCTTGTTG 551 
Observed        TTGTAGGTACTTCAAACGCAGCTACACCAATTACTGAAGATAAAGTTCCTTTGCTTGTTG 600 
                ************************************************************ 
 
Expected        TAGATGTTTGGGAACATGCTTATTATGTAGATCATCGTAATGCACGCCCTGCTTATTTAG 611 
Observed        TAGATGTTTGGGAACATGCTTATTATGTAGATCATCGTAATGCACGCCCTGCTTATTTAG 660 
                ************************************************************ 
 
Expected        AGAAATTCTATGCTCATATTAATTGGGAATTTGTTGCAAAAGCTTACGAATGGGCTTTAA 671 
Observed        AGAAATTCTATGCTCATATTAATTGGGAATTTGTTGCAAAAGCTTACGAATGGGCTTTAA 720 
                ************************************************************ 
 
Expected        AAGAAGGCATGGGATCAGTTAGCTTTTATGCAAATGAACTTCACCCTGTAAAATAAGCGG 731 
Observed        AAGAAGGCATGGGATCAGTTAGCTTTTATGCAAATGAACTTCACCCTGTAAAATAAGCGG 780 
                ************************************************************ 
 
Expected        CCGCATCGTGACTGACTGACGATCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCCT 791 
Observed        CCGCATCGTGACTGACTGACGATCTGCCTCGCGC-------------------------- 814 
                **********************************                           
 
Figure 4.2 Alignment of the expected and constructed sequence of the insert in pGEX-4T1-
sodB. The colours and symbols in the figure represent: pGEX 5’ sequencing primer (arrows), gst 
(yellow), restriction enzyme recognition sites: BamHI at 5’ end and NotI at 3’ end (red), sodB 
sequence (blue), stop codon (purple), plasmid backbone (grey). 
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4.3.2 Construction of strains for expression of MBP-tagged Campylobacter antigens 
Apart from cj0089, which failed to re-amplify by PCR, each of the nine genes intended for 
purification of the cognate proteins through the MBP system were successfully amplified from the 
pGEX-4T1 plasmids, ligated into the pMal-p2x plasmids and transformed in E. coli XL1 Blue. 
Sequencing of plasmid DNA from these strains indicated that none of the constructs contained 
mutations (data not shown). Alignment of the expected and obtained sequences for pMal-p2x-sodB 
only is given in Figure 4.3 as an example. 
 
Expected        GATGAAGCCCTGAAAGACGCGCAGACTAATTCGAGCTCGAACAACAACAACAATAACAAT 60 
Observed        -----------------------------TTCGAGCTCGAACAACAACAACAATAACAAT 31 
                                             ******************************* 
 
Expected        AACAACAACCTCGGGATCGAGGGAAGGATTTCAGAATTCGGATCCATGTTTGAATTAAGA 120 
Observed        AACAACAACCTCGGGATCGAGGGAAGGATTTCAGAATTCGGATCCATGTTTGAATTAAGA 91 
                ************************************************************ 
 
Expected        AAATTACCTTATGATACCAATGCTTTTGGTGATTTTTTGAGTGCTGAAACTTTTAGCTAT 180 
Observed        AAATTACCTTATGATACCAATGCTTTTGGTGATTTTTTGAGTGCTGAAACTTTTAGCTAT 151 
                ************************************************************ 
 
Expected        CATCATGGAAAACATCACAATACTTATGTTACAAATCTAAATAATCTTATTAAAGATACT 240 
Observed        CATCATGGAAAACATCACAATACTTATGTTACAAATCTAAATAATCTTATTAAAGATACT 211 
                ************************************************************ 
 
Expected        GAATTTGCAGGTAAAGATCTTGTAAGTATTATCAAAACTTCAAATGGGGGCGTATTTAAT 300 
Observed        GAATTTGCAGGTAAAGATCTTGTAAGTATTATCAAAACTTCAAATGGGGGCGTATTTAAT 271 
                ************************************************************ 
 
Expected        AACGCAGCTCAAGTTTATAATCATGATTTTTATTTTGATTGCATTAAGCCAAGTACAGGC 360 
Observed        AACGCAGCTCAAGTTTATAATCATGATTTTTATTTTGATTGCATTAAGCCAAGTACAGGC 331 
                ************************************************************ 
 
Expected        TGTGGCTGTGGCGGTTCATGTCAAAGTATAGATGCTAATTTACAAGCGGCACTAGAAAAA 420 
Observed        TGTGGCTGTGGCGGTTCATGTCAAAGTATAGATGCTAATTTACAAGCGGCACTAGAAAAA 391 
                ************************************************************ 
 
Expected        GAATTTGGATCTTTAGAAAATTTCAAAGCTGAATTCATCAAAGGTGCTACAGGAGTTTTT 480 
Observed        GAATTTGGATCTTTAGAAAATTTCAAAGCTGAATTCATCAAAGGTGCTACAGGAGTTTTT 451 
                ************************************************************ 
 
Expected        GGTTCAGGATGGTTTTGGTTAGTTTATAATACTAAAAATCAAAAACTAGAATTTGTAGGT 540 
Observed        GGTTCAGGATGGTTTTGGTTAGTTTATAATACTAAAAATCAAAAACTAGAATTTGTAGGT 511 
                ************************************************************ 
 
Expected        ACTTCAAACGCAGCTACACCAATTACTGAAGATAAAGTTCCTTTGCTTGTTGTAGATGTT 600 
Observed        ACTTCAAACGCAGCTACACCAATTACTGAAGATAAAGTTCCTTTGCTTGTTGTAGATGTT 571 
                ************************************************************ 
 
Expected        TGGGAACATGCTTATTATGTAGATCATCGTAATGCACGCCCTGCTTATTTAGAGAAATTC 660 
Observed        TGGGAACATGCTTATTATGTAGATCATCGTAATGCACGCCCTGCTTATTTAGAGAAATTC 631 
                ************************************************************ 
 
Expected        TATGCTCATATTAATTGGGAATTTGTTGCAAAAGCTTACGAATGGGCTTTAAAAGAAGGC 720 
Observed        TATGCTCATATTAATTGGGAATTTGTTGCAAAAGCTTACGAATGGGCTTTAAAAGAAGGC 691 
                ************************************************************ 
 
Expected        ATGGGATCAGTTAGCTTTTATGCAAATGAACTTCACCCTGTAAAATAAGTCGACCTGCAG 780 
Observed        ATGGGATCAGTTAGCTTTTATGCAAATGAACTTCACCCTGTAAAATAAGTCGACCTGCAG 751 
                ************************************************************ 
 
Expected        GCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACC 801 
Observed        GCAAGCTTGGCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACC 811 
 
Figure 4.3. Alignment of the expected and observed insert sequence of pMal-p2x-sodB. 
Colour coding is as for Figure 4.2. Restriction enzymes sites are for BamHI at the 5’ and SalI at 
the 3’ end.  
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4.3.3 Assessment of ease of purification of the GST-tagged recombinant antigens 
 Small scale induction and purification experiments for each of the cloned 
Campylobacter antigens revealed that the following proteins had sufficient yield and 
solubility to allow their testing in vivo: GST-Cj0089, GST-FspA, GST-Tpx, GST-SodB, 
GST-CjaA, GST-FliD, GST-FlgK, GST-FlgE2 and GST fused to the 7th extracellular loop 
of PorA (GST-PorAL7). An example of a relatively soluble recombinant antigen (GST-
SodB) in contrast to a poorly soluble one (GST-Cj0090) is given in Figure 4.4. To further 
demonstrate the poor solubility of GST-Cj0090, a Western blot with an anti-GST antibody 
was run (Figure 4.5). This revealed the presence of a GST-only truncation in the GST-
Cj0090 preparation, which accounted for the majority of the protein observed within this 
preparation. No such truncation was observed for GST-SodB. 
 
 
 
Figure 4.4 Preliminary small scale purifications for assessment of ease of purification of 
recombinant proteins. A. SDS-PAGE followed by Coomassie staining of samples collected 
during purification of SodB, given as an example of a recombinant protein that could be 
purified in sufficient quantity. B. SDS-PAGE followed by Coomassie staining of samples 
collected during purification of Cj0090, given as an example of a protein that could not be 
purified in adequate quantities. The final yield is an interplay between factors such as protein 
solubility, yield during induction, affinity for the purification resin and ease of elution.  
In each figure lanes are as follows: (1) whole cell lysate of cells pre-induction; (2) whole cell 
lysate post-induction; (3) supernatant after cell lysis; (4) pellet after cell lysis; (5) glutathione 
sepharose beads after sample binding; (6) glutathione sepharose beads after three washes; (7) 
the first eluate; (8) the second eluate; (9) glutathione sepharose beads after elution. 
The expected size of both GST-SodB and GST-Cj0090 is 50kD and is indicated by the black 
arrows. 
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Figure 4.5. Assessment of purity of the GST-SodB and GST-Cj0090 protein 
preparations used for assessment of ease of purification. This was done through Western 
blotting with an anti-GST antibody. Panels A. and B. and lanes in each panel are the same as 
in Figure 4.4. In both figures, for both antigens, the insoluble pellet obtained following lysis 
of bacterial cells in the 50ml cultures was re-suspended in 1ml of PBS, resulting in a 50x 
concentration of the sample compared to the supernatant. Within the eluates, no obvious 
bands are seen on the Coomassie gel that do not react with the anti-GST antibody, 
suggesting the protein preparations contain low levels of contamination with proteins other 
than those of interest. The black arrows indicate the expected band corresponding to GST-
SodB and GST-Cj0090 and the red arrow indicates a likely GST-only truncation (the band is 
of the size of GST alone and reacts strongly with the anti-GST antibody). 
 
4.3.4 Production of the GST-tagged recombinant antigens tested in vivo 
 Cultures of E. coli Rosetta strains expressing GST-CjaA, GST-FlgE2, GST-FlgK, 
GST-FliD and GST-Cj0089 were grown at 28 ºC and induced with 0.1 mM IPTG. Cultures 
of the strains expressing GST, GST-PorAL7, GST-FspA, GST-SodB and GST-Tpx were 
grown at 37 ºC and induced with 1 mM IPTG. For the purification of the latter antigens, 
500ml of culture were used each time. For the purification of GST-CjaA, GST-FliD and 
GST-Cj0089 6 litres of culture were used each time. For the purification of the remainder of 
the antigens 2 litres of culture were used each time. In total, two protein preparations were 
made for GST-SodB and different protein preparations for each vaccination in the case of 
GST-CjaA and GST-FliD. As far as could be discerned from SDS-PAGE and Western blot 
analysis, independent preparations of the same antigen were similar. The remainder of the 
recombinant antigens were obtained in sufficient quantity from a single purification. 
 Typical preparations of each antigen are shown in Figure 4.6. Silver staining 
indicated the presence of a band of the size of GST alone in the GST-Cj0089, GST-CjaA and 
the flagellar component antigens (Fig 4.6B). Assessment of the identity of this band was 
made through a Western blot with an anti-GST antibody (Fig 4.6C) and strong reactivity 
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indicated that the 25kD band was most likely GST. Furthermore, this Western blot indicates 
the presence of a number of other protein species that are possible truncations within the 
flagellar component antigens, however the bands with the strongest reactivity were of the 
expected size for fully translated proteins. Truncations may reflect premature termination or 
post-translational processing. Yield during purification is given for each protein in Table 4.4. 
 
 
Figure 4.6. Typical protein preparations of each of the Campylobacter antigens used as 
vaccines in vaccination and challenge experiments in chickens. Coomassie staining (A) 
and silver staining (B) of typical protein preparations. The identity and expected molecular 
weight of the proteins are as follows: (1) GST, 25 kD; (2) GST-PorAL7, 29 kD; (3) GST-
Cj0089, 35 kD; (4) GST-FspA, 40.5 kD; (5) GST-Tpx, 43kD; (6) GST-SodB, 50kD; (7) 
GST-CjaA, 55kD; (8) GST-FlgK 92kD; (9) GST-FliD, 95kD; (10) GST-FlgE2, 99kD. C. 
Assessment of purity of typical protein preparations of each of the Campylobacter antigens 
used as vaccines in in vivo trials in chickens via a Western blot with an anti-GST antibody. 
In all panels the red arrows indicate truncations of the proteins of a size equal to GST only. 
The high molecular weight band in lane six may indicate a multimer of this protein species. 
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Table 4.4 Approximate yield of recombinant GST-tagged Campylobacter antigens from 
single protein purification experiments. Yield is given as mg per litre of LB broth culture. 
Recombinant protein Approximate yield (in mg/l) 
GST 13.4 
GST-PorAL7 17.4 
GST-Cj0089 0.25 
GST-FspA 14.6 
GST-Tpx 15.4 
GST-SodB 19.8 
GST-CjaA 0.3 
GST-FlgK 0.9 
GST-FliD 0.4 
GST-FlgE2 2.8 
 
 
4.3.5 Production of MBP-tagged antigens used in ELISAs 
 The E. coli XL1 strains expressing the MBP-CjaA and MBP-FliD recombinant 
antigens were grow at 27 ºC and induced with 0.1 mM IPTG. Strains expressing the 
remainder of the MBP-tagged antigens were grown at 37 ºC and induced with 0.5 mM IPTG 
as per manufacturer’s instructions. The entire purification process is exemplified through 
samples taken during purification of MBP-SodB and shown through a Coomassie stained 
SDS-PAGE gel in Figure 4.7A. Identification of the MBP-SodB recombinant protein was 
undertaken through a Western blot with an anti-MBP antibody (Figure 4.7B). This revealed 
the presence of a protein species of the size expected for a MBP-only truncation expressed 
from the pMal-p2X plasmid (c. 46kD) and of a protein species of the size expected for the 
endogenous MBP expressed from the chromosome of E. coli XL1 (43.4 kD). All purified 
proteins were validated in the same way.  
 
4.3.6 Role of Cj0424 in virulence and colonisation 
4.3.6.1 Role of Cj0424 in virulence in a wax moth (Galleria mellonella) model 
 In order to strengthen the rationale for testing Cj0424 as a candidate antigen and to 
apply 3R principles for reduction of animal use, the role of Cj0424 in vivo was initially 
assessed through the use of Greater wax moth (Galleria mellonella) larvae. This model has 
been reported to detect the attenuating effect of mutations in factors known to influence 
chicken colonisation (Champion et al, 2010). 
When tested in the wax moth larvae model of virulence, a statistically significant 
increase in the median time to death was observed in the group inoculated with the cj0424 
mutant (67.17h) compared to the wild-type group (median time to death: 27.84h; p = 0.0013; 
Figure 4.8). Survival of larvae inoculated with the complemented strain was similar to the 
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Figure 4.7. Purification of MBP-SodB as an example of MBP-tagged recombinant 
Campylobacter antigen purification. A. Coomassie staining of an SDS-PAGE gel of 
samples collected during purification of MBP-SodB. B. Assessment of purity of the samples 
shown in panel A via a Western blot with an anti-MBP antibody. In each figure lanes are as 
follows: (1) whole cell lysate of cells pre-induction; (2) whole cell lysate post-induction; (3) 
supernatant after cell lysis; (4) pellet after cell lysis; (5) amylose beads after sample binding; 
(6) amylose beads after three washes; (7) the first eluate; (8) the second eluate; (9) amylose 
beads after elution. The expected size of MBP-SodB is 60kD. The black arrow indicates a 
truncation of the protein of a size equal to the size of MBP alone as expressed from the 
pMal-p2x plasmid (c. 46kD). The red arrow indicates a protein of size equal to the size of the 
endogenous MBP in E. coli (43.4 kD). 
 
levels observed with the wild-type and the median time to death (26.29h) was significantly 
lower than for the mutant group (p = 0.0002). The proportion of larvae alive at 24 hours (as 
used to score virulence of C. jejuni 11168H mutants by Champion et al, 2010) was on 
average 55% in the wild-type group, 50 % for the complemented group and 13% in the 
∆cj0424 mutant group.  
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Figure 4.8. Survival of Galleria mellonella larvae inoculated with C. jejuni 11168H wild-
type, ∆cj0424 mutant and ∆cj0424::cj0424 complemented strains. Data is presented as 
the mean of three independent replicates each using ten larvae per treatment. Plots marked 
with different letters were significantly different (p < 0.001). 
b 
a 
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4.3.6.2 Role of Cj0424 and Cj0423 in chicken colonisation 
 When testing the wild type, ∆cj0424 mutant and the ∆cj0424::cj0424 complemented 
strains in chickens, no bacteria were recovered from any of the birds during the first 
experiment. The failure of the three C. jejuni strains to colonise during the first experiment 
was most likely due to their lack of motility as observed visually under the microscope and 
through soft agar diffusion test (data not shown). While the strains were re-selected for 
motility through clonal expansion of single colonies for the second experiment, this only 
partially improved motility. During a second experiment low bacterial numbers were 
recovered from only 30% of the birds (data not shown). 
 In order to firmly establish whether Cj0424 plays a role in chicken colonisation, 
each of above three C. jejuni 11168H strains were re-made in a parent stock originating from 
a new vial ordered from the National Collection of Type Cultures (NCTC). The newly made 
strains exhibited high and similar levels of motility as observed visually under the 
microscope and in the soft agar diffusion test (Figure 4.9). The newly made strains were then 
tested in vivo in chickens at two different challenge doses and all birds were colonised to 
high levels. During this experiment, the only statistically significant reductions were 
observed at 1 week post-challenge in the mutant and complemented groups compared to the 
wild-type strain (Figure 4.10). However, complementation did not restore the phenotype and 
no reductions were observed at the two subsequent sampling time-points. 
As both Cj0424 and Cj0423 were claimed by the Kelly laboratory to mediate 
resistance to cationic antimicrobial peptides at the time of the study, the possibility of 
redundancy within the system was assessed through the testing of a double mutant that does 
not produce either protein. When compared to the wild-type and complemented strain in 
chickens no reductions in colonisation were observed at any time-points, at neither of the 104 
or 106 CFU/bird challenge dose (Figure 4.10). 
 
 
Figure 4.9. Soft agar diffusion test for the wild-type, ∆cj0424 mutant and 
∆cj0424::cj0424 complemented strains. Plates in the image are in the order given in the 
figure title from left to right. 
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Figure 4.10. Effect of ∆cj0424 mutation on the ability of C. jejuni 11168H to colonise 
chicken caeca. The three strains were tested at a dose of 106 CFU/bird (A) or 108 CFU/bird 
(B). Each graph shows the mean level of colonisation in each of the groups tested. Six birds 
were sampled in each group at each of the time-points. The groups tested included a wild-
type strain (blue bars), a ∆cj0424 strain (red bars) and a ∆cj0424::cj0424 strain (green bars). 
Error bars represent the standard error of the means (SEM). Significant differences are 
denoted by * for p ≤ 0.05. 
  
 
Figure 4.11. Effect of ∆cj0424-cj0423 double mutation on the ability of C. jejuni 11168H 
to colonise chicken caeca. The three strains were tested at a dose of 104 CFU/bird (A) or 106 
CFU/bird (B). Each graph shows the mean level of colonisation in each of the groups tested. 
Six birds were sampled in each group at each of the time-points. The groups tested included 
a wild-type strain (blue bars), a ∆cj0424-cj0423 strain (red bars) and a strain trans-
complemented with both genes (green bars). The error bars represent the SEM. 
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4.4. Discussion 
 Affinity purification of Campylobacter antigens via the GST system was chosen due 
to previous vaccination studies reporting the successful induction of protection against 
colonisation in a murine model using GST-PorA (Islam et al, 2010). In specialised 
laboratories using highly optimised conditions and pipetting robots, the 6xHis-tag has been 
found to be able to give similar purity but higher yield compared to the GST tag (Scheich et 
al, 2003). However, studies in other laboratories using manual purification found the 6xHis 
tag to result in protein preparations of lower purity even though it may give better yield 
compared to the GST-system (Lichty et al, 2005; reviewed by Vaugh, 2005). Additionally, 
GST-tagged protein purification has been advocated as having a good balance between ease 
of use, yield and cost (Lichty et al, 2005). 
Cloning of all the 21 selected antigens into the pGEX-4T1 plasmid, for expression as 
GST-tagged recombinant proteins, was successful at the first attempt and sequencing showed 
no mutations in any of the clones obtained. Purification of the GST-tagged proteins was met 
with various levels of success and proteins that have been reported to be free in the cytosol 
(Tpx, SodB) or normally secreted (FspA1) were easily purifiable. The flagellar proteins, 
while they were purified in sufficient quantities for in vivo testing, yielded lower amounts of 
recombinant protein per unit of culture volume. Lastly, while some of the membrane-bound 
proteins were purified (CjaA, Cj0125) they required large volumes of culture or the use of 
truncation to known extracellular domains that normally exist in aqueous phase (PorAL7).  
A study into the purification of a large spectrum of recombinant mammalian proteins 
in E. coli through affinity tags found that molecular weight, number of contiguous 
hydrophobic residues and the presence of low complexity regions correlate with soluble 
protein expression, however, the grand average of hydropathicity (GRAVY) did not correlate 
with successful soluble expression (Dyson et al, 2004). Furthermore, the TM Finder 
programme (Deber et al, 2001) has been shown to be able to predict transmembrane domains 
in proteins based on thresholds of segment hydrophobicity and non-polar phase helicity. 
Work leading to the development of this programme showed that 97% of transmembrane 
domains available in SWISS-PROT and TMbase have an index of hydrophobicity 
approximately equivalent or higher to that of a string of 20 alanine residues and as such this 
threshold can be used for prediction of transmembrane domains (Liu and Debber, 1998). 
Work from the same group also showed that an index of helicity can be also used for 
improving transmembrane domain predictions when helicity was determined in non-polar 
media but not in polar media (Wang et al, 1999). As the majority of the proteins that were 
difficult to purify in this study have numerous transmembrane domains, it is possible that the 
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presence of long sections of numerous consecutive hydrophobic residues within these 
proteins may have resulted in them being insoluble, rather than having high GRAVY. 
Additionally, large tags used in purification, such as GST, can interfere with folding 
of recombinant proteins into their native conformation (as reviewed by Smith et al, 2003). 
This may have been another factor that accounted for the difficulty of purification of some of 
the antigens selected in this study. Protein folding may have also accounted for the increased 
yield observed with induction of some of the other proteins at lower incubation temperatures 
as it has been proposed that this observation could be due to improved protein folding, 
allowing for either the GST tag or the recombinant antigen to fold correctly under these 
conditions. Studies showed improved expression of individual proteins at lower temperatures 
in bacteria (e.g. Kataeva et al, 2005) and yeast (e.g. Li et al, 2001) but this is protein 
dependent and may only apply to proteins of larger sizes as a study of 20 human protein with 
molecular weights of under 20kD did not find enhanced solubility or yield at lower 
temperatures (Hammarstrom et al, 2002). 
The same aspects discussed above apply to purification of the 9 Campylobacter 
antigens using the MBP-system. Esposito and Chatterjee (2006) review methods of 
enhancing solubility of recombinant proteins and describe numerous studies that report the 
successful use of MBP as a fusion partner for enhanced solubility. However, the effect may 
be dependent on particular proteins and is likely to need empirical resolution. In this study, 
although not formally assessed, the change to the MBP tag did not appear to enhance 
solubility as the purification of the less soluble GST-tagged proteins required large volumes 
of cultures (2 litres) even when MBP-tagged, compared to the purification of the highly 
soluble proteins (500ml in the case of each tag). 
As with expression of GST-CjaA and TetC-CjaA, truncations of the size of GST 
alone were observed in some of the protein preparations, particularly in those that had poorer 
solubility. The presence of rare codons in the DNA sequence at the start of heterologous 
genes has been discussed in Section 3.4 as a possible reason for premature termination.  
Additionally, it is possible that secondary structures at the 3’ end of the gst gene are involved 
in termination of translation. Signals beyond the stop codon, such as modification of the 
DNA strand and features encoded within the secondary structure of the mRNA at the 3’ end 
of genes have been shown to contribute to accurate termination of transcription in eukaryotes 
(Birnstiel et al, 1985).  
With regard to the assessment of the role of Cj0424 in colonisation, the failure of the 
C. jejuni 11168H strains to establish infection in the first two experiments was most likely 
due to them being non-motile. The importance of motility and the presence of flagella for 
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chicken colonisation have been described in Chapter 1. The passage history of the 11168H 
isolate from the Kelly laboratory was unclear. Even though initial evidence suggested that 
Cj0424 mediates resistance to cationic antimicrobial peptides in vitro and primed our studies 
in Galleria and chickens, more recent studies undertaken by Jonathan Butler (Prof. David 
Kelly’s group, University of Sheffield) have shown no significant differences in resistance to 
cationic peptides between the wild-type, Δcj0424 and Δcj0424::cj0424 strains in vitro. As 
such, the functions of Cj0424 in C. jejuni 11168H and other strains in which it is present 
remains unknown. The lack of a colonisation defect in the Δcj0424 or the double mutant is 
perhaps unsurprising given that Cj0424 is only present in less than 50% of the 
Campylobacter strains sequenced and there appears to be no association of these strains with 
poultry. A nucleotide BLAST of the Cj11168_0424 sequence reveals 14 C. jejuni strains that 
have a gene with over 99% sequence identity. Out of these, the host of origin of 4 strains is 
not given but 8 of the remaining strains were isolated in human clinical cases and two 
originate from ruminants. 
The nine GST-tagged Campylobacter antigens that were described in this chapter as 
having been purified in adequate quantities were tested in chickens as recombinant subunit 
vaccines for their protective affect against Campylobacter colonisation. Furthermore, the 
magnitude and nature of the immune response induced by vaccination was measured and the 
data related to these aspects are given in the next chapter. 
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5. Evaluation of recombinant subunit vaccines against 
Campylobacter colonisation in chickens 
 
5.1 Introduction 
 Nine recombinant subunit vaccines were produced in sufficient quantities for their 
protective efficacy against Campylobacter colonisation to be tested in chickens. Published 
literature reporting the use of subunit recombinant anti-Campylobacter vaccines in broilers 
was summarised in Section 1.5.4. Rational selection of antigens was discussed in Section 
4.2. 
 Previous experiments using Salmonella-vectored CjaA undertaken in our group 
(Buckley et al, 2010) and independent unpublished reports using both live vectored and 
subunit recombinant vaccines, suggest high variability of the protective effect observed 
when CjaA is used as an antigen, with some experiments demonstrating protection while 
others showed no differences compared to mock-vaccinated controls. This effect appears to 
be independent of the experimental and vaccine design, suggesting this may be an intrinsic 
property of CjaA or due to variability in the challenge strain. The underlying mechanisms for 
this variability are unknown. CjaA is processed as a lipoprotein and is also glycosylated in 
Campylobacter (Wyszynska et al, 2008) and expression of recombinant CjaA in E. coli may 
lead to different processing to that of the native protein in Campylobacter. Furthermore, 
variation of glycosylation may be used as an immune evasion mechanism by Campylobacter 
in vaccinated birds. Due to the variability in CjaA’s protective effect, recombinant subunit 
vaccines were tested with the aim of identifying an antigen or combination of antigens that 
confers improved protection compared to CjaA or that would provide more replicable 
protection across independent experiments. Such an antigen would allow future testing of 
optimised vaccines across a reduced number of independent replicates. 
 
 
5.2 Materials and methods 
5.2.1 Validation of immunogenicity of CjaA, FliD and Cj0089 
Immunogenicity of CjaA, FliD and Cj0089 following Campylobacter infection was 
described previously (Shoaf-Sweeney et al, 2008). At the time of their use in vaccination 
experiments, their antigenicity in Campylobacter-infected but non-vaccinated birds was 
assessed through a Western blot using sera from PBS-vaccinated birds (Section 3) 
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challenged at 4 weeks of age with C. jejuni M1. Pooled sera were used at a 1:100 dilution 
and bound serum IgY detected using an HRP-conjugated rabbit anti-chicken Ig (Sigma 
Aldrich) at a 1:3000 dilution. 
 
5.2.2 Vaccination experiments 
Nine GST-tagged recombinant Campylobacter antigens were tested for their 
protective efficacy in chickens. For parity with previous experiments in our group, an 
experimental design similar to that described by Buckley et al (2010) was used. This was 
described in detail in Section 2.15.2. However, there were a number of modifications to the 
study design. Firstly, the GST tag was used for purification of recombinant antigens instead 
of the 6xHis tag as it was found that this tag resulted in protein preparations with higher 
purity (data not shown). Secondly, due to local availability White Leghorn birds were used 
instead of Light Sussex birds. Furthermore, the TiterMax® Gold adjuvant (Sigma, UK) was 
used instead of TiterMax®. According to the manufacturer, this adjuvant has improved 
efficacy compared to the standard version and induces higher levels of antigen-specific 
antibodies. Lastly, the amount of each antigen was standardised according to molecular 
mass, in order to deliver 4.3x10-10 moles, the number of moles present in 14 μg of 6xHis-
CjaA, as used by Buckley et al (2010). For this calculation, the molecular weight of each 
entire GST-tagged Campylobacter antigen was taken into account. The amount of each 
antigen delivered to each bird at each of the vaccinations is given in Table 5.1.  
 
Table 5.1. Amount of GST-tagged recombinant antigens used in vaccination trials. 
 
Antigen Molecular mass (in kD) 
Mass delivered per bird 
per vaccination (in μg) 
GST 25 13.2 
GST-PorAL7 29 14.9 
GST-Cj0089 35 17.7 
GST-FspA 41 20.4 
GST-Tpx 43 19.5 
GST-SodB 50 22.4 
GST-CjaA 55 27.2 
GST-FlgK 92 41.7 
GST-FliD 95 44.5 
GST-FlgE2 99 46.3 
 
 During each vaccination experiment, GST and GST-CjaA were used as negative and 
positive controls respectively. As in the study by Buckley et al (2010) vaccines were 
delivered in a 1:1 mix with TiterMax® Gold, with 50 μl being delivered on each side of the 
thorax subcutaneously, using a calibrated Hamilton’s repeat dispenser and syringe. In total, 5 
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vaccination experiments were run using recombinant antigens. Excluding the 
aforementioned control groups, the groups tested in each vaccination experiment and their 
purpose are given in Table 5.2. Where multivalent vaccines were administered, each vaccine 
was delivered to a dose equal to that administered for univalent vaccines. As such, the total 
dose of vaccine was 2 or 3 fold higher than when administered individually. 
 
5.2.3. Assessment of humoral immune responses 
 For each vaccination experiment, the induction of antigen-specific serum IgY and 
bile IgA was assessed in individual birds in each of the groups. This was done by ELISA, as 
described in Section 2.15.4. In order to avoid detection of antibodies against the GST portion 
of each recombinant antigen, the MBP-tagged recombinant proteins described in Section 
4.3.5 were used. Appropriate coating concentrations and serum dilutions for each antigen 
were determined by chequerboard analysis and chosen to give readings within the linear 
range of representative serial dilutions.  
The MBP-tagged antigens were used in ELISAs for measurement of antigen-specific 
serum IgY at the following coating concentrations: 2 μg/ml for measurement of responses 
against SodB and FlgK, 1 μg/ml for measurement of responses against FspA, FliD and 
FlgE2 and 0.5 μg/ml for measurement of responses against CjaA, PorAL7 and Tpx. Sera were 
diluted 1:500 for measurement of responses against CjaA, FliD and PorAL7, 1:250 for 
measurement of responses against SodB, FspA and TpX and 1:100 for measurement of 
responses against FlgK and FlgE2. Responses against Cj0089 were not measured as attempts 
to re-clone cj0089 into pMal-p2X failed. 
 Antigen-specific bile sIgA responses were measured for CjaA and SodB vaccinated 
birds only and both antigens were used at a 1 μg/ml concentration. Sera were diluted 1:250 
for measurement of sIgA against both antigens. 
 Additionally, for the FliD, SodB and CjaA antigens, fold-changes in serum IgY 
levels were determined in individual birds at each time-point by dividing the OD450nm reading 
in vaccinated birds by the mean OD450nm reading of GST-vaccinated control birds averaged 
across the respective time-point. A linear regression of these measurements on caecal 
Campylobacter counts in each bird was used to assess whether the level of antigen-specific 
serum IgY induction correlated with caecal Campylobacter counts. 
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Table 5.2. Groups tested in each of the vaccination experiments using recombinant 
subunit vaccines. In each experiment GST and GST-CjaA groups were included as 
negative and positive controls respectively. 
 
Vaccination 
experiment 
Aim of the 
experiment 
Groups 
included 
Aim of individual group 
1 
Testing individual 
antigens 
GST-PorA 
Identifying an antigen with improved protection 
compared to CjaA 
GST-FspA 
Identifying an antigen with improved protection 
compared to CjaA 
GST-FliD 
Identifying an antigen with improved protection 
compared to CjaA 
GST-FlgE2 
Identifying an antigen with improved protection 
compared to CjaA 
2 
Testing individual 
antigens 
GST-SodB 
Identifying an antigen with improved protection 
compared to CjaA 
GST-FlgK 
Identifying an antigen with improved protection 
compared to CjaA 
GST-Tpx 
Identifying an antigen with improved protection 
compared to CjaA 
3 
Repeat testing of 
antigens 
conferring 
reduction in 
caecal 
Campylobacter 
colonisation in the 
previous 
experiments 
GST-FspA 
Re-testing an antigen that conferred a reduction of 
minimum 1log10 in the preliminary screen, even if it 
was not statistically significant 
GST-SodB 
Re-testing an antigen that conferred a reduction of 
minimum 1log10 in the preliminary screen, even if it 
was not statistically significant 
GST-FliD 
Re-testing an antigen that conferred a reduction of 
minimum 1log10 in the preliminary screen, even if it 
was not statistically significant 
GST-Cj0089 
Identifying an antigen with improved protection 
compared to CjaA; could not be tested in 
experiment 2 due to low number of birds hatched 
4 
Testing of 
protective 
antigens singly 
and in 
combination 
GST-SodB 
Control group for the groups testing a multivalent 
vaccine 
GST-FliD 
Control group for the groups testing a multivalent 
vaccine 
GST-SodB + 
GST-FliD 
Assessing if multivalent vaccines confer improved 
protection 
GST-SodB + 
GST-FliD + 
GST-CjaA 
Assessing if multivalent vaccines confer improved 
protection 
5 
Assessing 
heterologous 
protection and 
testing Cj0424 as 
a vaccine 
candidate 
GST-SodB Assessment of heterologous protection 
GST-FliD Assessment of heterologous protection 
GST-Cj0424 
Assessment of potential as a vaccine candidate of 
a novel protein involved in resistance to cationic 
antimicrobial peptides* 
GST-6xHis-
CjaA 
Assessing whether tag used for purification may 
affect variability in protection observed with CjaA. 
 
*As described by Halah Al-Haideri at the time of testing. 
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5.2.4 Determination of the subcellular localisation of SodB 
 The subcellular localisation of SodB was assessed through immunofluorescent (IF) 
staining of C. jejuni 11168H cells, as described in Section 2.16. C. jejuni 11168H were 
permeabilised for 30 minutes in 10% (v/v) Triton-X100 (where indicated) and fixed for 30 
minutes in 4% PFA (w/v), both diluted in PBS. Pooled sera from GST-SodB vaccinated 
birds, collected at 24 dph, before challenge, were used as primary antibody at a 1:500 
dilution. Bound serum IgY was detected with an AlexaFluor-488-conjugated goat anti-
chicken IgY (AbCam), used at a 1:500 dilution. Images were taken on a DLMB fluorescent 
microscope (Leica), with the fluorescence intensity set for the image of interest and kept 
constant throughout the experiment. 
 The results of the IF staining were confirmed through Western blotting of outer 
membrane, periplasmic and inner membrane subcellular fractions of C. jejuni 11168H with 
the same sera from GST-SodB vaccinated birds used for immunofluorescent staining. The 
subcellular fractions were made by Halah Al-Haideri (University of Sheffield) using the 
method described in Section 2.17. Sera were used at a 1:100 dilution and bound IgY was 
detected with an HRP-conjugated rabbit anti-chicken IgY antibody (Simga Aldrich) used at a 
1:3000 dilution. 
   
5.2.5. Ability of anti-FliD serum IgY to neutralise its target 
 The ability of anti-FliD serum IgY to recognise and neutralise its target was assessed 
through a soft agar diffusion test. For this, a 10 μl sterile plastic loop was used to inoculate 
an overnight culture of C. jejuni M1 into the centre of 0.3% (w/v) MH agar plates by 
stabbing. Plain MH agar plates were used as negative controls and plates containing 1:100, 
1:1000 or 1:10,000 (v/v) serum from GST-FliD vaccinated birds collected at 24dhp (before 
challenge) were used to assess the ability of anti-FliD antibodies to neutralise their target. 
Furthermore, this was also assessed by mixing an overnight culture of C. jejuni M1 with an 
equal volume of undiluted serum from GST-FliD vaccinated birds, followed by a 1 minute 
incubation with gentle agitation. Slides were then examined for evidence of agglutination 
and motility both with the naked eye and under the microscope, using a 40x magnification. 
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5.3 Results 
5.3.1 Validation of natural immunogenicity of CjaA, FliD and Cj0089 
 Western blotting with pooled sera collected at three weeks post-challenge from PBS-
vaccinated birds used as negative controls during the first vaccination experiments which 
were challenged with C. jejuni M1 at 4 weeks old, confirmed previous reports that CjaA, 
FliD and Cj0089 are antigenic in Campylobacter infections in chickens (Figure 5.1). 
However, the protein samples were prepared through denaturing SDS-PAGE and as such 
only linear epitopes were detected by Western blotting. While the other antigens were also 
assessed for antigenicity, they did not react with sera from Campylobacter infected chickens 
suggesting that linear epitopes of these antigens are not recognised by the chicken’s immune 
system during infection with this bacterium (data not shown) or that these epitopes are not 
expressed during in vitro culture. 
 
Figure 5.1. Confirmation of antigenicity of CjaA, FliD and Cj0089 in primary C. jejuni 
infection in chickens. This was tested through Western blotting with sera collected from 
birds injected with PBS and infected with C. jejuni M1 during the first vaccination trial 
testing attenuated live-vectored vaccines. Sera were obtained at three weeks after challenge 
with C. jejuni M1. Antigens are shown in two panels (A and B) as they were each tested at 
the time of their use in vaccination experiments. Arrows to the right of each lane indicate the 
expected molecular weight of each antigen tested. 
 
5.3.2 Testing of individual recombinant antigens for protection against homologous 
C. jejuni colonisation 
Nine novel antigens were separately tested for their ability to confer protection 
against C. jejuni colonisation, initially across two independent experiments. Two separate 
experiments were run due to space constrains within the containment animal facility. 
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5.3.2.1. Protection against caecal colonisation 
 The colonisation kinetics in each of the groups vaccinated with individual GST-
tagged C. jejuni antigens in the first two vaccination experiments are shown in Figure 5.2. 
Second order hierarchical general linear models (GLMs) taking into account the time of 
vaccination and treatment group were fitted for each individual experiment (R2 = 0.5 for 
each experiment). Even though reductions of 1log10 CFU/g were observed with FliD at 48 
dph (Figure 5.2A) and with SodB and CjaA at 56 dph (Figure 5.2B), these were not 
statistically significant. No statistically significant differences were detected between groups 
when the entire course of colonisation was considered. As no statistical significance was 
detected, average colonisation across the entire duration of the experiments was used as a 
measure of potential protective effect. The largest differences between groups vaccinated 
with Campylobacter antigens and the GST-only control group were observed in the GST-
FliD (-0.24), GST-CjaA (-0.18) and GST-FspA (-0.14) groups within the first experiment 
and the GST-CjaA (-0.34) and GST-SodB (-0.27) groups within the second experiment. The 
numbers in brackets are the differences in average course of colonisation as estimated by 
each GLM. 
 
5.3.2.2. Antigen-specific serum IgY responses 
 Apart from FlgK, antigen-specific serum IgY induction was observed in all 
vaccinated groups within the first two experiments at a minimum of a single time point. 
Antigen-specific serum IgY against CjaA, SodB and FliD was induced at all time-points and 
are shown in a later section as an average of all the experiments in which they were tested. 
The data for FlgK, FlgE2, Tpx and PorAL7 are given in Figure 5.3. GST-Tpx induced 
significant increases in serum IgY at all time-points (p = 0.04 at week 3 and p < 0.01 at all 
other time-points). GST-FlgE2 only induced significant increases in serum IgY at 49 dph (p 
= 0.04) and GST-PorAL7 only induced significant increases at 56 dph (p = 0.03). Even 
though the fold-increase in serum IgY was higher at 42 and 49 dph than at 56dph in the 
GST-PorAL7 vaccinated group, these were not statistically significant due to a low number of 
birds being samples (n=4) and high variability observed amongst responses in individual 
animals. These results suggest that the vaccines were successfully administered. 
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Figure 5.2 Caecal colonisation by C. jejuni M1 of birds vaccinated with different 
recombinant GST-tagged Campylobacter antigens. Antigens were tested in two separate 
trials (A. and B.) due to space constraints. Each trial included a GST and a GST-CjaA 
vaccinated group as negative and positive controls respectively. Caecal Campylobacter 
counts were determined by serial dilution of caecal contents collected at post-mortem 
examinations. Between 3 and 6 birds were sampled at each of the time-points in each of the 
treatment groups. The error bars represent the SEM. For all treatment groups colour-coded in 
the legend GST-tagged recombinant antigens were used. 
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Figure 5.3. Induction of antigen-specific serum IgY in birds vaccinated with the GST-
tagged recombinant Campylobacter antigens that were tested once only. Data is 
expressed as fold-change in OD450nm from the average OD450nm reading of the GST only 
vaccinated group, calculated at each time-point individually. Between 3 and 6 birds were 
sampled per time-point per treatment group. Significant differences from the GST only 
vaccinated group are denoted by * for p<0.05, ** for p<0.01 and *** for p<0.001. For all 
treatment groups colour-coded in the legend GST-tagged recombinant antigens were used. 
The dotted line marks no change from the GST-vaccinated controls. 
 
5.3.3. Repeat testing of antigens that were indicated as potentially protective during 
the initial experiments 
 Antigens that were identified as being potentially protective within the first two 
vaccination experiments were re-tested in a third experiment.  
5.3.3.1 Protection against caecal colonisation 
The data obtained in the third vaccination experiment are given in Figure 5.4.A. 
When analysed independently, a second order hierarchical GLM taking into account the time 
of sampling and the treatment group (R2 = 0.22) revealed significant reductions in the entire 
course of colonisation of the GST-SodB (p = 0.004) and GST-FliD (p = 0.02) vaccinated 
groups compared to the GST-only vaccinated group. Furthermore, the GST-SodB vaccinated 
group also induced significantly improved protection compared to the GST-CjaA vaccinated 
group (p = 0.013). Post-hoc Dunnet’s tests were not able to distinguish individual time-
points at which reduction were statistically significant. No significant reductions were 
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observed in the GST-Cj0086 vaccinated group, where GST-Cj0086 was tested for the first 
time due to insufficient birds being hatched during the previous experiment. 
The data was also analysed averaged with the previous experiments using two 
separate third order hierarchical GLMs in which only control groups tested concomitantly 
were included. These GLMs took into account interactions between experiment number, 
time of sampling and treatment group. Average data of experiments testing GST-SodB 
relative to controls is given in Figure 5.4.B. The GLM (R2 = 0.39) indicated that the course 
of colonisation of the GST-SodB vaccinated group was significantly different from that of 
the GST vaccinated group (p < 0.023). Post-hoc Dunnet’s tests identified a significant 
difference at 56 dph, when the caecal colonisation in the GST-SodB vaccinated groups was 
reduced by 1.6log10 CFU C. jejuni/g caecal contents compared to the GST (p = 0.004) group. 
No significant differences were observed compared to the GST-CjaA vaccinated group or 
between the GST-CjaA vaccinated group and the GST vaccinated group. Average data of 
experiments testing GST-FliD or GST-FspA relative to controls is given in Figure 5.4.C. The 
GLM (R2 = 0.47) indicated that the course of colonisation of the GST-FliD vaccinated group 
was significantly different from that of the GST (p < 0.001) and the GST-CjaA (p < 0.001) 
vaccinated groups. Post-hoc Dunnet’s tests identified significant differences at 49 dph, when 
the caecal colonisation in the GST-FliD vaccinated groups was reduced by 2log10 CFU C. 
jejuni/g caecal contents compared to both the GST (p < 0.001) and the GST-CjaA groups (p 
< 0.001).  
 
5.3.3.2 Antigen-specific serum IgY responses 
Significant induction of antigen-specific serum IgY antibodies was observed in each 
of the groups tested in the third vaccination experiment. The average induction of serum IgY 
against GST-FspA is shown in Figure 5.5. Significant induction was observed at all time-
points (p =0.01 at challenge and p < 0.001 at all other time-points). The induction of serum 
IgY against SodB and FliD is shown in a later section averaged across all experiments in 
which it was tested. 
 
5.3.4. Multivalent vaccines against C. jejuni colonisation in chickens 
 Following the observation that subunit recombinant vaccines based on FliD and 
SodB conferred protection against caecal colonisation by C. jejuni in chickens, an 
experiment was carried out to assess whether multivalent vaccines that combine SodB and 
FliD, with or without CjaA, can confer improved protection compared to univalent vaccines. 
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Figure 5.4. Caecal colonisation by C. jejuni M1 of birds vaccinated with recombinant 
GST-tagged Campylobacter antigens tested in duplicate. A. Caecal colonisation data from 
the third vaccination trial. Between 4 and 6 birds were sampled at each time point in each of 
the groups. Significant differences are described in Section 5.3.2.1. Cj0086 was tested for the 
first time in this study (See Table 5.2) B. and C. Average caecal colonisation across the two 
experiments testing GST-SodB relative to controls and GST-FliD or GST-FspA relative to 
controls respectively. Data is presented separately with concomitantly tested controls. 
Between 7 and 12 birds were sampled at each time-point in each of the groups. Error bars 
represent standard error of the mean. Significant differences are denoted by * (p < 0.05). For 
all treatment groups colour-coded in the legends GST-tagged recombinant antigens were 
used. 
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Figure 5.5. Induction of antigen-specific serum IgY against FspA in vaccinated birds. 
Data is shown as an average of both vaccination experiments in which GST-FspA was 
tested. ELISAs were run on MBP-FspA. Error bars represent SEM. Significant differences 
from the GST only vaccinated group are denoted by ** for p < 0.01 and *** for p < 0.001. 
 
5.3.4.1 Protection against caecal colonisation 
 A second order hierarchical general linear model on the data collected during the 
fourth vaccination experiment alone (R2 = 0.46) found that the colonisation course of the 
group vaccinated with a bivalent vaccine comprising of both GST-SodB and GST-FliD was 
significantly different from that of the groups vaccinated with GST only (p = 0.012), GST-
SodB only (p = 0.01) and GST-FliD only (p < 0.001), but surprisingly owing to higher levels 
of caecal colonisation within this group. Post-hoc Dunnet’s tests indicated significant 
difference between the bivalent SodB-FliD and the GST only (p < 0.001) vaccinated groups 
at 56 dph. No individual time-points were distinguished when compared to the GST-SodB 
and the GST-FliD vaccinated groups. The caecal colonisation by C. jejuni M1 within this 
experiment is given in Figure 5.6 and shows that the group vaccinated with the combination 
of GST-SodB and GST-FliD had higher counts than the aforementioned groups to which its 
course of colonisation was significantly different. This suggests that combining SodB and 
FliD does not have a beneficial additive effect and that it may, in fact, decrease the 
protective effect observed with individual antigens. However, interpretation of this data 
should be made with caution given no significant reduction were observed in the GST-SodB 
and GST-FliD individually vaccinated groups compared to the GST only control. 
Furthermore, while a decrease in caecal Campylobacter colonisation was seen from weeks 1 
to 4 post-challenge during the previous experiments, it was not as marked as in the current 
** 
*** 
*** 
*** *** 
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trial. During this experiment, the caecal colonisation of C. jejuni M1 declined by more than 
2.5log10 between weeks 2 and 4 post-challenge in the GST control group. 
 
 
Figure 5.6. Caecal colonisation data in birds vaccinated with univalent and multivalent 
recombinant Campylobacter vaccines. Caecal Campylobacter counts were determined by 
serial dilution of caecal contents collected at post-mortem examinations. Between 4 and 6 
birds were sampled at each of the time-point in each of the treatment groups. The error bars 
are the SEM. Significant differences in the course of colonisation between different groups 
are described in Section 5.3.4.1. For all treatment groups colour-coded in the legend GST-
tagged recombinant antigens were used. 
 
5.3.4.2 Antigen-specific serum IgY responses 
 The induction of antigen-specific serum IgY responses in the GST-SodB group was 
measured in ELISAs using MBP-tagged coating antigens and this data is given in a later 
section as an average of all experiments. The data for GST-CjaA tested singly and in 
combination with GST-SodB and GST-FliD is given in Figure 5.7.A and demonstrates the 
induction of antigen-specific serum IgY in both groups at all time-points. MBP-CjaA was 
used in these ELISAs. MBP-tagged antigens were initially purified in insufficient quantitates 
to measure the induction of specific responses against SodB and FliD in the groups 
vaccinated with the multivalent vaccines and in the univalent FliD vaccinate group. 
Subsequent attempts to purify MBP-SodB and MBP-FliD failed to produce recombinant 
antigens that cross-reacted with serum IgY in ELISAs (data not shown). However, these 
antigens reacted with an anti-MBP antibody and with antigen-specific serum IgY (using sera 
from vaccinated but non-challenged birds) in Western blots (data not shown), suggesting 
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possible mis-folding of the recombinant antigens or failure of these recombinant antigens to 
bind to the ELISA plates. Due to this, the GST-tagged SodB and FliD recombinant antigens 
were used in ELISAs to measure the response against the entire recombinant protein and 
these were compared to the reactivity of each serum to GST alone. The data is shown in 
Figure 5.7.(B-D) and significant increases in serum IgY against the GST-tagged antigens 
compared to the GST only control group indicate an increase in antibodies due to 
vaccination. Furthermore, the significant decrease in reactivity to GST only in the groups 
vaccinated with the GST-tagged recombinant antigens may indicate that the increase in 
serum IgY against the GST-tagged antigens was due to induction of Campylobacter-antigen 
specific serum IgY. As the molecular weight of each GST-tagged antigen was taken into 
account to deliver an equal number of moles of each antigen, the molar amounts of GST 
were identical in the GST-only control group and the other treatment groups.  This suggests 
that the Campylobacter antigens delivered in this study may have higher intrinsic 
immunogenicity compared to the GST tag, resulting in a significant decrease in the amount 
of serum IgY produced against GST in birds vaccinated with Campylobacter antigens. 
 
5.3.5. Average data across all trials testing protection against homologous challenge 
 Given the variability in the protective effects observed across independent replicates, 
the ability of SodB and FliD to reduce caecal Campylobacter counts was assessed in 
comparison with the GST and GST-CjaA control groups tested in all vaccination 
experiments using homologous challenge, even when not tested concomitantly. This 
comparison was made in order to increase the statistical power and it was enabled by the 
design of the vaccination experiments being kept identical across all vaccination trials and 
the use of a challenge strain originating from the same bacterial stock. 
 
5.3.5.1 Protection against caecal colonisation 
The mean caecal colonisation levels across all four experiments using homologous 
challenge with the C. jejuni M1 strain is given in Figure 5.8. A second order hierarchical 
GLM was used as fitting of a third order model was not possible due to the GST-SodB and 
GST-FliD vaccines not being tested in all four experiments. The initial model highlighted the 
presence of a large number of data points from individual birds with large residuals. 
Residuals are calculated as the difference between the observed and expected value for 
individual animals. Large residuals are used as an indication of data points that do not fit the 
model well and can be considered outliers. In order to optimise the model, the first two  
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Figure 5.7. Induction of antigen-specific serum IgY in birds vaccinated with univalent and multivalent vaccines. A. Induction of CjaA-
specific serum IgY measured in ELISAs using MBP-CjaA as a coating antigen. B-D. Induction of serum IgY against GST-SodB, GST-FliD and 
GST only expressed as average OD450nm readings obtained in ELISAs using GST-tagged recombinant antigens. Between 4 and 6 birds were 
sampled per group per time-point. Error bars represent the SEM. Significant differences from the GST only vaccinated group are denoted by * for 
p < 0.05, ** for p < 0.01 and *** for p < 0.001. All treatment groups colour-coded in the legend were vaccinated with GST-tagged recombinant 
proteins. 
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outliers with the largest residuals in each of the GST, GST-CjaA and GST-SodB groups 
were removed. The residuals for these were at least 2log10 for the GST group and 3log10 for 
the GST-CjaA and GST-SodB groups. No outliers were identified in the GST-FliD 
vaccinated group. The re-fitted model (R2 = 0.44) indicated that the course of colonisation in 
the GST-SodB vaccinated birds was significantly different compared to that in the GST (p = 
0.005) and the GST-CjaA (p = 0.003) vaccinated groups. Furthermore, the course of 
colonisation in the GST-FliD vaccinated group was also significantly different to that of both 
the GST (p < 0.001) and the GST-CjaA (p < 0.001) vaccinated groups. Post-hoc Dunnet’s 
tests identified significant reductions of 1.3 log10 CFU/g in the SodB vaccinated group at 56 
dph compared to both control groups and of approximately 1.7 log10 CFU/g in the FliD 
vaccinated group at 49 dph compared to both control groups (all p < 0.001). These data 
suggest that both the FliD and the SodB antigens confer improved protection compared to 
CjaA when using the current experimental design. No significant reduction was observed 
with GST-FliD at week 4 post-challenge, but the reduction in colonisation at week 3 post-
challenge, followed by the lack of a reduction increase in caecal colonisation at week 4 post-
challenge was observed in each of three independent trials run. 
 
 
Figure 5.8. Average caecal colonisation by the homologous strain C. jejuni M1 in 
chickens vaccinated with GST, GST-CjaA, GST-SodB and GST-FliD averaged across 
all experiments. The data includes four replicates for the GST and GST-CjaA controls and 
three replicates for each of the GST-SodB and GST-FliD controls. Error bars are the SEM. 
Between 12 and 22 birds were used per antigen per time-point. Significant differences to 
both control groups are indicated by post-hoc Dunnet’s tests are indicated by *** for p < 
0.001.  
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5.3.5.2 Antigen-specific humoral responses 
The induction of SodB- and CjaA-specific serum IgY was measured through 
ELISAs using the MBP-tagged recombinant antigens and the data obtained is given in Figure 
5.9.A. Averaged across all trials in which they were tested, both SodB (tested in 3 
experiments) and CjaA (tested in 4 experiments) induced antigen-specific serum IgY at all 
time-points tested. The induction of antigen-specific serum IgY against FliD was measured 
through ELISAs using GST-FliD as the coating antigen as the amount of MBP-FliD 
available was insufficient to measure antibody induction in the fourth experiment. This data 
is shown in Figure 5.9B and 5.9C. and indicates the induction of serum IgY against FliD at 
all time-points measured. 
The induction of antigen-specific bile sIgA was also measured for the GST-CjaA 
and GST-SodB vaccinated birds. These ELISAs were undertaken on MBP-tagged 
recombinant antigens and the average data across all experiments is given in Table 5.3. No 
induction of antigen-specific bile sIgA was observed at any of the time-points in any of the 
experiments. A lack of antigen-specific bile sIgA induction was also observed in the study of 
Buckley et al (2010). As such, measurement of bile sIgA for the other antigens used for 
vaccination was not performed. 
 
5.3.5.3 Functional characterisation of antigen-specific serum IgY antibodies 
 Linear regressions between caecal Campylobacter counts and the level of serum IgY 
antibodies against SodB and CjaA indicated that there was no correlation between antibody 
production and protection within these treatment groups (Figure 5.10.A and B). However, a 
linear regression between OD450nm readings (obtained in ELISAs measuring reactivity to 
GST-FliD) and caecal Campylobacter counts within the GST-FliD vaccinated group 
indicated a statistically significant positive correlation (p = 0.004; Figure 5.10.C). Even 
though this relation was weak, it indicates that birds with higher serum IgY responses had 
higher levels of C. jejuni M1 within their caeca, suggesting that this type of immune 
response is not likely to be responsible for the protection observed. Furthermore, soft agar 
diffusion assays and slide agglutination tests suggested that serum IgY against FliD do not 
neutralise their target (data not shown). However, no commercial antibodies were available 
to use as positive control (e.g. anti-flagellin antibodies). 
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Figure 5.9. Induction of antigen-specific serum IgY in birds vaccinated with GST-FliD, 
GST-SodB and GST-CjaA. A. Induction of CjaA-specific serum IgY (averaged across four 
experiments) and SodB-specific serum IgY (averaged across three experiments). ELISAs 
were run with MBP-tagged proteins as coating antigens. B. Induction of serum IgY against 
GST-FliD in GST-FliD vaccinated birds expressed as average OD450nm reading. C. Induction 
of serum IgY against GST in GST-FliD vaccinated birds expressed as average OD450nm 
reading. Between 12 and 22 birds were sampled per group per time-point. Significant 
differences from the GST only vaccinated group are denoted by * for p < 0.05, ** for p < 
0.01 and *** for p < 0.001. 
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Table 5.3 Measurement of antigen-specific bile sIgA in GST-CjaA and GST-SodB 
vaccinated birds. Average data from three experiments is shown for SodB and from four 
experiments for CjaA. Between 12 and 22 birds were samples per group per time point. 
Coating antigen Vaccine group Mean OD450nm for antigen specific bile secretory IgA 
MBP-SodB 
GST-SodB 1.01 (±0.34) 1.02 (±0.33) 1.05 (±0.33) 1.27 (±0.31) 
GST 1.04 (±0.50) 1.09 (±0.40) 1.26 (±0.31) 1.22 (±0.28) 
MBP-CjaA 
GST-CjaA 0.62 (±0.31) 0.93 (±0.19) 0.73 (±0.26) 0.89 (±0.21) 
GST 0.81 (±0.24) 0.83 (±0.15) 0.76 (±0.37) 0.67 (±0.37) 
 
 
Figure 5.10. Correlations between antigen-specific serum IgY induction and caecal 
Campylobacter counts for groups vaccinated with GST fusions to SodB, FliD or CjaA. A 
and B. Linear regression of fold-change in antigen-specific serum IgY in individual GST-
SodB and GST-CjaA vaccinated birds on their caecal Campylobacter counts. ELISAs were 
performed on MBP-tagged recombinant protein. C. Linear regression of OD450nm readings 
(measured in ELISAs on GST-FliD) in GST-FliD vaccinated birds on their caecal 
Campylobacter counts. ELISAs were performed on GST-FliD and as such specific reactivity 
against FliD could not be accurately determined in order to calculate a fold-change. For all 
panels, the average caecal colonisation across both caeca was used.  
 
In addition, the ability of SodB antibodies to recognise their target on the surface of 
the bacterium was assessed through immunofluorescent staining of C. jejuni 11168H cells. 
Contrary to previous reports that described SodB as being present in the outer membrane 
proteome of C. jejuni (Watson et al, 2014), this experiment indicated that SodB is not 
present on the surface of C. jejuni (Figure 5.11.A). This finding was validated by Western 
blotting of C. jejuni 11168H subcellular fractions, which revealed the presence of SodB only 
within the periplasmic space (Figure 5.11.B). The purity of the fractions was demonstrated 
by Western blotting with αCapA (an outer membrane auto-transported adhesin; Ashgar et al, 
2007) or αMfrA (a periplasmic fumarate reductase subunit associated with an inner 
membrane complex; Guccione et al, 2010). However, no assessment of cytoplasmic 
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contamination of the periplasmic fraction was carried out and as such the presence of SodB 
within the periplasm cannot be clearly dissociated from its presence within the cytoplasm. 
These assays also demonstrate cross-reactivity of serum IgY against C. jejuni M1 SodB 
antibodies with native C. jejuni 11168H SodB. Before these experiments were carried out, 
cross reactivity was demonstrated through a Western blot of whole cell lysate of C. jejuni 
M1 and 11168H using sera from GST-SodB vaccinated birds, which showed reactivity of 
SodB from both Campylobacter strains with the antibodies raised against C. jejuni M1 SodB 
(data not shown). 
 
   
 
Figure 5.11. Subcellular localisation of SodB in C. jejuni cells. A. Immunofluorescent 
staining with sera from GST-SodB and GST only vaccinated birds collected on the day of 
challenge, before oral gavage. Bacterial cells were fixed with 4% (w/v) PFA and, where 
indicated, permeabilised with 10% (v/v) Triton-X100, both diluted in PBS. B. 
Immunoblotting of inner membrane, outer membrane and periplasmic subcellular fractions 
of C. jejuni 11168H with sera from the same GST-SodB vaccinated birds used in panel A. 
 
5.3.6 Assessment of protection against heterologous challenge 
 A vaccine that could be used in the field would have to induce cross-protection 
against different C. jejuni strains and following the observation above that antibodies raised 
against C. jejuni M1 SodB cross-react with C. jejuni 11168H SodB and the high level of 
primary sequence conservation of SodB in sequenced Campylobacter species, an experiment 
was carried out to assess whether SodB and FliD could confer protection against 
heterologous challenge. Furthermore, the same experiment aimed to assess whether the lack 
of the protective effect observed with GST-CjaA in the previous vaccination experiments 
was due to the fusion partner as previously a 6xHis-CjaA recombinant antigen was shown to 
be protective (Buckley et al, 2010). Birds were therefore vaccinated with the C. jejuni M1-
derived antigens indicated in Table 5.2 and challenged at four weeks of age with C. jejuni 
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11168H rather than M1. The same trials also tested Cj0424 for its ability to confer 
homologous protection against C. jejuni challenge. 
 
5.3.6.1 Protection against caecal colonisation 
A second order hierarchical GLM (R2 = 0.76) did not identify significant differences 
between the entire course of colonisation in any of the group. The course of caecal 
colonisation by the C. jejuni 11168H heterologous challenge strain is given in Figure 5.12. In 
contrast with colonisation by C. jejuni M1, colonisation levels with C. jejuni 11168H were 
lower at 1 week post-challenge. Of particular note, 6xHis-tagged CjaA was not protective, in 
contrast to the observations of Buckley et al (2010), though several features of the 
experimental design differed.  No protection against homologous challenge was observed 
with Cj0424. 
 
 
Figure 5.12. Heterologous protection against caecal colonisation by C. jejuni 11168H in 
birds vaccinated with the GST-SodB, GST-FliD, GST-Cja and 6xHis-CjaA cloned from 
C. jejuni M1 and homologous protection against C. jejuni 11168H in birds vaccinated 
with 6xHis-Cj0424. Between 4 and 6 birds were sampled at each of the time-point in each 
of the treatment groups. The error bars represent the SEM. The groups colour-coded in the 
legend were vaccinated with GST-tagged antigens apart from those denoted otherwise. 
 
5.3.6.2. Antigen-specific serum IgY responses 
 Induction of serum IgY against CjaA was measured in ELISAs using MBP-CjaA 
and is shown in Figure 5.13.A. The same figure also shows induction of serum IgY 
responses against 6xHis-CjaA and 6xHis-Cj0424, measured in ELISAs using the 6xHis-
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tagged recombinant proteins as coating  antigens. Vaccination with GST-CjaA resulted in 
significantly higher anti-CjaA serum IgY levels at all time-points. Apart from at 49 dph, the  
6xHis-CjaA vaccinated birds showed significant increases in serum IgY at all other time-
points. Cj0424 failed to induce specific serum antibodies at any of the time-points tested, at 
least at the limit of detection of the assay used. 
 The induction of serum IgY antibodies against FliD and SodB was measured by 
ELISA using the GST-tagged recombinant proteins as coating antigens and the obtained data 
is given in Figure 5.13.B-D. Significant induction of serum IgY against FliD was observed in 
the GST-FliD vaccinated group at all time-points. No significant induction of serum IgY was 
observed against SodB in the GST-SodB vaccinated group. However, a significant reduction 
in the reactivity towards GST in the GST-SodB vaccinated group compared to the control 
group and the high reactivity of sera from GST only vaccinated birds against GST-SodB 
suggest possible saturation of the assay and measurements outside the linear range. More 
accurate determination of the serum IgY responses against GST-SodB could be determined 
through optimisation of this assay for this particular experiment through a separate 
chequerboard analysis. 
 
 
5.4 Discussion 
 The experiments described above demonstrate that SodB and FliD are protective 
against caecal colonisation by the homologous C. jejuni M1 strain and add two novel 
protective antigens to the limited repertoire of those described in the literature. These 
antigens also conferred improved protection compared to CjaA using the current vaccines 
and delivery protocols, however CjaA failed to elicit protection. As such, whether SodB and 
FliD would confer improved protection using different vaccine and experimental designs, in 
which CjaA would be also protective, remains to be established. Furthermore, even though 
one aim of the study was to find antigens that may confer improved consistency of the 
protective effect across replicate experiments, the protective effect observed with both FliD 
and SodB varied within the three experiments in which they were tested. This may suggest 
that the variability observed may not be due to CjaA itself but it may be caused by other 
properties of the experimental design such as dose of antigen, adjuvant used, timing of 
vaccination and variability of the inoculum used for challenge. These aspects and 
experiments to address them are discussed in the general discussion (Section 6) of this thesis. 
 The lack of protection observed with CjaA is in contrast to previous observations 
(Buckley et al, 2010). As discussed in Section 3, a number of differences in experimental  
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Figure 5.13. Induction of antigen-specific serum IgY in birds vaccinated with the C. jejuni M1 SodB, FliD and CjaA antigens or with 
the C jejuni 11168H Cj0424 antigen and challenged with the C. jejuni 11168H strain. A. Average fol- change in OD450nm in birds 
vaccinated with GST-CjaA, 6xHis-CjaA and 6xHis-Cj0424. B and C. Induction of serum IgY against GST-SodB (panel B) and GST-FliD 
(panel C) in vaccinated and control birds expressed as mean OD450nm. D. Induction of serum IgY against GST in GST-SodB, GST-FliD 
vaccinated and control birds expressed as mean OD450nm.  The key for panel D applies also to panels B and C. Error bars represent the SEM. 
Significant changes from the GST only vaccinated group are denoted by * for p < 0.05, ** for p < 0.01 and *** for p < 0.001. Apart from 
where indicated otherwise, birds were vaccinated with GST-tagged recombinant antigens. 
6xHis-Cj0424 
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design could account for the discrepancy. In addition to the use of a different breed of 
chickens, in the case of recombinant subunit vaccines, a different tag used for affinity 
purification and a different adjuvant may also account for the lack of a protective effect. 
While GST-PorA has been reported in the literature to induce protection against 
Campylobacter challenge in mice (Islam et al, 2010), the use of the GST tag in this study 
may have inadvertently resulted in delivery of a reduced dose. During purification of GST-
CjaA, a truncation of the size of GST alone that reacted with an anti-GST antibody in 
Western blots was observed (Figure 4.6) This truncation accounted for approximately half 
the protein preparation and given that the amount of antigen delivered was standardised 
according to the total protein present in each antigen preparation, it is likely to have resulted 
in the delivery of a dose approximately half of that intended. Previous studies using various 
antigens report improved protection at doses over 100 μg per bird so a dose that would 
potentially be as low as 7 μg of CjaA per bird may be insufficient to elicit the appropriate 
immune responses. Whether this was the case cannot be ascertained due to lacking an 
immune correlate of protection, the fact that CjaA-specific serum IgY was induced in all 
vaccinated birds and the lack of a dose-response vaccination experiment. 
With regards to the adjuvant, the TiterMax® Gold is described by its manufacturer to 
confer improved induction of humoral responses. However, this type of response may not be 
the major contributor to the protective effect observed and as such the use of this adjuvant 
may have contributed to decreased protection. The hypothesis that humoral responses (in 
particular serum IgY and bile sIgA) may not be the immune mechanism responsible for 
protection is supported by a number of observations in this study. Firstly, there was a lack of 
correlation between serum IgY induction and caecal colonisation levels in the GST-SodB 
vaccinated birds. Secondly, a positive correlation between these parameters within the GST-
FliD vaccinated group suggests that a heightened antigen-specific serum IgY response may 
be detrimental to the protective effect induced by vaccination. Additionally, SodB proved 
protective in spite of its absence from the bacterial surface (at least at levels detectable in the 
assays used) suggesting that direct neutralisation of the bacteria via antibodies is unlikely to 
be the mechanism of protection. Also, the lack of neutralisation of FliD by serum IgY 
supports this latter assumption, however the results of those experiments should be 
interpreted with caution in light of lacking an adequate positive control. Lastly, preliminary 
splenocyte recall assays undertaken during the fourth vaccination experiment on birds 
vaccinated with GST-FliD indicated a statistically significant correlation between caecal 
Campylobacter counts and splenocyte proliferation in response to stimulation by GST-FliD 
(data not shown). However, no characterisation of the proliferating cellular population was 
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undertaken and even though a correlation was present, protection against caecal colonisation 
was not observed within that particular study relative to the GST control. While the findings 
suggest pointers towards the type of immune response induced by vaccination, the 
limitations of these experiments preclude firm conclusions about which arm of immunity is 
responsible for protection following vaccination. Future studies to quantify antigen-specific 
splenocyte proliferation are needed to build statistical power to the point where robust 
conclusions can be drawn. 
Due to the variability observed within the replicate studies testing SodB-, FliD- and 
CjaA-based vaccines, caution should be exercised when interpreting the results obtained 
when testing other antigens only once, in particular those obtained within the experiments 
testing multivalent vaccines and heterologous protection. Ideally multiple replicates of 
experiments testing each parameter should have been performed. However, this would 
require significantly more resources than were available for this doctoral project.  
Whilst this study adds two novel antigens that can be used as vaccines against 
Campylobacter to the limited repertoire described in the literature, the vaccine would require 
further optimisation before being suitable for field use. Furthermore, a plethora of questions 
with regards to the mechanism of action of these vaccines remain unanswered. Future 
directions of research are discussed in the final section of this thesis. 
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6. Discussion 
 
6.1 Summary  
 The current study aimed to refine vectored vaccines for the control of 
Campylobacter in poultry, initially through the use of avian pathogenic E. coli (APEC) as a 
vector for a TetC-CjaA fusion. The use of PoulVac® E. coli, a ∆aroA APEC vaccine, as a 
vector for CjaA resulted in induction of serum IgY against both CjaA and TetC; however, no 
protection was observed against C. jejuni with either this vaccine or with the previously 
described Salmonella Typhimurium ΔaroA vaccine expressing TetC-CjaA (Buckley et al, 
2010) that was used in this study as a control. Differences in experimental design between 
this study and those described previously, which may account for the lack of protection 
observed within this study, were discussed in earlier sections. They notably include the use 
of a different chicken line and route of administration. Additionally, codon optimisation of 
CjaA did not improve expression though this may reflect the culture conditions and the lack 
of optimisation of the N-terminal TetC fusion partner. While these experiments demonstrate 
the potential of inducing an immune response through vaccination with PoulVac® E. coli, 
further experiments would be required to assess its usefulness as a vaccine vector.  
 Due to the lack of a protective effect using live vectored vaccines and the variability 
in responses to vaccination observed within this and previous studies (Buckley et al, 2010), 
the remainder of this study focused on the search for an antigen or combination of antigens 
that may confer an improved magnitude, timing or replicability of protection compared to 
CjaA. Following identification and cloning of 21 candidate antigens, nine were tested in 
chickens for their protective efficacy against homologous challenge. Two of these antigens, 
SodB and FliD, were observed to confer statistically significant reductions in caecal 
Campylobacter carriage at 49 and 56 days post-hatch. However, the CjaA-based vaccine did 
not induce protection, in contrast with previous reports on the use of 6xHis-CjaA as a 
recombinant subunit vaccine (Buckley et al, 2010). Potential reasons for the disparity in the 
protective effect were discussed in Section 5.4 and include the use of a distinct bird line, 
fusion tag for purification and adjuvant. The FliD and SodB vaccines conferred a significant 
improvement over the CjaA vaccine in this study, albeit the latter was not protective. 
Furthermore, the timing of protection was not improved from previous studies in our group 
describing the use of CjaA as a vaccine (Buckley et al, 2010). Further experiments, using an 
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optimised study design, are required in order to assess whether SodB and FliD could confer 
improved protection compared to CjaA, in the case of the CjaA-based vaccine being itself 
protective. 
Nevertheless, this study described two new antigens that could be used in vaccines 
against Campylobacter. Furthermore, novel insights into the nature of the protective immune 
response were revealed, which suggest that antibody responses, either as serum IgY or bile 
sIgA, may not play the major role in protection. The magnitude and timing of the antibody 
responses did not correlate with protection and in the case of FliD, increased serum IgY 
responses were observed to be detrimental to vaccine-induced protection. Furthermore, 
serum IgY from SodB and FliD vaccinated birds failed to agglutinate bacteria and protection 
was observed with SodB in spite of its cytoplasmic/periplasmic localisation. As such, it is 
likely that other mechanisms such as mucosal IgA or cell-mediated immunity may play a 
role in protection. Preliminary data obtained from assays measuring splenocyte proliferation 
in response to stimulation by the antigens used in vaccination identified a negative 
correlation between the level of splenocyte proliferation and caecal Campylobacter 
colonisation in GST-FliD vaccinated birds. However, the nature of the proliferating cells was 
not assessed. Future vaccination experiments should include such assays, but in addition they 
should also identify and characterise the cells that proliferate. Additional experiments are 
required to formally demonstrate the role of each of these arms of the immune response in 
vaccine-mediated protection and a potential study design is suggested below. 
 
6.2 This study in the context of other research 
 Even though live vectored vaccines were not protective against caecal 
Campylobacter colonisation, this study opens the possibility of the use of PoulVac® E. coli 
as an attenuated vector, with a demonstrated safety record (EMA, 2012), for the delivery of 
heterologous antigens. If optimised, the use of this vector has the potential to allow more 
cost-effective vaccine production, a more facile administration compared to injectable 
vaccines and it would have the added benefit of concomitantly controlling collibacillosis, a 
disease that adversely affects poultry and farmers. These needs of the poultry industry have 
been recognised by numerous other studies that have reported the used of attenuated 
bacterial vectors for delivery of recombinant subunit vaccines against Campylobacter and 
these are summarised in Section 1.5.4. 
The variability observed within the vaccination experiments using live vectored 
vaccines but also within those using SodB, FliD and CjaA as recombinant subunit vaccines 
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indicate that intrinsic properties of either the study design or of Campylobacter are likely to 
account for the effect observed. Given the available literature, it may be concluded that study 
and vaccine design have an impact on the protective effect observed. CjaA has been 
described to confer a 6 log10 CFU/g reduction in caecal Campylobacter when vectored in an 
attenuated S. Typhimurium vector (Wyszynska et al, 2004), a 1-2 log10 CFU/g reduction 
when vectored within another S. Typhimurium vector (Buckley et al, 2010) and no 
protection when vectored in a delayed expression S. Typhimurium vector (Laniewki et al, 
2014a). Furthermore, even when used in recombinant form, 6xHis-CjaA was shown to be 
able to confer a reduction of approximately 2.5 log10 CFU/g (Buckley et al, 2010), but others 
have found no protection when a combination of GST- and 6xHis-tagged CjaA was used 
(Michael Konkel, personal communication). In addition, individual research groups report 
variation in the protective effect observed across replicates using identical experimental 
design, with some replicates demonstrating protection, while others do not: such variation 
was observed in experiments reported by Buckley et al (2010), within this study, within 
subsequent experiments using Salmonella vectored CjaA (Elzibeta Jagusztyn-Krynicka, 
personal communication) and within vaccination experiments using other antigens reported 
by collaborators in Zoetis and MSD Animal Health (unpublished data). Such variability in 
spite of a constant experimental design suggests that other factors may account for this 
effect. 
One possible cause is the intrinsic genomic plasticity of Campylobacter jejuni. 
Detailed insights into a potential genetic mechanism for adaptation were revealed at the time 
of the first whole-genome sequencing of a Campylobacter strain (Parkhill et al, 2000). This 
revealed the presence of homopolymeric tracts that have later been demonstrated to lead to 
phase variation in gene expression through on/off switching of genes induced by slipped-
strand mispairing during DNA replication (Gilbert et al, 2002; Guerry et al, 2002). More 
recently, research has identified high frequency stochastic variation within these regions that 
can lead to generation of as many as 50 strains from a single parent during the course of 
infection in a single human host (Thomas et al, 2014). It has been suggested that this ability 
to adapt may play a role in adaptation to selection pressure induced by vaccination (FSA, 
2015d). Additionally, another mechanism for the remarkable adaptability of Campylobacter 
were demonstrated through studies investigating the mechanisms of adaptation to the 
selective pressure of phage predation during chicken colonisation (Scott et al, 2007). Under 
these conditions, Campylobacter have the ability to re-arrange or excise up to a third of their 
genome in order to give rise to strains that are resistant to phage predation. Although these 
strains colonise chickens poorly, they have been shown to revert to a higher colonisation 
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potential upon removal of phage predation, further demonstrating the plasticity of this 
pathogen’s genome under selection or when selection is withdrawn. Furthermore, Bayliss et 
al (2012) describe high frequency mutations and on/off switching of genes involved in the 
variation of surface-exposed structures in Campylobacter, but was not able to model the 
drivers of these changes.  
This high genomic plasticity of Campylobacter may be responsible for the variation 
in protective effect observed across different vaccination experiments. While an inoculum 
originating from the same single colony was administered to all birds in all vaccination 
experiments during this study, it is possible that during culture of the original single colony 
for storage as a glycerol stock a high number of C. jejuni variants with different 
combinations of on/off switches of phase variable genes and even genomic rearrangements 
were generated. Each subsequent culture for the purpose of preparing the challenge inoculum 
is likely to have resulted in further variability and, in addition, adaptation of each culture to 
colonisation of the avian intestinal tract is likely to have resulted in further genetic variation. 
It is thought this may partly explain the unstable and unpredictable dynamics of C. jejuni 
populations during mixed infection of chickens with wild-type isogenic tagged strains 
(Coward et al, 2008). It is even possible that due to the stochastic nature of strain selection, 
individual birds become colonised with strains of C. jejuni with different genetics. As such, 
it is likely that to improve replicability, future vaccination experiments would require the use 
of a higher number of birds per time-point per treatment group than were used in this study. 
This is supported by power calculations using the variance observed within the current 
vaccination experiments suggesting that approximately 10 birds should be used per group 
per time-point to be able to detect a 1 log10 CFU/g reduction in caecal colonisation with 80% 
power and a type I error rate of 0.05. 
This study presents preliminary data with regards to the nature of the immune 
response that is associated with vaccine-induced protection. While the majority of studies 
describing anti-Campylobacter vaccines in chickens published to date focus on the 
measurement of serum IgY as a measure of vaccine immunogenicity, the current study 
suggests that this type of immune response may not be associated with protection. One study 
attempted to describe the nature of the cellular immune responses and showed an increase in 
the percentage of cells in the caecal tonsils expressing CD4, CD3 and Bu-1 markers 
following vaccination but no significant change was detected in CD8+ cells (Laniewski et al, 
2014a). This suggests activation of T helper cells and B cells but not of cytotoxic T cells and 
a possible dominance of humoral immune responses. Of note is that no significant reductions 
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in caecal colonisation by Campylobacter were observed within that study. The lack of 
protection may be due to a lack of activation of the cell-mediated arm of immunity.  
It is possible that the protective effect of vaccination is exerted through the action of 
cell-mediated immunity on a yet unidentified site/niche of C. jejuni persistence within the 
intestinal tissues of the chicken. In support of a role of cell-mediated immunity in vaccine-
mediated protection is also the fact that, in contrast with natural infection with Salmonella, 
for which the crucial role of cell-mediated immunity in clearance at primary infection has 
been demonstrated (Beal et al, 2006), Campylobacter infection does not activate cell-
mediated immunity efficiently in the chickens and establishes long-term colonisation. In 
contrast, Campylobacter infection activates cell-mediated immunity in humans and this has 
been linked to clearance of the pathogen (reviewed in Section 1.2.3). Additional experiments 
that could elucidate and potentiate the nature of the protective immune responses induced by 
vaccination are suggested below.  
A small number of recent studies described the induction of high level protection 
against caecal colonisation using both live-attenuated vectored vaccines and subunit 
recombinant vaccines. Layton et al (2011), describe the induction of a 6log10 CFU/g 
reduction in caecal colonisation following administration of a short peptide of CjaD surface-
expressed in S. Typhimurium, co-delivered with the immunostimulatory molecule CD154. 
However, prior to field use of such a vaccine it is likely to be required to demonstrate that 
the vector does not remain in the birds at the point of slaughter and/or that the CD145 
molecule present would not induce immunomodulatory effects in humans should the vaccine 
enter the food-chain. Using recombinant FlpA, Neal-McKinney et al (2014) demonstrate the 
induction of a 6log10 reduction in caecal Campylobacter colonisation, however two doses of 
250 μg of recombinant protein were used. While highly effective, the cost of producing such 
a vaccine would preclude its field use in broilers. 
While vaccination offers the prospective of a widely-applicable and facile measure 
to control Campylobacter contamination of chicken carcasses, no effective experimental 
vaccine is currently close to a marketable stage. As such, it is likely that this is a long-term 
measure, while in the short term other measures such as improved biosecurity, carcass 
decontamination, consumer education, etc may have to be used to effect a reduction in 
human campylobacteriosis. Even in the long-term, it is likely that vaccination would be 
combined with other such measures in order to maximise the reduction in 
campylobacteriosis, as was the case with the introduction of the Red Lion Code for control 
of Salmonella in chickens. 
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6.3 Limitations of this study 
 While the current study identified two novel candidate antigens that could be used in 
vaccines against Campylobacter in poultry and opened the possibility that PoulVac® E. coli 
may be used a vector, it also has a number of limitations that are discussed herein. Firstly, in 
the case of the experiments testing live vectored vaccines, no protection was observed with 
any of the vaccines tested, including the S. Typhimurium vectored CjaA vaccine. This 
resulted in the inability to assess whether PoulVac® E. coli is a significant improvement 
compared to Salmonella when vectoring Campylobacter antigens. 
 Secondly, due to the high variability in protective effect observed with experimental 
vaccines against Campylobacter across individual replicates, the results of some of the 
experiments testing recombinant subunit vaccines should be interpreted with caution. The 
initial testing of the nine candidate Campylobacter antigens relied on a single replicate and it 
is possible that with further replicates other antigens may have proven protective. However, 
the resources available within a doctoral project precluded the repeat tested of all candidate 
antigens identified initially. As such, measures other statistically significance were used for 
initial selection, namely the modelled magnitude of reduction in caecal colonisation across 
the entire course of colonisation compared to the GST-only vaccinated group. Furthermore, 
the experiments testing multivalent vaccines and protection against heterologous challenge 
were also undertaken only once and as such firm conclusions cannot be drawn from these 
studies. Likewise, it is possible that further replicates of these studies may reveal significant 
reductions in caecal Campylobacter colonisation. 
  In addition, even though this study provided preliminary data on the nature of the 
protective immune response induced by vaccination, fine characterisation of this response 
was not carried out. While antibody responses did not correlate with caecal Campylobacter 
counts, only serum IgY and bile sIgA were measured. It is possible that measurement of 
local caecal IgA would reveal an association between Campylobacter colonisation and 
humoral immune responses. Measurement of mucosal IgA was attempted for the SodB and 
FliD vaccinated groups during the last vaccination experiment, however, no antigen-specific 
antibodies were detected even though dot-blots with an anti-IgA antibody revealed the 
presence of this isotype within the samples. As the birds were raised under SPF conditions, 
the lack of adequate controls meant that it was not possible to assess the efficacy of the 
extraction procedure using measurements of reactivity against an antigen known to be 
present and immunogenic. Furthermore, given the lack of a protective effect within this 
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particular experiment, it was also not possible to determine whether the lack of antigen-
specific mucosal IgA was due to failure of the vaccines to induce adequate levels of 
immunity or whether this is genuinely a feature of experimental vaccines against 
Campylobacter in poultry. Due to all these limitations data relating to mucosal intestinal IgA 
was not presented within this thesis. In addition, even though a correlation between 
splenocyte recall and caecal Campylobacter colonisation was observed in the GST-FliD 
vaccinated birds in the experiment testing multivalent vaccines, that experiment did not 
demonstrate statistically significant protection in the GST-FliD vaccinated birds when 
analysed in isolation. This, combined with the lack of characterisation of proliferating cells, 
makes it impossible to distinguish even between T and B cells as the proliferating cells 
within this assay. 
 Lastly, a layer line was used in this study, reflecting the need to hatch synchronously 
a large number of eggs. This would be more difficult to achieve with a less prolific broiler 
line and if eggs were to be bought from external sources, it is likely they would originate 
from Campylobacter-positive flocks given its widespread presence in commercial flocks. 
The presence of maternally-derived antibodies may affect the immune responses in ways that 
have not yet been determined. Such antibodies may sequester antigens preventing the 
induction of an adequate immune response or they may opsonise vaccines, enhancing 
protection. Future experiments should assess the efficacy of an optimised vaccine in a broiler 
line given that differences between the immune response have been described between layers 
and broilers in certain studies. Koenen et al (2002) describe that broilers respond to 
vaccination with keyhole limpet haemocyanin (KLH) with a humoral response dominated by 
IgM and a low level of cellular response, whereas layer birds produce mainly IgY and show 
higher levels of cellular responses. However, other studies using different antigens found no 
differences in the magnitude of cellular responses between broilers and layers but confirmed 
higher levels of antibody induction in broilers (Parmentier et al, 2010). 
 Even in the face of the limitations described above, the data that demonstrated 
protection using SodB and FliD as GST-tagged recombinant vaccines against 
Campylobacter in chickens stand scrutiny. This data was obtained across three independent 
replicates for the treatment groups and four replicates for the control groups. Even though 
none of the individual experiments attained statistical significance due to the insufficient 
number of birds used, each replicate demonstrated the same pattern of reduction in caecal 
colonisation. However, the reduction in caecal colonisation varied from 0.5 to 2.5 log10 for 
each of the two antigens across replicate experiments. 
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6.4 Future work 
Before further optimisation of the vaccines described in this study is undertaken, 
future experiments should aim to determine the nature of the protective immune response 
associated with protection in vaccination experiments described to date. This information 
would then allow rational development of vaccines. One possible experiment that would 
allow us to formally demonstrate the role of antibody versus cell-mediated immunity would 
be vaccination of existing homozygous mutant chickens lacking the joining (J) segment of 
the Ig heavy chain gene (Schusser et al, 2014). Ig heavy chain production is eliminated in 
these birds and no antibody response is elicited on immunisation with keyhole limpet 
haemocyanin, while migration of B cell precursors into the bursa of Fabricius is unaffected 
and other immune cell types appear normal. However, subsequent maturation of B cells and 
their migration from the bursa are blocked. Even though such an experiment could use the 
vaccines described within the current study, given their limited efficacy and variability in 
response, a large number of transgenic birds would be required. As such, the experiment 
could make use of other, more protective recombinant vaccines that have recently been 
described in the literature, such as those based on FlpA and described by Neal-McKinney et 
al (2014). Following determination of their genotype by PCR, birds of each type would be 
given the FlpA-based vaccine or would be mock-vaccinated, followed by challenge with C. 
jejuni according to the experimental protocol described within the aforementioned study. 
The experiment could measure systemic and local humoral responses in blood and caecum 
respectively. Induction of specific antibodies in intact birds but not Ig-/- birds should be 
observed. Splenocyte proliferation should also be assessed, with additional characterisation 
of the type of cells that proliferate, through the use of FACS analysis. Additionally, total 
RNA from spleen, liver and caecal tonsil could be used for analysis of the expression of 
signature cytokines at each of these sites through qRT-PCR and FACS analysis could also be 
used to determine the cellular composition of these tissues. Immune molecules to be 
analysed may include the Th1 signature cytokine IFN-γ, the Th2 signature cytokine IL-13, 
the proinflammatory cytokine IL-1β and chemokine CXCLi2, and the T regulatory cytokines 
IL-10 and TGF-β4. This experiment may also be undertaken using surgically or chemically 
bursectomised chickens, although additional characterisation of each bird would be required 
to ensure meaningful conclusions can be drawn. Use of chemical bursectomy (e.g. using 
cyclophosphamide or testosterone treatment) brings the risk that proliferating cells other than 
B cells may be targeted. Surgical bursectomy is technically difficult and concern exists 
regarding appropriate analgesia and/or anaesthesia during regulated procedures. 
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A project recently funded by the Biotechnology and Biological Sciences Research 
Council (BBSRC) will evaluate the use of glycosylated vaccines for the control of 
Campylobacter, vectored by Salmonella or APEC live-attenuated vaccines. The experiment 
described above for the investigation of the nature of the protective immune response 
induced by vaccination could also include a glycosylated form of the vaccine (e.g. 
engineered to express the C. jejuni heptasaccharide on the bacterial surface and/or fused to 
Campylobacter antigens using the pglB coupling system). Comparison of glycosylated and 
non-glycosylated vaccines would result not only in novel insights into the avian immune 
system and its response to glycosylated antigens but also in comparative immunology 
highlighting differences and similarities to mammalian responses to such antigens. 
 Following description of the nature of the protective immune response induced by 
vaccination, other studies could investigate the use of different adjuvants for vaccine 
optimisation. Such adjuvants could include not only tradition adjuvants, but also cytokines 
and chemokines. As experiments would have to evaluate each adjuvated vaccine compared 
to a group vaccinated without adjuvant and to a group receiving the adjuvant administered 
alone, only two adjuvants could be tested per experiment under the conditions currently 
available to us. One such experiment could test a mixture of IL-12 and IL-18 to augment Th1 
responses or IL-6 to boost Th2 responses. A separate experiment could test a mixture of 
CCL19 and CCL20 (which respectively attract mature and naïve APCs) or CXCL13 (which 
attracts B cells and Th2 cells). In addition to testing the impact of molecules that recruit 
APCs, testing of molecules that drive APC proliferation and/or antigen presentation could 
also be undertaken. Experiments could evaluate recombinant chicken CSF-1 (which drives 
APC proliferation) or a combination of IL-6 and IL-21 which may drive differentiation of T 
follicular helper cells. All such experiments could include the characterisation of the induced 
immune responses in a similar manner to that in the experiment described above. 
 Should antibodies be shown to be vital for protection, identification of 
immunodominant antigens and even epitope mapping within these antigens could be carried 
out using antibodies induced by natural or experimental infection. Studies have previously 
identified antigens recognised by maternal antibodies (Shoaf-Sweeney et al, 2008). Such 
antigens could then be tested as vaccine candidates or birds could be passively immunised 
with antibodies directed against these antigens could be delivered through probiotic bacteria 
secreting fragments of these antibodies or use of hyperimmune serum/egg yolk antibodies. 
Should cell-mediated immunity be shown to be vital for protection, antigens and/or epitopes 
that induce this response during Campylobacter infection could also be determined, even 
though this is more technically challenging. Predictions of T-cell epitopes could be made in 
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silico and these could be tested for their ability to stimulate immune cell proliferation in 
vitro. Additionally, cultures of antigen-presenting cells could be fed whole cell 
Campylobacter lysates. MHC-epitope complexes from these cells could be extracted and the 
bound epitopes eluted and identified by mass spectroscopy. These epitopes or the whole 
antigens from which they derive may then be tested as vaccines against Campylobacter in 
chickens. Furthermore, comparative studies to identify T-cell epitopes could be done using 
chicken and human cell lines as these may reveal additional antigens involved in clearance 
of human campylobacteriosis. 
 Using the information gained from the experiments described above, an appropriate 
adjuvant could be used in future vaccination experiments that would aim to optimise the 
protocol of vaccination. Such optimisation could include the administration of the vaccine at 
different times in the life of the chicks. While previous research suggested that 
administration of the primary vaccination to day old, 4-day-old or 8-day-old chicks does not 
affect the magnitude or timing of the protective effect observed (Buckley et al, 2010), the 
data derived from a single experiment using only three birds per group per time-point. 
Additional experiments using higher number of birds are required to formally demonstrate 
the effect observed. Other studies describe highly protective vaccines when the primary 
vaccination is administered to 6-day-old birds (Neal-McKinney et al, 2014), but no 
comparisons are made to birds vaccinated on the day of hatch. Future experiments could also 
investigate the use of in ovo vaccination. In addition, the vaccine could be administered to 
layer birds and the protective effect of maternal antibody transfer to progeny may be 
investigated. One other aspect of the vaccination protocol that could be optimised is the dose 
of the vaccine. Previous studies that undertook dose-titration experiments suggest that doses 
over 100 µg are required for the induction of the maximal protective effect observed, with 
doses as high as 250 or 500 µg required in certain cases (reviewed in Section 1.5.3). 
 While the above experiments could be carried out using recombinant subunit 
vaccines, it is likely that a vaccine that would be used on a wide scale in the field would 
require vectoring to be cost-efficient for wide-scale use. Optimisation of the vector attributes 
should be undertaken and lessons learnt from the studies described above could be used. 
While delivery in live-attenuated bacteria is likely to stimulate a stronger immune response 
compared to delivery of a recombinant antigen alone, appropriate adjuvants or 
cytokines/chemokines could be used to further improve this response. Additionally, 
information from dose-titration experiments could be used to design an expression system 
that would deliver an appropriate amount of antigen. Furthermore, using live-attenuated 
vaccines, the impact of route of vaccination may also be tested. Using a single, optimised 
 
152 
 
vaccine and experimental design, trials could test in parallel vaccines delivered via the 
subcutaneous, intramuscular or oral routes. Delivery of a vaccine against Campylobacter via 
the oral route and/or as a spray, may be preferable in the field due to ease of application. 
 Lastly, a highly optimised vaccine should undertake preliminary testing under field 
conditions. A key requirement of an effective avian Campylobacter vaccine will be its ability 
to repel the diverse phylogenetic lineages and phase-variants of C. jejuni that broilers may 
encounter. As such, the efficacy of an optimised vaccine should be tested in broilers housed 
in a manner typical of commercial practice. The experimental design should use challenge 
with C. jejuni via exposure to litter contaminated with C. jejuni or seeder birds in contact 
with vaccinated birds. Litter could derive from flocks known to be highly-positive for C. 
jejuni. Vaccinated and mock-vaccinated birds could be housed in separate enclosures to 
prevent cross-contamination and to ensure exposure to an equal quantity of contaminated 
litter. Evidence from experimental and theoretical modelling studies suggests that if the level 
of caecal Campylobacter colonisation is maintained under 3 log10 CFU/g transmission of the 
pathogen between individual birds within a flock is impaired (Rotariu et al, 2013). This 
highlights that keeping treatment and control groups separately may impact on the 
magnitude of the protective effect observed under field-simulating conditions. In addition, 
such an experiment could further evaluate the effect of reducing intestinal Campylobacter 
contamination on the contamination of the carcass following processing. Scotland’s Rural 
College facilities at Auchincruive include an experimental slaughter line and this could be 
used for separately processing control flocks and vaccinated flocks, provided thorough 
disinfection of the plant is used between the two groups. Such an experiment would provide 
a direct measurement of how well a reduction in intestinal carriage would translate into 
reduced carcass contamination. 
 
 
6.5 Conclusion 
 The current study adds two novel antigens, namely SodB and FliD, to the limited 
repertoire described to date in published literature related to vaccines against Campylobacter 
in chickens. In addition, it provides preliminary evidence into the nature of the protective 
immune response induced by vaccination, suggesting that antibody may not be the main 
mediator of the observed effect. However, further experiments are needed to formally 
demonstrate the nature of the immune response mediating protection and future studies into 
development and refinement of anti-Campylobacter vaccines for use in chickens should be 
undertaken in a rational manner, informed by such evidence. 
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Appendix I 
Conservation (% nucleotide identity) of the C. jejuni antigens used in these experiments as candidate vaccines across 20 C. jejuni strains. 
C. jejuni 
strain 
Gene 
 
accD cadF cj0088 cj0089 cj0090 cj0536 
cj11168
_0424 cjaA cjaC cmeA cmeC flaA flgE2 flgK fliD flpA ggt omp18 porA tpx sodB fspA 
11168 98 99 98 98 99 99 100 98 99 97 100 81 98 100 96 98 
Not 
present 99 83 99 99 99 
81176 99 99 99 99 99 99 
Not 
present 98 99 98 99 99 84 98 98 99 99 99 83 99 99 
99 
81116 99 100 100 100 100 100 
Not 
present 100 100 98 99 100 91 99 99 100 99 100 84 
10
0 100 
99 
R14 99 99 99 99 99 99 99 97 99 98 99 80 86 99 96 98 
Not 
present 99 95 99 99 
99 
CG8421 99 99 98 99 99 99 
Not 
present 98 99 98 99 79 86 99 97 98 
Not 
present 99 95 99 99 
99 
RM3196 99 99 99 99 99 99 99 98 100 98 97 85 84 99 96 98 99 99 83 99 98 
99 
YH001 98 99 98 98 99 99 99 98 99 97 100 80 98 98 100 98 
Not 
present 99 83 99 99 
99 
ICDCC07
001 98 99 99 99 99 99 99 98 99 98 97 85 98 99 96 98 99 99 85 99 98 
99 
00-0949 98 99 98 98 99 98 99 98 99 98 99 81 100 100 96 98 
Not 
present 99 83 99 99 
99 
01-1512 98 99 98 98 99 98 99 98 99 98 99 80 98 100 96 98 
Not 
present 99 83 99 99 
99 
IA3902 98 99 98 98 99 98 
Not 
present 98 99 97 100 81 86 100 96 98 
Not 
present 99 84 99 99 
99 
PT14 98 99 98 98 99 99 99 98 99 97 99 80 92 99 98 98 
Not 
present 99 95 99 99 
99 
00-1597 98 99 98 98 99 98 
Not 
present 98 99 98 99 81 86 98 98 98 
Not 
present 99 94 99 99 
99 
S3 98 99 98 99 99 99 
Not 
present 98 99 98 99 79 92 99 97 97 
Not 
present 99 94 99 99 98 
00-6200 98 99 98 98 99 98 99 98 99 97 100 81 86 99 96 98 
Not 
present 99 83 99 99 99 
F38011 98 99 98 99 99 99 99 98 99 98 99 82 92 98 99 98 
Not 
present 99 83 99 99 98 
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C. jejuni 
strain 
Gene 
 
accD cadF cj0088 cj0089 cj0090 cj0536 
cj11168
_0424 cjaA cjaC cmeA cmeC flaA flgE2 flgK fliD flpA ggt omp18 porA tpx sodB fspA 
00-2544 98 99 98 98 99 99 99 98 99 97 100 81 87 100 98 98 
Not 
present 99 83 99 99 
99 
00-2426 98 99 98 98 99 98 99 98 99 97 100 81 87 100 98 98 
Not 
present 99 83 99 99 
99 
00-2538 98 99 98 98 99 99 99 98 99 97 100 81 87 100 98 98 
Not 
present 99 83 99 99 
99 
RM3197 99 99 99 99 99 99 99 98 99 98 97 85 98 99 96 98 99 99 83 99 98 
99 
M1 100 100 100 100 100 100 
Not 
present 100 100 100 100 100 100 100 100 100 100 100 100 
10
0 100 
99 
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